Data integration in the life sciences. A protein family-based approach. by Vroling, B.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/93556
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.

Data integration in the life sciences
A protein family-based approach
een wetenschappelijke proeve op het gebied 
van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen op woensdag 11 april 2012 
om 12.30 uur precies 
door
Bas Vroling
Geboren op 8 mei 1984 
te Hengelo (ov)
Promotor
 Prof. Dr. G. Vriend
Manuscriptcommissie
 Prof. Dr. A.P. IJzerman
  Leiden University
 Prof. Dr. J. de Vlieg
 Dr. S.R. Pettifer
  University of Manchester, United Kingdom
 Prof. Dr. J.A. Smeitink
 Prof. Dr. H. G. Brunner
                                                                                                                                                                                                                                                                                                   
 

 5
CONTENTS
Scope and summary 7
Chapter 1  Introduction 
                   GPCRs: past, present and future 13 
                   Harvesting the information from a family of proteins 41
Chapter 2  GPCRDB: information system for G protein-coupled receptors 59
Chapter 3  Systematic generation of in vivo G protein-coupled receptor  
                   mutants in the rat 77
Chapter 4  Taming information overload in the life sciences 97
Chapter 5  Integrating GPCR-specific information with full text articles 103
Chapter 6  GPCR-OKB: the G Protein Coupled Receptor Oligomer  
                   Knowledge Base 121
Chapter 7  Overview of the MCSIS framework  127
Chapter 8  NucleaRDB: information system for nuclear receptors 145
Samenvatting 153
Dankwoord 157
Curriculum Vitae 159
List of publications 161

SCOPE AND SUMMARY
8Advances in the life sciences have enabled scientists to study the elements that comprise 
the machinery of life in ever-increasing detail. The first pharmacological experiments were 
performed on crude tissues and glands, generating relatively simple data both in terms of size 
as well as complexity. Using pen and paper, a scientist could deal with all the experimental 
results. These days, the complexity of experimental science has increased enormously. 
Scientists can simultaneously study multiple elements in the living cell at the atomic level. 
As a result of the increase in resolution and the use of high-troughput techniques we witness a 
phenomenal rise in the quality, quantity and complexity of data. Consequently, the computer 
has become essential for life scientists to process data, integrate results and design new 
experiments.
A large number of specialised biological repositories were created to accommodate for 
the massive increase in experimental data. These repositories serve as online warehouses 
for specific types of biological data. Examples of such databases are the Protein Data Bank 
(PDB), which holds structural data for biological molecules, UniProt, which contains protein 
sequence information, and the Chembl database, which contains information on the activities 
of small molecules on biological entities. These databases are invaluable for researchers, 
as they contain high-quality, up-to-date experimental data. However, most researchers tend 
to focus their research on one molecule, rather than focussing on one experimental data 
Figure 1. Growth of literature and data repositories since 1985. This figure shows the percentage of 
the current volume for three repositories between 1985 and the present day. All three repositories grow 
exponentially. This exponential growth stands in sharp contrast to the limited abilities of researchers 
to deal with this increase of data and information; the amount of published literature is increasing 
exponentially, but the number of papers a researcher can read remains constant.
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type. Instead of using many large monolithic resources to extract information and manually 
integrate this information, these scientists would rather use a resource that is focused on one 
(class of) molecule(s) that holds many data of different types that are validated, integrated, 
and presented in a user-friendly fashion specific for their molecule or class of molecules.
Systems that focus on one class of molecules are termed Molecular Class-Specific 
Information Systems (MCSISs). Already in 1991, before the days of the World Wide Web, 
the need for such systems was recognized and plans were made to develop an email-based 
information system for G protein-coupled receptors (GPCRs). In 1992, the GPCRDB email 
system was functioning at the EMBL, and in 1994 it was rewritten by Florence Horn as 
an HTML-based system. Since then, the GPCRDB is known to researchers as the one-stop 
resource for obtaining GPCR-related information, and it has been used and cited extensively. 
Over the years the system has continously been updated and optimised in many ways, a 
process that is continuing to this day. 
In 1990 GPCRs were chosen as the MCSIS research topic because of their medical 
relevance and their importance to the pharmaceutical industry. In addition, GPCRs are, from 
a bioinformatics standpoint, enormously interesting molecules to work with. We do not have 
a clear understanding of the intricate ways these molecules function, and the lack of direct 
structural data prevents us from gaining insights through structural interpretations. To further 
our understanding of GPCRs we therefore have to make the best possible use of data that we 
do have at our disposal. MCSISs such as the GPCRDB provide researchers with all the data 
and facilities they need to gain as much insight as possible by using many different kinds of 
data.
The work described in this thesis is the result of the efforts to explore novel ways of 
utilizing systems that collect, validate, and integrate heterogeneous information on specific 
classes of proteins. Chapter 1, the general introduction, comprises two subchapters that were 
published as two separate reviews in two books. The first part of the introduction, chapter 
1a, discusses the history of GPCR research, from the first experiments in the early 1900’s up 
to the publication of the first crystal structures of ligand-mediated GPCRs in 2008, together 
with an outlook of the major challenges that still remain to be solved. The second part of the 
introduction, chapter 1b, deals with the types of (bio)informatics technologies that can be 
used to create information systems for a family of proteins, together with a short overview of 
a number of techniques suited for extracting information from multiple sequence alignments. 
These chapters do not cover the avalanche of GPCR structures that became available in 2010 
and later; we are still working on their analysis.
The GPCRDB, a test bed for MCSIS technology is discussed in chapter 2. The GPCRDB 
contains experimental data on sequences, ligand binding constants, mutations, and oligomers, 
as well as many different types of computationally derived data such as multiple sequence 
alignments and homology models.  This chapter describes the steps involved in collecting 
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and generating data, as well as the technologies and infrastructure needed to present the data 
in a user-friendly fashion. 
The availability of integrated data offered by the GPCRDB can be essential in steering the 
experimental work in the lab. Chapter 3 describes a large collection of chemically induced 
in vivo GPCR mutants in rats. Using comprehensive computational analyses the impact of 
these mutations on normal receptor function was predicted. Based on these predictions rats 
were selected for further characterization. We experimentally show that a nonsense mutation 
in the melanocortin receptor 4 Mc4r and a missense mutation in the lysophosphatidic acid 
receptor Lpar1 indeed result in loss-of-function phenotypes. 
To perform the studies described in chapter 3, a large amount of literature was analysed 
by hand, which was a laborious and tedious task. With the ever-increasing amount of 
(GPCR) literature (figure 1), these types of studies are becoming more difficult. Information 
overload is compromising the ability of researchers to keep up with advances in their fields. 
Simultaneously, increasing time pressures are compelling researchers to get to information 
in relevant papers much more efficiently. To let researchers deal more effectively with the 
combination of data present in the literature and data in information systems such as the 
GPCRDB, we have explored novel ways of integrating domain-specific data with scientific 
articles. In chapter 4 and chapter 5 we describe software that performs this integration in an 
intuitive and non-invasive fashion. The software automatically retrieves relevant information 
from the GPCRDB and displays it both within and as an adjunct to an article, thereby allowing 
researchers to extract more knowledge more swiftly from literature. Putting the contents of 
scientific literature in the context of the information in the GPCRDB does not only lead to 
faster and more efficient information extraction, but can also greatly extend the lifetime of 
especially articles published before the first crystal structures were published by putting ‘old’ 
data in the context of ‘new’ insights and structures. 
In chapter 6 we show that MCSIS technology can serve as a stepping-stone for other 
data resources. Here, the GPCRDB is used to create a database of GPCR oligomerisation 
information, building on the core data present in the GPCRDB while maintaining a close 
integration with the original data. 
Chapter 7 describes the architecture and implementation details of the MCSIS framework, 
which can be used to create information systems for any protein family. In chapter 8 we show 
that the technologies developed for creating the GPCRDB and related technologies such as 
described in chapter 2, 4 ,5 and 7 can indeed be easily applied to other molecular families. 
We have created a MCSIS containing information about nuclear receptors. This information 
system gives access to the same tools and functionalities as the GPCRDB, including a web 
interface, extensive webservice access and a nuclear receptor-specific PDF reader.
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INTRODUCTION
Over 1000 human genes encode G protein-coupled receptors (GPCRs). The ligands 
that bind or otherwise activate these receptors are heterogeneous and include photons, 
odors, pheromones, hormones, ions, neurotransmitters, and proteases. GPCRs transmit 
signals from outside the cell to amplification cascades controlling sight, taste, smell, slow 
neurotransmission, cell division, etc. GPCRs were long thought to perform a relatively 
straightforward role; coupling the binding of agonists to the activation of G proteins, which 
in turn leads modulation of other downstream effector proteins. However, in recent years 
it has become clear that many GPCRs have much more complex signalling characteristics. 
Many GPCRs are constitutively active, and this allows for a fine-grained control of the 
amount of G-protein activation, being subject to regulation by agonist as well as inverse 
agonists (1). Signalling can occur by using multiple subtypes of G proteins, or without using 
G proteins altogether (2). Desensitization processes can involve multiple pathways, including 
phosphorylation events, arrestin-mediated receptor internalization, receptor recycling, and 
lysosomal degradation (3-5). The reason for this multifaceted behaviour may be the fact that, 
while there are only about 1000 GPCRs that can be activated by an even smaller number of 
endogenous agonists, these receptors need to cater for many 1000s of different messages 
that the whole organism needs to be able to transmit internally. The exact mechanism of this 
switching between different functions is unknown.
All GPCRs form a bundle of seven transmembrane (TM) helices, connected by three 
intracellular and three extra-cellular loops. Although sequence similarities within a single 
family can be lower even than 25%, there are a number of conserved sequence motifs that 
imply shared structural features and activation mechanisms.
GPCRs are a major target for the pharmaceutical industry as is reflected by the fact that 
more than a quarter of all FDA approved drugs act on a GPCR (6). Despite intensive academic 
and industrial research efforts over the past three decades, little is known about the structural 
basis of GPCR function, in particular, the switches between different functions, referred to 
above, and between the active and inactive states of these receptors (7). 
Some of the major questions relevant to fundamental research into GPCR pharmacology 
include the following: What residues are critical for ligand binding and for the activation of G 
proteins or other proteins? What do different receptor families have in common with regard 
to their activation mechanism? And which residues are responsible for the differences and 
should thus especially, or especially not be influenced by potential drug molecules? 
The GPCR field was without new structural information for almost a decade, but a number 
of high-resolution crystal structures have become available recently, giving the GPCR field a 
big stimulus. As is often the case in such situations, researchers mainly focused on the unique 
and exciting aspects of these structures, tending to overstate the relevance and importance of 
the differences. The new structures provide us with new insights, but they are not the holy 
grail of structural biology of the GPCR field, and many questions, limitations, and challenges 
remain.
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A SHORT HISTORY
Since the beginning of the 19th century, pharmacologists have studied the dose-dependent 
effects of neurotransmitters, peptides and other chemicals on tissues, organs, and animal 
models. Langley and Dale were the first who explicitly stated the idea of a ‘receptive 
substance’ on reactive cells (8). They performed their experiments on muscle preparations 
and salivary glands. The targets that they were investigating later turned out to be G protein-
coupled receptors and ion channels. During the next 50 years, the elementary concepts of 
Langley and Dale were developed into the receptor theory by using physiological techniques 
to study receptors (9). 
The field of receptor studies was mainly a pharmacological field until -in the 1960s and 
early 1970s- biochemists became involved in the search for the molecular basis of hormone 
and drug action. This led to the rapid discovery of the elements that make up the signalling 
cascades that couple hormones to the intracellular effector proteins. Sutherland discovered 
the enzyme adenylyl cyclase (10), which is responsible for the synthesis of cAMP, and 
cAMP itself (11) that mediates the actions of many receptors. Around the same time, Krebs 
discovered the cAMP-dependent protein kinase (12) and Gilman had demonstrated the 
existence of a protein, Gs, that functioned as a transducer between hormone receptors and 
adenylyl cyclase (13, 14).
The impact of these discoveries was enormous; for the first time scientists could study 
receptors at a level much closer to the actual signalling than was possible ever before. 
No longer was it necessary to measure complex physiological responses such as muscle 
contraction or gland secretion; now it was possible to measure direct downstream effects 
such as secondary messenger generation.
After the discovery of downstream effectors, researchers were searching for an even more 
direct measure to study receptors. There was a need for a means of identifying and studying 
receptors directly, so that their properties no longer needed to be inferred from downstream 
effects. Radioligand binding methods provided these means, and the development of 
radioligand binding methods during the 1970s transformed the field of receptor research 
(15-18). By using these techniques, it was now possible to develop approaches to analyze 
receptor interactions with G proteins (19). This ultimately led to the development of the 
‘ternary complex model’, which provided a way of quantifying coupling efficiency of the 
receptors to the G proteins (20, 21). 
Radioligand binding methods also allowed for new types of ligand binding studies. New 
chemical compounds could now be tested systematically, and binding profiles were generated 
on membrane preparations from different tissues. This led to the first evidence for receptor 
subtypes expressed in different tissues.
The development of radioligand binding methods was not only of great importance for 
the study of receptor properties in native environments. New technologies that built on the 
principles of molecular recognition were introduced, such as radioligand techniques for 
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determining ligand binding and activity, and affinity chromatography, which allowed for 
the creation of enriched and purified sources of receptors. In 1979, the Lefkowitz group was 
able to purify the β2-adrenoceptor by using a broad range of already available β2-adrenergic 
ligands and a combination of already existing and new affinity chromatography procedures 
(22). Receptors were reconstituted in phospholipid vesicles with purified G protein and the 
catalytic moiety of adenylate cyclase, thereby proving that the purified β2-adrenoceptor was 
indeed the functional receptor (23-25).
In 1982, Ovchinnikov determined the amino acid sequence of rhodopsin using classical 
protein sequencing techniques. The amount of protein needed for these techniques was 
relatively large, but the easy access to retinal rod preparations allowed Ovchinnikov to 
obtain the necessary amounts of receptor needed for the sequencing. An extensive study 
that included a combination of bioinformatics and biochemistry showed that rhodopsin 
had a 7TM architecture and the fact that it had this in common with bacteriorhodopsin was 
quickly noted (26, 27). Bacteriorhodopsin is a photon-driven retinal binding proton pump for 
which, in 1975, Henderson and Unwin (28) had determined a 7TM topology using electron 
microscopy techniques. After the discovery that bacteriorhodopsin as well as rhodopsin had 
a 7TM architecture, it was concluded that this 7TM topology was a common feature of light-
sensitive proteins (26).
In 1986 came an important breakthrough: the cloning of the hamster β2-adrenoceptor 
(29). The gene for the β2-adrenoceptor was intronless, a feature that is also seen in many 
other GPCR family members (30-33). The sequence of the β2-adrenoceptor revealed that 
this receptor shared sequence similarity and a predicted 7TM topology with rhodopsin (29). 
At the time it was well known that both the β-adrenoceptor and rhodopsin were interacting 
with G proteins in a stimulus-dependent fashion, but the fact that both receptors also shared 
structural similarity was not anticipated. Since the sequencing of rhodopsin, the 7TM 
architecture was thought to be the hallmark of light-sensitive proteins, but now it became 
clear that this topology was likely to be a common structural feature of all GPCRs. This idea 
was confirmed in the following years by the cloning of an ever-increasing number of GPCRs. 
The GPCRs were cloned based on similarity with already cloned family members. Because 
of this required similarity with already cloned GPCRs, it took a while until any distantly 
related receptors were discovered.
Not all of the newly cloned receptors had a known function or a known natural ligand. These 
receptors for which the sequence was known, but the function and/or endogenous ligand was 
unknown, are termed ‘orphan receptors’. The first example of an orphan receptor was the 
clone ‘G21’, which was isolated from a genomic DNA library shortly after the cloning of the 
β2-adrenoceptor (34). This receptor was ‘deorphanized’ by Fargin et al. (35). The strategy to 
‘deorphanize’ the orphan receptors was to express the orphan GPCR of interest in eukaryotic 
cells by DNA transfection, and use the membranes of these cells as targets for testing the 
binding abilities of potential ligands. This strategy is now known as reverse pharmacology 
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(36, 37). Vassart and co-workers were the first to use PCR for finding new GPCRs (38), and 
continued to work on deorphanizing GPCRs till today, with great success (39-41)
With the availability of a large body of cloned receptors, the focus of the GPCR research 
field shifted towards unravelling the structural features responsible for the many aspects of 
receptor function. By using a wide range of molecular genetics techniques, ranging from 
site-directed mutagenesis approaches to the creation of chimeric receptors, the regions of the 
receptors responsible for G protein coupling and ligand binding were determined (42, 43). 
The coupling of G proteins was attributed to the intracellular loops, whereas the binding of 
ligands, depending on the receptor subtype, was found to take place in the outward regions 
of the membrane-spanning domain and sometimes also partly in the extracellular domains. 
The mutagenesis work provided a clarification of a previously unexplained phenomenon 
whereby many GPCRs were known to possess an intrinsic high background activity in the 
absence of a ligand, and led to the development of an interesting new concept: constitutive 
activity (44). In 1992, Cotecchia had created a chimeric receptor by replacing four residues of 
the third intracellular loop of the β2-adrenoceptor with residues from the α1b-adrenoceptor 
(45). This chimeric receptor had a surprising feature; it had the ability to signal measurably 
in the absence of an agonist. This feature was termed constitutive activity, and it was defined 
as ligand-independent activity resulting in the production of a second messenger even in 
the absence of an agonist. It was found that virtually any substitution in that region led to 
increased constitutive activity (46). It was hypothesized that this activity arose due to the fact 
that these mutations disrupted interactions that normally keep the receptor in an inactive state 
(47). It was found that many diseases were linked to naturally occurring mutations in GPCRs 
that resulted in constitutively active receptors (48).
Constitutive activity is not limited to mutant receptors. In fact, even before Cotecchia 
described the first constitutively active mutant, Costa and Herz had already described 
the constitutive activity of the wild-type δ-opioid receptor (49). Since then, numerous 
observations have indicated that the basal activity of a wild-type GPCR might vary from 
totally inactive to fully active, depending on the nature of the GPCR.
Inverse agonism was already long known, but the discovery of (mutant inducible) 
constitutive activity made this concept accessible to experimentation in the GPCR field. 
Inverse agonists are a class of ligands that are capable of reversing the constitutive activity 
by stabilizing the inactive state of the receptor (49, 50). Before the discovery of constitutive 
activity in GPCRs, these compounds had been indistinguishable from antagonists (51, 52).
By the mid-1980s, it had become clear that both rhodopsin and the β2-adrenoceptor were 
phosphorylated in a stimulus-dependent way (53, 54). The phosphorylation seemed to be 
related to the process of receptor inactivation or desensitization. A small family of proteins, 
the G protein-coupled receptor kinases (GRKs), was found to perform this phosphorylation 
(55). 
In 1986, Wilden and Kuhn reported a small protein that bound to phosphorylated rhodopsin, 
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leading to steric exclusion of transducin (56). This protein was named arrestin.
In a search for similar mechanisms for the β2-adrenoceptor, Lefkowitz et al. (57) found that 
the GRKs alone were not sufficient for desensitization, and that another factor was needed. 
They found this factor and named it β-arrestin (58), after the arrestin compound found by 
Wilden and Kuhn. Phosphorylation of the receptor stimulates the binding of β-arrestin, 
leading to steric exclusion of G proteins, inhibiting further signalling. These two families, 
the GRKs and the arrestins, appear to regulate essentially all of the seven-transmembrane 
receptors . These proteins share, together with the heterotrimeric G proteins, the ability to 
interact virtually universally with all of the receptors in a stimulus-dependent fashion.
For a decade, the structure of bacteriorhodopsin was the only structure available that 
remotely resembled anything like a GPCR. In 1990 low-resolution electron cryo-microscopic 
models of bacteriorhodopsin were published (59). Hibert et al and Dahl (60) were the first to 
produce 3D models for GPCRs (61). These models were built using bacteriorhodopsin as a 
template. When the bovine rhodopsin structure became available (62), it was seen that these 
models were very imprecise (63), but for many years they were the best bioinformatics could 
do, and they certainly helped the entire GPCR field think about sequence/structure – function 
relations (64). Many mutation studies were guided by these first (poor) models, and they 
aided the studies aimed at elucidating the function per residue.
August 4, 2000 is an historical date in the GPCR field. On that day, the structure of bovine 
rhodopsin (62) became available, providing researchers with the first high-resolution crystal 
structure of a GPCR. The X-ray structures of bovine rhodopsin and bacteriorhodopsin are 
significantly different, and the structure of bovine rhodopsin provided some interesting and 
some unexpected features (63). The structure showed an 8-th helix that immediately after 
helix VII sticks out parallel to the cytosolic membrane surface, exactly as was predicted by 
Oliveira et al (65) a year earlier. The transmembrane helices were quite irregularly shaped 
when compared to those of bacteriorhodopsin; helix II contained an α-bulge, and a part of 
helix VII was shaped as a 310 helix. Moreover, sequence alignments and modelling studies 
reveal that it is likely that the α-bulge in helix II is not always at the same place, or even 
present at all (66). In contrast to popular belief, the loops did not all stick out into the solvent, 
as the extracellular loop IV-V formed two β-hairpins that were folded on top of the retinal, 
between the helices. The first GPCR structure has not yet had the impact on the GPCR field 
that we, before August 2000, expected that it would have. This is probably caused by the 
fact that most models, despite their sometimes great imprecision, provided enough structural 
information to explain most experiments, and because we simply do not yet know enough 
about GPCRs to fully appreciate all the things that this structure taught us.
The end of 2007 was the start of a small explosion of structural information on GPCRs. 
With the publication of four structures of β-adrenoceptors (67-70) and one of the human 
adenosine receptor (71), nearly a decade of structural silence had come to a close. At a first 
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glance, all these structures look highly similar with eight well superposable helices. The 
largest differences were observed in loop IV-V. As the loop IV-V is intensively involved in 
crystal packing contacts in all known structures, it is not known yet whether these differences 
are real, and whether they have functional importance.
GPCR signalling was long thought to consist of one ligand, activating one monomeric 
GPCR, affecting downstream adaptor proteins via one heterotrimeric G protein. However, over 
the years, the idea that GPCRs function as oligomers got increasing amounts of experimental 
backing. The first suggestions that GPCRs might form oligomers dates from the beginning 
of the 1980s, when Conn and co-workers used a bivalent antibody that had a gonadotrophin-
releasing hormone (GnRH) antagonists attached. Their data implied that this ‘conjugated’ 
antagonist might be capable of acting as an agonist that promoted “microaggregates” of 
GnRH receptor (GnRHR) leading to biphasic regulation of receptor surface expression (72, 
73). Evidence from ligand binding and studies of inhibition using free transmembrane helices 
provide strong support for the notion that GPCRs act as dimers. A peptide derived from a 
β2-adrenoceptor transmembrane domain inhibits both receptor dimerization and activation 
(74) or possibly even oligomers (75). It would take a long time before the first direct physical 
evidence for GPCR dimerization would become available. In 2003 Fotiadis showed the 
existence of rows of rhodopsin receptors within retinal disc membranes by using atomic 
force microscopy (76). The dimer model has been furnished with support from bioinformatics 
studies (77) in which the interfaces between putative dimer interaction sites can be identified. 
These theoretical studies were anticipated by an early, seminal, experimental observation 
from the Lefkowitz laboratory (78) of negative cooperativity in GPCRs. Lefkowitz probably 
anticipated the later finding of dimers as he concludes this article with: “Further investigation 
is required to elucidate the molecular mechanisms responsible for negatively cooperative 
site-site interactions and the possible regulatory functions they serve”; besides that we can 
now be fairly certain that dimer formation is at the basis of this phenomenon, this statement 
is still valid, 35 years later.
The simplest model for GPCR activation is shown in figure 1. Actually this model is an 
oversimplification, as the existence of dimers is not taken into account. 
It should be kept in mind that all states interconvert very rapidly; the law of mass action 
ensures that binding of most molecules such as ligands, G proteins, antibodies, arrestins, etc., 
Figure 1. Model of GPCR activation. 
This model does not take dimer 
formation or cytosolic protein binding 
into account, yet. Note that the rest state 
is only a ‘virtual’ state that consists of a 
mixture of R and R*. 
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makes the equilibrium shift in the direction of that bound state. This is nicely illustrated by 
experiments in which receptors are shown to bind their ligand more tightly if more G protein 
is present (summarized in 79). The existence of allosteric modulators therefore is no surprise, 
and indeed these were found as early as in 1987 (80). The thermodynamic treatment of these 
modulators can still be improved greatly in the GPCR field. A large number of so-called 
allosteric modulators have been reported in the literature, and Christopoulos (e.g. (81)) has 
described them in a series of reviews. It is difficult -mainly because allosteric modulation was 
known in other receptor fields already before it was also discovered for GPCRs- to pin-point 
the original discovery of this phenomenon.
 
GPCR STRUCTURES
GPCRs are notoriously hard to crystallize. Proteins that are naturally present in an aqueous 
phase can usually be crystallized reasonably well, but the crystallization of membrane 
proteins has proven to be very difficult. Structure information is available for many GPCRs 
and the GPCRDB provides a list of about a hundred GPCR-related wwPDB entries. Most of 
these structure files, however, correspond to extra-membrane domains and of those nearly all 
GPCR RESIDUE NUMBERING
A number of general GPCR residue numbering schemes have been suggested and used 
over the years. These all allow consistent residue numbering across multiple proteins, 
independent of their sequential numbers. The underlying principle is that residues with 
the same general residue number have equivalent locations in their tertiary structures 
and consequently in the multiple sequence alignments. One of the first proposed 
schemes was the Oliveira numbering scheme (also known as the GPCRDB numbering 
scheme). In this scheme, residues get a 3-digit residue number, where the first number 
refers to the helix, and the second two indicate the position in the helix, where the most 
conserved residue in each helix is rounded to a near multiple of ten (this scheme is used 
in this review).
A second numbering scheme is the structure-based numbering system of Joyce 
Baldwin. This system identifies a residue on the basis of its location (Latin number) 
within each TM helix (roman number). Notably, using the structure-based, Baldwin 
numbering system, residue 13 in each of the seven TMs line up in the middle of the 
TMs.
A third scheme, and arguably the mostly used scheme, is the Ballesteros and 
Weinstein numbering scheme. Here, residue numbers are in the format ‘TM.n’, where 
the number before the period indicates the number of the transmembrane helix, and 
the number after the period indicates the residue position with respect to the most 
conserved residue position in the helix, which gets the number 50.
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are extra-cellular. In addition to the inherent instability of GPCRs, one of the major problems 
is expressing GPCRs in large enough quantities in a form suitable for crystallization. For the 
determination of the structures that came available since 2007, it was in all cases necessary to 
jump through quite a large number of hoops to artificially stabilize the proteins. 
In contrast to other fields where structures are leading experiments, in the GPCR field 
experimental data such as site-directed mutagenesis experiments, affinity labeling techniques, 
and ligand binding studies (including so-called ‘2D mutations’ (82, 83), whereby the receptor 
and ligand are mutated in tandem, also called the ‘Gold Standard’) are leading the way in 
understanding the relation between GPCR sequence, structure, and function.
Figure 2. Bovine rhodopsin structure (62), PDB ID 1F88). Helices are shown in blue, strands in red, 
loops and very irregular helices in various shades of green, and retinal in yellow. Heavy metal atoms 
and sugar groups are left out for clarity.
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RHODOPSIN
Rhodopsin was the first, and for a long time, the only GPCR structure available. In 2000 
the first structure was published (62) and later a number of additional structures followed. 
The significance of these events can hardly be underestimated, as they provided a framework 
for the understanding of a large body of experimental data that was available for a long time 
already.
The fact that rhodopsin was the only structure available for seven years is mainly due to 
the fact that rhodopsin is available in large amounts from bovine eye rod preparations, and 
due to the fact that rhodopsin is relatively stable compared to other GPCRs. Rhodopsin is not 
a ligand-mediated GPCR, and its sequence similarity to other class A receptors is fairly low. 
Despite having an enormous impact on the GPCR field, the rhodopsin structures were less 
suitable for modeling ligand-mediated structures than was initially anticipated (63). 
The rhodopsin structure revealed a series of -sometimes very surprising- facts: 
• Several helices are highly irregular, displaying highly uncommon features such as 
α-bulges and 310 helix parts in the middle of a helix.
• An eighth helix, immediately after helix VII, indeed runs parallel to the membrane 
surface, as predicted by Oliveira et al. (65).
• Although a few predictions to the contrary were made (84), it was generally expected that 
the arrangement of GPCR helices would globally be similar to that of bacteriorhodopsin, 
and many models were constructed based on this concept (61, 60, 85). Even though the 
global helix packing agreed with in silico predictions, all homology models were too far 
off to have been of any use for structure driven drug design (63).
• By far the largest surprise in the bovine rhodopsin structure was the fact that the IV-V 
loop, or extracellular loop 2 (ECL2), did not stick-out into the extra-cellular space, but 
rather was tucked away between the transmembrane helices as a β-hairpin. This was 
unexpected, especially because no other protein in the PDB database contains a loop 
that folds inside/in-between the rest of the protein. This observation, however, did solve 
one of the larger problems modelers had to deal with, namely, how to model the bridge 
between the cysteine in helix III that resides two helical turns deep into the membrane 
and the cysteine in the loop IV-V that was generally expected to be located outside the 
membrane region. 
LIGAND-MEDIATED GPCRS
It was not until the end of 2007 that the structures of the first ligand-mediated GPCRs were 
successfully determined. Almost simultaneously, two structures of the β2-adrenoceptor were 
published (67, 68), soon to be followed by the structures of the β1-adrenoceptor (69) and 
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the A2A-adenosine receptor (71). In contrast to the crystallization of rhodopsin, obtaining 
ligand-mediated GPCR crystals is very difficult, because GPCRs contain unstructured 
regions, and tend to cycle between various conformations spontaneously (86). To obtain high 
quality crystals, the receptors must be very stable and of a conformational homogeneity. To 
achieve this, a number of different tricks were applied. This includes the use of antibody 
complexes (67), fusion proteins (71, 68), tight binding ligands (67, 71, 68, 69, 87) and 
stabilizing mutants (69).  Although impressive, when interpreting a receptor structure model 
it is important to keep in mind the fact that in GPCRs there is an intricate relation between 
stability and the different aspects of receptor function.
When comparing the now available structural information, the first thing that one notices 
is the similar overall architecture of the transmembrane segments. While the helices of the 
different structures are remarkably similar, the differences at the extracellular side are very 
large. The differences are present both in the structure of this region as well as the interactions 
with the ligands. 
It is important to keep in mind that when one looks at a crystal structure, this structure 
does not need to be in the orientation that the molecule would have under physiological 
conditions. When looking at TM1 in the β1-adrenoceptor (figure 3), we can see a very strange 
helix conformation. This peculiarly shaped helix has not led to much excitement in the GPCR 
field, because everyone ‘knows’ that such helices do not occur in vivo and that this strange 
conformation is caused by contacts in the crystal. 
Crystal contacts do not always have such large effects, but it is wise to be aware of the 
effects these contacts can have and keep this effect in mind when interpreting a structure. We 
have shown the crystal packing interactions of a single receptor unit in the 2VT4 structure in 
figure 5. It can be seen that the amount of crystal contacts is very large.
Figure 3.  Abnormal helix bending of TM1 
(orange) in 2VT4.
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When the crystal structures of the non-rhodopsin GPCRs came out, the helix in loop IV-V 
caused a lot of excitement, as this was a surprising feature. This region, however, is a region 
that has many crystal packing interactions. In figure 4, we have coloured the regions that 
form contacts in the crystal for a number of GPCR structures. This figure clearly shows that 
Figure 4. Top: 2 structures of bovine rhodopsin (left Palcewski 1F88, right Schertler 1GZM) Bottom 
left β2-adrenoceptor, bottom right adenosine α2a. Helices are blue, strands red, loops and turns several 
shades of green, the ligand yellow, and purple bars indicate a contact with a partner in the crystal.
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the extra-membrane areas, and especially the extra-cellular areas, are very involved in crystal 
packing interactions. Because of this, we must be cautious when interpreting these structural 
features, and be aware that they do not have to be an accurate representation of the ‘real’ 
orientation of these parts. This implies that we cannot be certain about the spatial location of 
these areas, and, perhaps even worse, we cannot even be certain if they have any structure or 
that they are disordered and got ordered by binding either the ligand or the crystal partners, 
or both.
On the other hand, the fact that the helix in loop IV-V is present in both the β1-adrenoceptor 
structure (2VT4) and the β2-adrenoceptor structure (2RH1) does provide support to the 
argument that these structural features in loop IV-V are real. However, loop IV-V is thought 
to have a number of different functional roles (ligand binding, ligand selectivity, roles in 
activation), implying that loop IV-V is not present in one static conformation. It is more likely 
that this loop can exist in a number of conformations. This in turn implies that little energy 
is needed to change the orientation, which brings us back to the argument that especially in 
these regions crystal contacts can have great influence on the orientation of these elements 
in the crystal. 
Figure 5. The β1-adrenoceptor (2VT4) crystallizes as a tetramer. This figure uses the same colouring 
scheme as figure 4, but now the three partners in the crystallized asymmetric unit are shown as a purple 
cartoon and a 10 Å thick layer of residues in the crystal partners is drawn in thin purple lines.
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The ligands bound to the adrenoceptor structures are both inverse agonists, meaning that 
they suppress the constitutive activity displayed by the receptor by stabilizing the inactive 
state. The ligand bound to the α2-adenosine receptor is an antagonist, meaning that this 
compound has no influence on the constitutive activity of the receptor, but just prevents the 
receptor from being activated by endogenous ligands. 
The different effects of these compounds must be visible in the structures, and one 
would expect the inverse agonists, which have to alter the receptor’s conformation, to have 
substantially more interactions with the receptor’s active site than the antagonist, which 
basically just needs to sit ‘in the way’.
The different binding modes of these ligands are illustrated in figure 6. This clearly shows 
that the antagonist compound does not have a lot of interactions within the binding pocket (it 
is even partially located outside the binding pocket), whereas the inverse agonists are firmly 
located deep in the binding pocket and having intensive interactions with the receptor.
In comparison with rhodopsin, the extracellular region of the adrenergic receptors is very 
open. The most prominent feature, which came as a surprise to many, is the existence of a 
short helical segment in the second extracellular loop. In the adenosine structure this small 
helix is not present. Rather, the presence of four disulfide bridges results in one part of the 
extracellular domain to be highly ordered, forming a small β-sheet, whereas another part 
of ECL2 was not visible in the electron density maps due to high flexibility In both the 
adrenergic structures and the adenosine structure, the last few residues of ECL2 are located 
right above the ligand-binding pocket. 
The extracellular region, and especially the second extracellular loop, is thought to be 
Figure 6. The active site cavity in 
the 2VT4 β1-adrenoceptor shown in 
yellow. The inverse agonists in the two 
adrenoceptor structures (2RH1, 2VT4), 
after superposing them using only the 
seven helices, are shown respectively as 
blue and red ball & stick models. The α2-
adenosine antagonist in 3EML, again after 
superposing the structure on just the seven 
helices, is represented by purple balls. 
The inverse agonists have interactions 
deep down in the binding pocket while the 
antagonist seems to be ‘just in the way’, 
higher up in the pocket.
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of great importance for a lot of functional aspects. It contains a conserved cysteine bridge, 
which is the most conserved aspect throughout all GPCR families. This cysteine bridge, 
paradoxically, connects the most conserved region to the most variable part of the receptor 
(ECL2).  Because of its conservation it must have an important function, which makes it all 
the more important to learn everything possible about its structure.
FROM SEQUENCE TO STRUCTURE 
The sequences of the transmembrane regions of GPCRs can be aligned very well, due to 
the presence of a number of very conserved residues, providing ‘anchors’ for the sequence 
alignment. The loop regions, on the other hand, are notoriously difficult to align. Very little 
structural information is available for the loops, and the sequence variability between receptor 
subtypes is very large, both in terms of residue contents and in terms of size. 
In the latest release of the GPCRDB (88), the stretch of residues around the conserved 
cysteine in loop IV-V (ECL2) has been included in the alignments. The previous release of 
the GPCRDB, dating back a few years, did not contain this information yet. In the hope to 
shed light on the strange conservation patterns of loop IV-V and the cysteine bridge, we have 
investigated the conservation and correlation patterns of the cysteines present in the second 
extra cellular loop of a subfamily of the Class A receptors, the amine receptors. 
THE CONSERVED CYSTEINE BRIDGE IN THE EXTRA CELLULAR DOMAIN
It has been long observed that there are two conserved cysteine residues in the extracellular 
half of nearly all class A GPCRs. The number of cysteines present in the extracellular regions 
Figure 7. The length (in residues) of the stretch of residues from C470 to the start of helix V. For each 
amine subfamily the minimum and maximum observed length is shown.
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(including the highly conserved cysteine at the beginning of TMIII, C315) varies. It has 
been hypothesized that at least one covalent bond between two cysteines is conserved for all 
Class A GPCRs, and that many Class B and Class C also have a similar, conserved bridge. 
Looking at the alignment of the amine receptor family, both C315 and C470 are extremely 
well conserved. 
For a number of GPCRs it has been experimentally determined that C315 and C470 form 
a disulfide bridge. Scholl and Wells (89) showed that the effect of mutating either of the 
two cysteines in the adenosine A1 receptor leads to a complete loss of insertion into the 
membrane. The same experiment performed in the muscarinic ACM1 receptor in rat showed 
the same results (90).  Direct evidence for the existence of a C315-C470 disulfide bridge in 
the β2-adrenoceptor and the adenosine receptor came with the publication of their crystal 
structures. 
LOOP IV-V, CYSTEINE BRIDGES AND LIGAND BINDING
Cysteine 315 is located at the beginning of TMIII. Based on the common overall TM 
architecture of GPCRs with known structure we can be fairly certain where this residue 
is located with respect to other conserved elements. Because of the covalent link between 
C315 and C470, we now can also position a part of the second extracellular loop in three-
dimensional space, despite the fact that this loop is extremely diverse in sequence. The 
fact that these two cysteines now can be anchored both in alignment space as well as in 
Figure 8.  The stretch of amino acids from C470 to the start of helix V is shown in purple. The cysteine 
bridge between C470 and C315 is shown in yellow.
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3-dimensional space leads to new ways of thinking about the interactions of the binding 
pocket with agonists, antagonists and inverse agonists. 
We analyzed the length of the stretch of residues from C470 to the start of helix V for all 
proteins in the amine family.  The length (in residues) is shown for each family within the 
amine receptor super family. Figure 7 shows that the length of the last part of the loop IV-V 
is fairly short for all families within the amine receptor family. Variation in lengths within 
families is a result of differences in subfamilies. I.e. the shortest stretch observed within 
the histamine family has a length of six residues and is observed in the subfamily of the 
histamine type 2 receptors, whereas all other histamine subfamilies a length of eight residues.
The fact that the last part of loop IV-V is fairly short (between 5 and 8 residues) in all 
amine receptors, and the fact that the distance from the top of helix III (C315) to the start of 
helix V must be bridged by this stretch, implies that these residues are located on top of the 
ligand binding pocket for all amine receptors, and this suggests that it must be involved in 
some aspects of ligand binding. 
In all the GPCR structures available to date, the stretch of amino acids between C470 and 
the start of helix V interacts extensively with the ligand in the ligand-binding pocket.   Due to 
the fact that both the position of C470 and the start of helix V are known, we can now assign 
with great confidence a new part of the ligand-binding pocket. This is illustrated in figure 8, 
where the part of loop IV-V that is possibly interacting with the ligands is shown in purple. 
All structural and much functional data that are available today show that residues 472, 
(sometimes also 473) and 474 interact with the bound ligand. Figure 9 shows the residues 
472 and 474 in the β2-adrenoceptor structure 2RH1 (68) interacting with the ligand. 
In the adenosine α2 receptor the situation is very similar. Kim et al (91) showed that the 
mutation E473A in the α2 adenosine receptor led to substantial changes in ligand binding 
Figure 9. Residues of the distal part of 
loop IV-V interacting with the bound 
ligand in the β2-adrenergic structure 
(2RH1).
30 | CHAPTER 1
potential. This is in line with the α2 adrenoceptor structure, which shows that E473 interacts 
with the bound ligand (see figure 10). Note that here the orientation of the ECL2 is slightly 
different from that in the 2RH1 structure, exposing residues 472 and 473 to the ligand, 
whereas in the 2RH1 structure residues 472 and 474 are facing the ligand.
Shi and Javitch proposed already in 2002 that the loop IV-V plays an important role in 
ligand binding in the entire amine receptor family (92). Based on the cysteine bridge that is 
present in the rhodopsin crystal structure, they modeled the DRD2 receptor and found two 
residues that were likely to interact with the ligand. Experiments (mutations to cysteines, 
followed by sulfhydryl accessibility studies) performed on the dopamine-2 receptor by Shi 
and Javitch have shown that also in the DRD2 receptor the residues 472 and 474 are part of 
the ligand-binding pocket, confirming this hypothesis (93).
It appears that residues 471 and 473 might be involved in interactions with large ligands, 
or ligands that bind higher up in the receptor. Experiments of Wurch and Pauwels (94) 
have shown that changing Q471 to leucine in canine 5HT1D enhanced ketanserin (large 
antagonist) affinity, while having no effect on 5HT (small agonist) binding. We think that this 
does not necessarily need to be an effect of the size of the ligand, but might also be related to 
the type of ligand: agonists enter deep down in the ligand pocket whereas antagonists –that 
only need to block entrance to the pocket to function perfectly- are expected to bind less deep 
in this pocket and thus are likely to contact other residues.
A number of studies have shown that mutations in the transmembrane ligand-binding 
domain did have large effects on agonist binding characteristics, but that these mutations did 
not have any effect on antagonist binding characteristics (82, 95). Zhao et al (96) showed 
that to convert the antagonist binding properties of the adenosine A1 receptor to those of 
the adenosine A2 receptor only three residues had to be mutated: residues 471, 472 and 473. 
This study also showed that mutations in the second extracellular loop do affect antagonist 
binding, but not agonist binding. 
We now have seen examples of what is very likely to be a common theme in amine 
receptors. The conservation patterns for the various cysteine residues observed in the 
Figure 10. Residues of the distal 
part of loop IV-V interacting with 
the bound ligand in the α2 adenosine 
receptor (3EML).
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alignments accurately reflect the observed cysteine bridges in the available crystal structures 
and agree with available experimental data.The residues after the conserved C470 are an 
integral part of the ligand binding pocket and can influence ligand binding properties as much 
as any ligand binding residue in the transmembrane domain. This knowledge is therefore of 
great significance for homology modeling and drug docking studies. In addition, this feature 
offers new routes to elucidating the reasons for the previously unexplained specificity for 
certain GPCR subfamilies. 
THE FUTURE
Where do we go from here? To move into a more rational mode of drug design we should 
much better understand the sequence – structure – dynamics – function relations of GPCRs. 
What are the important questions that should be answered to get us really further in terms 
of this understanding? What is the role of GPCR dimers, is dimer formation a regulatory 
mechanism or is the main role increasing the combinatorics of signaling? Or both? How 
do sequence differences relate to functional differences? Why are receptors so promiscuous 
when it comes to binding G proteins? The number of questions is still large, and a revival of 
the pharma industry critically depends on many answers in many of these fields.
The GPCR field has seen its share of bad models and models that were based on the 
selective use of references. Most models, either 3D models or mental models were backed up 
by carefully selected mutations. But a few things are clear. Figure 1 shows the generic GPCR 
situation. Most GPCRs show a low constitutive level of activity. Without any ligands they 
work at a fraction of their maximal activity. Figure 11 shows a very generic dose-response 
curve.
Inverse agonists move the arrow in figure 11 to the left and agonists to the right. All a 
pure antagonist needs to do is to avoid that agonists or inverse agonists can bind. So, a small 
molecule is most likely an antagonist if it binds in the upper half of the ligand-binding pocket 
where is only sits ‘in the way’ but doesn’t aid whatever processes (inverse) agonists trigger.
Figure 11. Generic dose-response curve. 
The (inverse) agonist dose of zero is 
indicated by an arrow.
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Much evidence points in the direction that GPCR activation requires partial disruption of 
the structure at the cytosolic side (97-99). This disruption can be achieved by mutations, by 
over-expressing G proteins, or by ligands, so that we can conclude that there isn’t one specific 
active conformation, but that there are many conformations that can bind and activate the G 
protein; perhaps the active forms are partially unfolded, an hypothesis that is supported by 
the lack of visible structure in the cytosolic domains in all GPCR structures solved so far. 
The fact that the latter observation was predicted by Oliveira et al in 1999, before any GPCR 
structure information existed, shows the power of mental models for GPCR research.
Many models have been published over the years that place GPCR activation in schemas 
that are variations on the theme R → R*. These schemes can be rather complicated and 
sometimes involve multiple, interacting thermodynamic cycles. Whatever model we come 
up with, in the end amino acids will have to do the work, in other words, models should not 
disagree with realities such as the laws of thermodynamics. Unfortunately, in nearly all cases 
the authors of R → R* models discuss GPCR activation as a series of consecutive steps such 
as “ligand binding causes a structural change that causes G protein binding”. Although useful 
for some lines of research, such models are wrong and often such a simplified model confuses 
more than that it clarifies. Obviously, ligand binding, G-protein binding, dimer formation, 
and even binding proteins involved in the down regulation all happen synchronously while 
some of these binding processes strengthen each other; e.g. positive cooperativity between 
agonist and G-protein binding because the agonist stabilizes the receptor conformation that 
is good for G-protein binding and G-protein binding stabilizes the conformation that is good 
for agonist binding. In other cases, processes compete. 
Another grand question is what actually happens residue by residue when a ligand or a 
G protein binds? Given that GPCRs are constitutively active at a measurable fraction of 
their maximal activity (which should be read as that there is at any moment of time a certain 
fraction of all receptors fully active while the majority is inactive), it seems most likely 
that all processes that are involved in activation are on-going all the time. Ligand binding, 
G-protein binding, etc., just shifts those equilibriums. Do residues flip from one rotameric 
state to the other as suggested by Balasteros (100), or do whole helices move as was observed 
by Farrens and coworkers (101), and in silico predicted by Fanelli (97) and later, in silico 
again coupled to ligand binding by Abagyan et al (102)? We suggest that there are a few 
mechanistic concepts shared between all GPCRs. One is the coupling to the G proteins that, 
looking at the high level of promiscuity, must be done highly similarly by all GPCRs; perhaps 
via the Arg340 salt bridge with the conserved aspartic acid in helix V of the G proteins, 
as suggested by Oliveira et al in 1999. The other common concept must relate to the ultra 
conserved cysteine bridge between the cysteine near the extracellular side of helix III and the 
cysteine in the loop IV-V. This cysteine bridge can ‘feel’ if a G-protein binds via its partner 
in helix III, and it can ‘see’ the ligand via its partner in the loop IV-V. We therefore suggest 
that, one way or another, this cysteine bridge plays an important role in the motions of amino 
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acids, helices, and domains that are related with signaling.
We don’t know yet why GPCRs form dimers. This can be related to regulation, to an 
extension of the signaling options, or, most likely, a combination of these two. Nevertheless, 
we can be certain that there must be ‘communication’ between the monomers in the dimer. 
Both the combinatorics- and the regulation hypothesis require that the one monomer knows 
the state of the other monomer in terms of ligand binding and G-protein coupling. Given the 
fact that both ligand binding and G-protein binding can be ‘felt’ by the conserved cysteine 
bridge, it doesn’t seem very farfetched to hypothesize that this cysteine bridge is also involved 
in dimer communication. How this is done, and which residues are involved is still unknown. 
We might speculate that the conserved Trp420 at the membrane surface of helix IV has a 
role in dimer formation. In that case, disturbance of the loop IV-V by whatever mechanism 
might also be ‘felt’ in helix IV and then thus also in the dimer interface. However, a role for 
helix VIII in dimer communication also cannot be excluded. The location at opposite sides of 
the helix bundle of Trp420 and helix VIII makes it unlikely that both suggested mechanism 
operate in tandem. 
There are enough questions to keep us all busy for decennia to come. Data from many 
different sources has played a role in much of the research we have cited in this article. We 
have collected most GPCR-related data in the GPCRDB. And we will keep working on this 
system. A thorough understanding of the sequence - structure - dynamics – function relations 
of GPCRs is so important for our future quality of life that our whole effort would already 
pay off if just one day, one person is browsing the GPCRDB and gets one idea that brings 
us one step closer to answering one of the main questions left regarding these intriguing 
molecules.
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INTRODUCTION 
The need for information about the functional roles of the elements comprising the 
human genome became larger than ever with the completion of its sequencing in 2003 (1-3). 
BioSapiens (4) is contributing to the ENCODE (5) program, which is providing a biologically 
informative representation of the human genome using high-throughput methods to identify 
and catalogue all functional elements. The ENCODE pilot project consisted of annotating 
1% of the genome (6). The presently ongoing functional annotation of the other 99% will be 
a crucial next step for many, diverse fields of science. 
The best, and most often used, tool for functional annotation is a direct sequence comparison 
between the homo sapiens sequence with unknown function and homologous sequences in 
other species for which the function is known. Most often this is done with BLAST or PSI-
BLAST, but threading methods and profile–profile comparison methods are also often used. 
This transfer of information from one protein to the other does not stop with the protein’s 
function. Types of information that can be transferred when a sequence alignment with a 
well-studied protein can be made include; dimer interface residues, active site residues, post-
translational modification sites, metal-binding sites, etc. The latter is important for research 
areas such as drug design or quantitative systems biology for which it is not only important 
what proteins do, but also how they do it. Answering that question requires that knowledge is 
obtained about the roles of individual amino acids in the various aspects of protein function. 
The use of multiple sequence alignments is not limited to just the transfer of experimental 
information. The footprints that evolution left behind in these sequences can be reconstructed 
from conservation and variability patterns, and a number of computational techniques exists 
that can harvest this information. Some of those will be discussed in this chapter. 
The final goal of most bioinformatics studies is answering biological questions that can 
widely vary in detail and complexity. Often it is needed to use all available information (3D 
structures, multiple sequence alignments, expression and distribution patterns, interaction 
information, etc.) to answer such questions. The G protein-coupled receptor (GPCR) family 
will be used to illustrate this because the GPCRDB (7-9) provides a molecular class specific 
information system (MCSIS) that holds much, heterogeneous data in a well organized and 
easily accessible form. With their 16,000 sequences, the GPCRs are one of the largest sequence 
families known to date. The additional availability of 10,000 well annotated mutations (10, 
11), more than 12,000 binding constants for ligands (12), a large number of well described 
disease phenotypes (13), genome locations and organizations, and an up-to-date annotated 
SNP database (14) make the GPCR family a great subject for inferring new information using 
a wide spectrum of bioinformatics techniques. 
INFORMATION TRANSFER 
Chothia and Lesk (15) studied the relation between sequence similarity and structure 
similarity, and they concluded that structures stay conserved in evolution much longer than 
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sequences. Sander and Schneider (16) later quantified this relation (see Fig. 1). 
A basic assumption in bioinformatics is that residues at equivalent positions in homologous 
proteins have similar functions. That implies that the function of a residue is determined by 
its location, while the residue type determines how that function is performed. A residue 
known to be in contact with the endogenous agonist in the mouse muscarinic type-3 receptor, 
for example, is most likely also involved in contacting the endogenous ligand in the human 
muscarinic type-1 receptor. Figure 5 shows an important aspartic acid that is conserved in 
all amine binding GPCRs in which it is always the counter ion for the positive amine group 
in the ligand. In the hormone receptor family, on the other hand, we always find a serine 
or threonine at this position that interacts with the ligand, while in the chemokine receptor 
family we find nearly invariably a tyrosine that interacts with the ligand at this same position. 
Carrying over information is the most elementary use of homology, but it can also be used 
to learn from the patterns of variability and conservation that evolution has left in a multiple 
sequence alignment. For example, if we hadn’t known yet that the aspartic acid in the amine 
receptors, the serine/threonine in the hormone receptors, and the tyrosines in the chemokine 
receptors all were involved in ligand binding, could we then have derived that knowledge 
from the multiple sequence alignment? 
Figure 1. The Sander and Schneider plot. If the percentage sequence identity at a given alignment 
length is above the curve, it is safe to transfer information and, for example, to build a 3D model by 
homology. In this example a user requested information about a protein that can be aligned with 60% 
sequence identity (over 100 amino acids) to a well-studied protein with known structure. The blue dot 
is above the ‘safe threshold curve’ so modelling is possible, and thus, all kinds of information transfer 
regarding the roles of individual amino acid is also possible. 
44 | CHAPTER 1
But first we will discuss a system to generate multiple sequence alignments in a wider 
context, the so-called molecular class specific information system. Such a system is not 
strictly needed to produce and analyse multiple sequence alignments, but it often is very 
beneficial to have all available information easily available. 
MOLECULAR CLASS-SPECIFIC INFORMATION SYSTEMS 
Studies that involve carrying over information from one protein to the other seem simple 
at a first glance. However, the amount of data that needs to be collected from heterogeneous 
sources, converted to syntactic and semantic homogeneity, validated, stored, and indexed, is 
enormous. And the data sources from which relevant data can be collected grow continuously, 
both in volume and in number. The enormous amount of data that is entered each day into 
databases and the literature is outstripping the ability of experimental scientists to keep pace. 
Large monolithic databases like SwissProt, EMBL, PDB, etc., are invaluable for biomedical 
scientists. Most scientists, though, tend to use many databases while concentrating on one 
molecule, or one family of molecules. The main aim of molecular class-specific information 
systems is to gather heterogeneous data from across a variety of electronic sources in order 
to draw new inferences about the target protein families. The number of experimental data 
types (primary data), is limited, but there are hardly any limits to the number of data types 
that can be derived computationally (secondary data). It is therefore important to consider the 
questions that the system should help answering when adding more and more computational 
data. 
G PROTEIN-COUPLED RECEPTORS 
Over 1000 human genes encode G protein-coupled receptors. The ligands that bind 
and activate these receptors are heterogeneous and include photons, odours, pheromones, 
hormones, ions, neurotransmitters, and proteases. GPCRs transmit signals from outside the 
cell to amplification cascades controlling sight, taste, smell, slow neurotransmission, cell 
division, etc. All GPCRs form a seven transmembrane (7TM) a-helical bundle, connected 
by three intracellular and three extra-cellular loops. Within some GPCR families the overall 
sequence identity between family members can be lower than 25%. 
GPCRs are a major target for the pharmaceutical industry as is reflected by the fact 
that more than 25% of all known drugs act on a GPCR (17). Some of the major questions 
relevant to GPCR pharmacology include the following: What residues are critical for ligand 
binding and for the activation of G-proteins or other proteins? What do different receptor 
families have in common with regard to their activation mechanism? And which residues are 
responsible for the differences and should thus especially, or especially not be influenced by 
potential drug molecules? The GPCRDB is designed to be a data storage medium, as well 
as a tool to aid biomedical scientists with answering questions like these by offering a single 
point of access to many types of data that are integrated and visualized in a user-friendly way. 
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The primary data in the GPCRDB are sequences, structures, and mutation and ligand 
binding data. Sequences are automatically imported from the SWISS-PROT and UNIProt 
databases (18). cDNA sequences are imported form the EMBL (19) databank. Structure 
data is retrieved from the PDB (20). Mutation data is obtained from the manually curated 
tinyGRAP (10, 11) database, as well as mutation data extracted from online literature using 
an automated procedure (21). SNP data comes from the NAVA system (14). 
The data organization in the GPCRDB is based on the pharmacological classification of 
GPCRs and the main way to access the data is via a hierarchical list of known families in 
agreement with this classification. For a specific family, users can access individual sequences, 
multiple sequence alignments (MSAs), the profiles used to perform the latter, snake-like 
diagrams and phylogenetic trees. Two-dimensional snake-like diagrams are used to represent 
and combine GPCR sequence, 2D structure and mutation information (22). Furthermore, 
entries can be retrieved using a query system, and data can be saved either using the WWW-
pages or via ftp access. One important dissemination and inference facility in the GPCRDB 
is a large series of Multiple Sequence Alignment (MSA) analysis tools. 
EXTRACTING INFORMATION FROM SEQUENCES 
During evolution certain residues can mutate almost without restrictions while other 
residues are so important for the function of the protein that they have never mutated. There 
are also residue positions that tend to be conserved in subfamilies but different between 
subfamilies. Different parts of the molecule are under different types of evolutionary pressure, 
leading to different patterns of conservation and variation that can be analyzed to learn more 
about the role of the individual residue positions. 
Residue conservation has been evaluated in multiple sequence alignments by means of 
variability (number of different amino acids found), Shannon entropy, and variance-based and 
score-matrix indices (23-25). The patterns of conservation in proteins have been described 
Figure 2. Cartoon representation of the human β2-
adrenoceptor structure. 
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as the fingerprints left by evolution in the structure (26), and they have been used for quality 
assessment and refinement of multiple-sequence alignments (24). Conserved residues are 
often clustered in certain regions of protein structures, sometimes at universally conserved 
positions (27), so called because they can form a motif characteristic of the fold. Sometimes, 
these positions are also found in the corresponding sequence segments of analogs, and their 
location often coincides with that of supersites (28). Many groups have used the identification 
of conservation patterns in proteins as a method to search for function. Some of these 
methods are based on energy calculations on proteins of known structure looking for charge 
and shape complementarities in protein and ligand surfaces that are thought to interact (29-
35). Kufareva et al. (36) predicted binding interfaces from single proteins with a known 3D 
structure. Other groups have predicted functional motifs using principal component analysis 
(37), analysis of physicochemical descriptors to score protein-protein interactions (38, 39), 
search for motifs in Blocks databases (40), or alignment of hinge regions (41). Some methods 
combine evolutionary information extracted from multiple sequence alignments with three 
dimensional structure information (42-45). 
CORRELATED MUTATION ANALYSIS 
It seems obvious that a residue conserved in a sequence family must be involved in a 
function common to that family, while a residue conserved only in subfamilies is likely to 
have the same functional role in all those subfamilies. This concept can work in two directions: 
deductive and inductive. In both directions correlations of conservation and variability 
patterns in a MSA are being analyzed. Most studies where these patterns are correlated with 
known facts tend to be deductive, while most studies that correlate these patterns against each 
other tend to be inductive, but scientific creativity can easily blur this division. 
The term correlated mutation refers to the tendency of pairs of residue positions to either 
mutate in tandem or stay conserved together, and correlated mutation analysis (CMA) is a 
technique for the identification of these patterns in a MSA. It has been originally described 
(46, 47) to predict physical contacts within proteins that could be used for structure prediction 
(see Fig. 3), but that is beyond the scope of this chapter. CMA was proven to be a powerful 
technique for predicting amino acid contacts at protein–protein interfaces, since correlated 
mutations tend to accumulate at the protein surface (48-50). Kuipers et al. (51, 52) and 
Oliveira et al. (53) determined correlations between residue positions and ligand binding 
characteristics of receptors to determine which residues were involved in that ligand binding.
Correlation studies on GPCRs 
Kuipers et al. (51, 52) and Oliveira et al. (53) determined the correlation between the 
absence and presence of residues and the binding or not binding of pindolol to GPCRs from 
the Class-A amine sub-family. In this example of deductive use of CMA they observed 
one asparagine in helix VII that correlated perfectly. This asparagine was mutated in the 
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serotonin 1a receptor to a valine which resulted in abolishing the binding. When an extra 
methyl group was introduced in the pindolol molecule, at the position where the interaction 
with the asparagine was predicted to take place, the binding was regained. This experiment 
is illustrated in Fig. 4. 
The recently solved β2-adrenoreceptor structure contains an inverse agonist that is highly 
similar to pindolol, and that has exactly the same active group between the ring system and 
the nitrogen as pindolol. The β2-adrenoceptor sequence is very similar to the sequence of 
the serotonin 1a receptor, and the β2-adrenoceptor also binds pindolol well, and it has an 
asparagine at the same position as the one mutated in the serotonin 1a receptor. Figure 5 
shows the location of the inverse agonist and this asparagine in the β2-adrenoceptor structure. 
Figure 3. Illustration of correlated mutation analysis. Several residues are shown in their structure 
context, in this example, two nearby a-helices. For these residues, six sequences (a–f) are shown as 
a multiple alignment. Positions 1 and 2 show correlated substitutions (connected by arrows), as do 
positions 5 and n. 
Figure 4. (a) The original binding mode of the ligand. (b) The mutation Asn386Val resulted in a loss of 
binding affinity, but when a methyl group was added to the ligand, binding affinity was restored.
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This prediction was made more than 13 years before its first experimental confirmation, and 
it was based on a deductive correlation study of heterogeneous data: an MSA and ligand 
binding studies. This example beautifully illustrates the deductive power of the CMA method. 
Oliveira et al. (48) used CMA in an inductive way to predict residue relations in GPRCs. 
Their reasoning was simple: if the mutation patterns of residue positions are strongly 
correlated, i.e. give a strong signal in a CMA analysis, then those residue positions must be 
involved in a common function. Other information like the position in the structure, ligand 
binding information, or mutation studies can then reveal which function was detected. When 
it was observed that correlated mutations accumulate at protein surfaces, the technique was 
used as a new approach to protein–protein docking and the prediction of protein–protein 
interfaces (49). The rationale behind this is that mutations at one of the interfaces must be 
compensated by a mutation in its counterpart. Gouldson et al. (54) used such intermolecular 
CMA studies to predict that many GPCRs form dimers. This idea was also used to identify 
homo-and hetero-dimerisation interfaces for GPCRs (54-60) as well as for G-protein – GPCR 
interfaces (53, 54, 61-64). 
EVOLUTIONARY TRACE METHOD 
The evolutionary trace method (ET) by Lichtarge et al. (42, 65, 66) is a special case of 
CMA. It can be used deductively and inductively. It predicts functionally important residues in 
a protein family given a three dimensional protein structure and a MSA. The starting point of 
the ET method is a MSA, which must contain sequences of a protein family with divergently 
related members. The tree is then partitioned into sub-groups corresponding to functional 
classes. A consensus sequence is then generated for each sub-group, and these sequences are 
compared. Residue positions that are conserved within sub-groups, but vary among them 
are called class-specific-or trace-residues. The rank of a specific residue is determined as the 
number of tree divisions needed for a residue to become a trace-residue. The trace residues 
are mapped on a 3D structure, and functional sites are indicated by the clustering of these 
Figure 5. The binding mode 
of the pindolol analogue in the 
b2-adrenergic receptor. The 
asparagine indicated by Kuipers 
et al. as responsible for pindolol 
selectivity is shown, as well as 
an aspartate that is absolutely 
conserved and essential for 
ligand binding 
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trace-residues. The ET method is illustrated in Fig. 6. Despite rather different approaches, 
CMA and ET are highly similar in what they can detect from an MSA. The ET method is 
restricted by the need to use a phylogenetic tree, and consequently cannot detect correlations 
that do not perfectly follow the tree branching pattern. 
Evolutionary trace analyses have been successfully applied in a number of studies (42, 65-
68). Dean et al. (67), for example, used the ET method to confirm that GPCRs might actually 
be domain swapped dimers. Sowa et al. (69) performed an ET analysis of 42 members of 
the RGS (regulators of G-protein signalling) family that revealed a novel functional surface, 
located next to the interface between the RGS and Ga. It was predicted that the G-protein 
effector subunit PDEg would bind the RGS-Ga complex by straddling both Ga and the newly 
discovered functional site. Indeed, mutagenesis of RGS based on the ET prediction revealed 
that three residues out of the six selected for mutagenesis had profound effects on the 
regulation of activity by PDEg. After the ET-based mutagenesis was completed, the crystal 
structure of RGS9Gi/taPDEg was solved by Slep et al. (70) and confirmed the predicted 
position of the PDEg interaction site on the RGS domain. 
These studies suggest that ET can be used for understanding protein functions if it can be 
applied at a large scale. Madabushi et al. (68, 71) streamlined the input preparation for an 
automated ET implementation. They also developed formal statistics to assess the significance 
of trace clusters, and tested its performance on proteins with diverse folds, structures, and 
Figure 6. The ET method. (a) 
The sequences in a protein 
family are aligned and a tree is 
generated. (b) For each class, a 
consensus sequence is created. 
The consensus sequences are 
compared, and trace residues 
are selected. (c) The three 
dimensional protein structure is 
used to map the trace residues. 
A functional site is indicated 
by the clustering of these trace 
residues. 
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evolutionary history. 
The ET method is by no means the only method available that performs this kind of 
analyses; we simply took ET as it is representative for a large class of methods. A number of 
other good tools and methods have been published that use positional comparison of amino 
acid types (e.g. TreeDet (72); SDPpred (73); etc.). 
ENTROPY-VARIABILITY ANALYSIS 
Conservation and variability patterns can be correlated with external information or with 
each other. Oliveira et al. (74) have developed a sequence analysis technique that harvests the 
information that is implicitly present in the variability and conservation at one single position 
in a MSA. This method is based on the combination of two sequence variability measures. 
The first is a Shannon-type entropy, while the second, variability, is simply the number of 
different amino acid types observed at one position in a multiple sequence alignment. They 
showed that there is a relation between the function of a residue and its location in a plot of 
entropy versus variability. 
The method was tested on four protein families for which very many sequences are available 
Figure 7. Entropy-variability plot indicating the relation between variability patterns and residue 
function. Residues in area 11 perform the main function of the proteins (G-protein binding in GPCRs). 
Residues in area 12 provide support to the residues in area 11. Residues in area 23 are involved in 
modulator binding (ligand binding in GPCRs). Residues in area 22 tend to be located between residues 
in the areas 23 and 12 and tend to be responsible for communication between these two sites. Finally, 
residues in box 33 are seldom found involved in any function. 
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and for which the function of nearly all residues have been well-established experimentally: 
globin chains, GPCRs, ras-like proteins, and serine-proteases (74). Positions related to the 
main function, related to co-factor or regulator binding, positions in the core of the protein, 
and positions not associated with any known function all tend to cluster in separate areas 
in the entropy-variability plots (see Fig. 7). This entropy-variability method is inductive; 
it can, for example, predict that a residue is involved in signal transduction, but additional 
information is needed to determine which signal that is, and how the signaling is done; or it 
can determine that a residue is involved in ligand/modulator binding but not what ligand or 
modulator is bound or how this binding takes place. 
Folkertsma et al. (75) used entropy-variability analysis together with structure and mutation 
data to find the functions of residues in the ligand-binding domain of nuclear receptors. 
Shulman et al. (76) obtained similar results using statistical coupling analysis, a powerful but 
much more complicated method that produces results that are highly similar to the entropy-
variability analysis method. 
SEQUENCE HARMONY 
Members of the GPCR family can be activated by a wide variety of ligands. These ligands 
range from a few atoms to large molecules. Certain residue positions in the ligand binding 
area therefore tend to be involved in ligand binding in just a few GPCR families. To find such 
positions, a method is needed that searches for residue positions that are conserved in certain 
families, but not in others. The sequence harmony (SH) method was developed by Pirovano 
and Feenstra (77, 78). In contrast to CMA methods mentioned above, which focus on sites 
that are conserved in one or both groups and subsequently select those sites that are different 
between these groups, the sequence harmony method can also detect sites that are not highly 
conserved within each of the groups. The input of the SH method is a multiple sequence 
alignment, which is split into two groups. For each group, as well as for the combined groups, 
entropies are calculated. The SH score is calculated using these entropies. Ye et al. (79) used 
the sequence harmony method to find GPCR residues that seem important for the function 
of just a few of the many GPCR families while being functionally unimportant in all other 
classes. 
DISCUSSION 
If we want to fully harvest the wealth of information available in the human genome, 
determining the function of proteins is the first and most important thing to do. After all, how 
can we make progress in system biology if we don’t know what to do with large numbers 
of important proteins? But after we have determined what a protein does, the natural next 
question is how it does it. We listed a small, but representative, series of commonly used 
techniques that have in common that a multiple sequence alignment is at their hearth, and we 
showed what these techniques could do in the field of GPCR research. Correlation studies 
and entropy/variability measures often provide a lot of information. This might not always be 
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the exact and correct answer to the questions asked, but these methods most certainly do steer 
experimental work very well. The strength of these methods was perhaps best illustrated by 
a study that revealed individual atomic contacts between a ligand and a GPCR many years 
before the first structural information became available. 
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ABSTRACT
The GPCRDB is a Molecular Class-Specific Information System (MCSIS) that collects, 
combines, validates, and disseminates large amounts of heterogeneous data on G protein-
coupled receptors (GPCRs). The GPCRDB contains experimental data on sequences, 
ligand binding constants, mutations, and oligomers, as well as many different types of 
computationally derived data such as multiple sequence alignments and homology models. 
The GPCRDB provides access to the data via a number of different access methods. It 
offers visualization and analysis tools, and a number of query systems. The data is updated 
automatically on a monthly basis. The GPCRDB can be found online at http://www.gpcr.
org/7tm/
INTRODUCTION
G protein-coupled receptors constitute a large family of cell surface receptors. They 
regulate a wide range of cellular processes, including the senses of taste, smell, and vision, 
and control a myriad of intracellular signalling systems in response to external stimuli. GPCRs 
are a major target for the pharmaceutical industry as is reflected by the fact that more than a 
quarter of all FDA approved drugs act on a GPCR (1). GPCRs are arguably one of the most-
researched classes of proteins, but despite intensive academic and industrial research efforts 
over the past three decades, little is known about the structural basis of GPCR function. 
From about 350 genes that code for the non-olfactorial receptors in the human species (2), 
only about 30 are truly validated therapeutic targets (3), indicating this family’s immense 
potential for future drug development. The fact that GPCRs can form homo-oligomeric and 
hetero-oligomeric complexes (4) has created a lot of new challenges and opportunities in 
the rational drug design process. In addition, a number of high-resolution crystal structures 
recently became available, providing new insights in receptor structure and function and 
giving the GPCR field a big stimulus.
Researchers who focus on one particular protein or a class of proteins are confronted 
with the fact that both the number and the size of databases are expanding at an ever-
increasing pace. Although many databases like PDB (5), UniProtKB (6), KEGG (7), EMBL 
(8), GenBank (9), etcetera are invaluable for their research, for the average wet-lab scientist 
these databases are less suitable for gathering, integrating, and updating different types of 
data in an easy and efficient manner. Studies that involve carrying over information from one 
protein to the other seem simple at a first glance, however, the amount of data that needs to 
be collected from heterogeneous sources, converted to syntactic and semantic homogeneity, 
validated, curated, stored, and indexed, is enormous.
The GPCRDB is a data source that holds a large amount of heterogeneous data in a 
well-organized and easily accessible form. This data is validated, internally consistent, and 
updated regularly. In addition to being a one-stop GPCR resource, the data in the GPCRDB 
facilitates inferring new information using a wide spectrum of bioinformatics techniques. 
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The GPCRDB is a paradigm for MCSIS technology (10, 11).
NEW FEATURES
The previous release of the GPCRDB (12) was almost entirely a static website, neither 
offering much dynamic content, nor possibilities for complex interactions or the use of 
computational tools. We addressed this problem by rewriting the entire system. The use of new 
tools and modern-day e-Science technologies has resulted in improved flexibility and greater 
user-friendliness. We have updated the methods for harvesting GPCR sequences, expanded 
the number of data types available, and added new tools and services to the GPCRDB. Nearly 
all of the functionality that is offered through the web interface is also available in the form 
of web services. This allows for the easy integration of the GPCRDB in custom built tools 
and scripts or in workflow management tools such as Taverna (13) and Pipeline Pilot (http://
www.accelrys.com/products/pipeline-pilot/). All pages now offer extensive context-sensitive 
help functionality, explaining what kinds of data are displayed and how to use the available 
interactive functionalities such as searching and computational tools. 
DATA CONTENT
The contents of the GPCRDB can be categorized in three classes: primary, secondary, and 
tertiary data. Sequence data, ligand binding constants, mutant information, structural data, 
and oligomer interactions make up the experimentally determined primary data. Data types 
such as multiple sequence alignments, homology models, correlation patterns, and entropy-
variability data are inferred from these primary data, and fall in the category of secondary, or 
computationally derived data. Curator provided interpretations and other user help facilities 
make up the tertiary data category. Table 1 shows a few vital statistics about the volume of 
the data content of the GPCRDB.
Table 1. Statistics for the September 2010 release of the GPCRDB.
Sequences 27045
Families (and multiple sequence alignments) 1270
Mutations 7703
Ligand binding data 12086
Protein structures 195
Homology models 22616
Residues 11290993
Species 1521
Oligomers 115
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PRIMARY DATA
Sequences
GPCR sequences are extracted from NCBI’s NR database, which is a non-redundant protein 
sequence database with entries from a set of sequence repositories that include GenBank 
CDS translations, UniProtKB, and PDB. GPCR sequences are selected by classifying them 
against a database of Hidden Markov Models (HMMs). For each of the protein families in the 
GPCRDB a HMM is available. These HMMs are created from multiple sequence alignments 
(MSA) of the previous GPCRDB release. HMM files are created with the HMMER software 
package (http://hmmer.wustl.edu/).
As a first step in harvesting GPCR sequences we perform a BLAST search with all the 
HMM consensus sequences against the NR database. By using a very relaxed cut-off value we 
collect a large number of resulting hits, including many false positives. This step is necessary 
to limit the amount of sequences that will be used for the actual classification while ensuring 
a minimal false-negative rate. This step reduced the search space (for the September 2010 
GPCRDB release) from about 11 million sequences to about 80 thousand. These hits are 
scored against the collection of HMMs to place them in the correct family or discard them as 
not being a GPCR sequence. Additional filter steps are applied such as filtering out sequence 
fragments and sequences that contain ambiguous amino acid characters, resulting in a final 
set of about thirty thousand sequences. The corresponding database entries of the selected 
sequences are retrieved with MRS (14) and additional data such as gene names and species 
information is extracted and stored. The GPCRDB holds for each sequence one principal 
access page. Figure 1 shows an example of such a page.
The protein detail page (Figure 1) contains a panel that visualizes sequence annotations 
such as helix boundaries, cysteine bridges and glycosylation sites. These annotations are 
loaded in real time using the DAS distributed annotation system (15, 16) and are visualized 
by Dasty2 (17), resulting in always up-to-date annotations. We use the UniProt DAS server 
to retrieve sequence annotations.
Ligand binding data
Binding constants are available for a large number of GPCR-ligand combinations and are 
obtained from various sources. For each GPCR we provide links, if possible, to the ChEMBL 
(18) and GLIDA (19) databases. In addition, ligand-binding information that is obtained from 
collections from P. Seeman (20) and Organon N.V. (21) is available. Since ligand binding data 
is very hard to obtain from the literature we encourage academic and industrial researchers 
to submit their ligand binding data to the GPCRDB in order to make this data accessible to 
the scientific community.
Mutations
The GPCRDB contains a large number of well-annotated mutations obtained from different 
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sources. We have two sets of mutations that were manually extracted from literature. Mutant 
data from the tinyGRAP database (22) contains references to scientific literature describing 
point mutations as well as insertions, deletions, and chimeric receptors. A collection of 
in-house manually extracted mutant data contains a few thousand point mutations and the 
effects of those mutations on the function of the receptor. We have extracted sentences from 
the papers that qualitatively describe the effects of these mutation and we have extracted 
quantitative data such as effects on ligand binding, expression, activation, or constitutive 
activity. 
In addition to the two manually curated datasets we also have a large body of mutations 
that were extracted from the literature by the software package MuteXt (23). A sentence 
describing the effects of the mutations is available for all mutations extracted by MuteXt. 
 
Structures
Structures are obtained from the PDB. Links to structures that were re-refined in the PDB_
REDO project (24) are included. We provide manually ‘cleaned’ monomers of the major 
GPCR PDB files that have been prepared for easy casual use by the life sciences community.
Oligomers
GPCR oligomerization has been an area of interest and controversy for many years. Recently 
there has been increasing evidence that both homo-dimers and hetero-dimers play a crucial 
role in GPCR signalling (25-27). The GPCR-OKB (28) is a database that stores manually 
extracted computational and experimental information about GPCR oligomerization. Lists of 
protomers, experimental details and, where available, inferred oligomer interaction sites are 
Figure 1. Screenshot of the principal 
protein sequence page of the human beta-
2 adrenoceptor. The top table contains 
details about the protein record and 
hyperlinks to the protein family browsing 
page and other data sources that contain 
information about this protein. The 
middle table holds the sequence in which 
each amino acid is linked to its own 
residue page. The bottom table holds 
annotations that are obtained in real 
time using the DAS (15) system.  
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available for all oligomers. This data has been fully integrated in the GPCRDB, making the 
information about both GPCR protomers and oligomers readily available. 
SECONDARY DATA
Multiple sequence alignments
Multiple sequence alignments (MSAs) are available for all families. MSAs are generated 
with WHAT IF (29) for all GPCR sub-families using hand-optimized sub-family specific 
profiles. Position-specific annotations such as secondary structure information and generalized 
residue numbers are stored in the profiles and are incorporated in the alignments. The general 
residue numbers are relative to the arbitrarily selected numbers for very conserved  residues 
and motifs such as the well-known E/DRY and NPXXY motifs. Using a profile to align a 
GPCR sub-family allows for the mapping of the general residue numbers on the sequences 
that are being aligned. The result is that the residues in the TM domains, helix VIII and 
sections of the loops are labelled with a general residue number. 
For creating alignments of parent GPCR families we make use of these general residue 
numbers. For all the GPCRs that are being aligned we select all the general residue positions 
that the sub-families have in common and create the alignment by listing, for each sequence, 
the residues at the selected positions. GPCR parent family alignments are thus not built using 
standard alignment algorithms but are created by selecting residues that are likely to share the 
same position in the three-dimensional structure.
 
Homology models
Despite the recent publication of a number of GPCR structures the amount of structural 
information on GPCRs is still very limited. We have built structure models of all Class 
A receptors to at least partially fill this gap. Information extracted from the profile-based 
multiple sequence alignments is used to generate high-quality sequence-structure alignments 
between GPCR sequences and a number of experimentally determined structures. Based on 
these alignments homology models of all GPCRs have been automatically created and will be 
automatically updated as more sequences become available. Template structures are selected 
based on sequence identity and a number of structure quality criteria. The homology models 
are created with WHAT IF and YASARA (30). Models will be automatically replaced when 
new structures become available that are better templates, with better being defined as either 
being solved with higher resolution data, or as having a higher percentage sequence identity.
Correlated mutation analyses
Correlated mutation analysis (CMA) is a technique that can find pairs of residues that 
remain conserved or mutate in tandem during evolution. Residues that show correlated 
behaviour in multiple sequence alignments are likely to be functionally related, and networks 
of those correlating residues indicate functional groups (31). The rationale behind this 
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analysis is that when a mutation occurs at a functionally important site, the protein either 
becomes functionally impaired or may acquire its original or a different function due to 
compensatory mutations at one or more other positions. Correlation scores are available in a 
number of different formats for all GPCR (sub)families. 
Entropy and variability data
The amount of entropy and variability that is observed for a certain position in multiple 
sequence alignment tells something about the types of pressures exerted on that position 
during evolution (32-34). Entropy-variability data is available for each multiple sequence 
alignment in the GPCRDB. We offer this data in tabular from, entropy-variability plots (35), 
and more advanced subfamily specific two-entropy plots (45) based on the original method 
described by Ye et al. (36) (Figure 2).
TERTIARY DATA
Figure 2. Screenshot of the interactive entropy and variability page. The multiple sequence alignment 
is shown in panel A. Residues are interlinked in all page elements, clicking results in highlighted 
selections. In panel B, the approximate location of this position in the 3D model of the transmembrane 
domain of class A GPCRs is shown in red and is annotated with general residue number information. 
The orange ball in the structure model indicates the approximate location of the assumed binding site 
for low molecular weight compounds of class A GPCRs. In panel C the user can choose among four 
display modes that describe the entropy and variability of all positions in the alignment; shown is the 
entropy cluster variant.
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Residue annotations
Residues in the GPCRDB are labelled with the original Oliveira et al. (37) numbering 
scheme as well as with residue numbers from the more recent Ballesteros-Weinstein scheme. 
Use of these general residue numbers allows for easy transfer of information between 
proteins. General residue numbers are available for all residues within conserved structure 
elements. These include all transmembrane helices, helix VIII, and a few sections in the 
loops. For each residue with a general residue number a short description of its properties and 
interactions is available. These descriptions are based on a manual analysis of the currently 
available crystal structures. 
Cytoscape networks
The GPCRDB provides cytoscape (38) network files for all GPCR families. These network 
files contain the proteins of a family with distances calculated from the family alignments. 
For all proteins the protein family information, species names and the amino acid types for all 
the residues annotated with a general residue number are available as attributes. This allows 
for complex analyses, such as colouring proteins by amino acids at a certain residue position 
to compare i.e. species or sub-type specific differences.
Mutation predictions
For all positions for which a general residue number is available we have investigated the 
most likely effects of mutations at these positions. Short fragments of text have been created 
that explain for each of these positions the likely effects of the mutation on structural and 
functional levels. References to key papers in which experimental evidence for these effects 
is available are included in the fragments. Examples of such effects are the loss of ligand 
binding affinity when mutating a residue in the ligand binding pocket, the loss of G protein 
binding when mutating residues at the G protein binding interface, and increased constitutive 
activity when residues are mutated a the interface between helix III and VI. 
Workflows
We have created a number of Taverna workflows that use the web services of the GPCRDB 
as a starting point for users who want to programmatically access the GPCRDB. Workflows 
are available that use the GPCRDB BLAST service, create custom-built alignments and 
retrieve several different data types. The workflows and documentation are available via the 
myExperiment web portal (39) and are tagged with ‘GPCRDB’. We encourage researchers 
to share their own workflows via the myExperiment portal.
DATA ACCESS
The GPCRDB provides fast and easy access to all its data and information. The GPCRDB 
does not merely lists available data, but all data types are fully integrated. For example, 
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mutations are accessible via the protein detail pages but can also be found at the residue 
level. The same holds true for oligomer interaction interfaces, where details about these 
interactions are available via the oligomer pages, but also via the protein detail pages of 
interacting members, as well as via the pages of residues that are reported in the interaction. 
This tight data integration makes it a very efficient resource to use. The GPCRDB’s user 
interface allows the user to easily navigate from one data type to another and often suggests 
multiple routes to explore the data, thereby hopefully generating ideas and questions while 
the user navigates the system.
The four fundamental facilities to be provided by information systems are browsing, 
retrieval, query, and inferencing. These four types of access have been an integral part of the 
GPCRDB set-up from the beginning. The total redesign of the GPCRDB that has taken place 
the past few years has allowed us to add novel access facilities in all these four categories.
 
BROWSING
The main way to access the data is via a hierarchical list of GPCR families, which is 
based on the pharmacological classification of GPCRs (40) (Figure 3). Users can traverse 
the GPCR family tree and view or download the data for a selected family. Available data 
types include multiple sequence alignments, entropy-variability analyses, and lists of family 
members. Alignments can be viewed in multiple ways. In addition to the classic HTML view, 
the GPCRDB offers an interactive multiple sequence alignment viewer (JalView (41)), that 
can show additional information about the MSAs, supports a number of viewing and sorting 
options, and that can be used to generate phylogenetic trees. Residues for which mutation 
data is available are hyperlinked in the alignments to pages that contain more details about 
those mutations.
The pages that display data on individual proteins (Figure 1) contain a large amount of data 
and links to other data sources. Table 2 lists the remote databases that have been indexed in 
the GPCRDB. Some of these remote data are actually most easily queried via the GPCRDB. 
On the protein detail page the sequence is displayed and each residue is hyperlinked to 
its individual page where additional information is listed about that specific residue; residue 
Figure 3. Screenshot of the GPCR 
family page. The GPCR family tree is 
shown on the left with the amine sub-
family expanded. On the right-hand 
side the data for the selected family 
(adrenoceptors) is shown.
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numbers in multiple numbering schemes, available mutation data for that specific residue and 
mutations at equivalent positions, and reported oligomeric interactions. 
Snake plots are available for all proteins in the GPCRDB (Figure 4). Residues for which 
mutations are available are hyperlinked from the snake plots to pages that contain details 
about those mutations. 
Other data types such as mutations, ligand binding constants and information about 
oligomerization states are displayed when available and links are provided to pages that 
contain more detailed information about those data (Figure 5). 
The pages with mutation details contain links to the scientific literature and if available in 
that literature, the qualitative and quantitative data on the effects of the mutations is displayed. 
The oligomer detail page contains links to the GPCR-OKB and to the individual protomers 
in the GPCRDB. If certain residues are involved in the oligomer interaction, hyperlinks to 
individual residue pages are available. 
RETRIEVAL
Data can be retrieved via the web pages and via the web services. The web services offer 
Table 2. Non-GPCRDB data facilities that can be found through the GPCRDB.
Database Type of data Address
GPCR-OKB (GPCR Oligomerization 
Knowledge Base)
Dimer information http://data.gpcr-okb.org/gpcr-okb/
GPCRRD (GPCR Restraint Database) Modelling restraints ht tp : / /zhanglab .ccmb.med.umich .edu/
GPCRRD/
GLIDA (GPCR Ligand Database) Ligand data http://pharminfo.pharm.kyoto-u.ac.jp/services/
glida/
gpDB (G Protein Database) G Protein data http://biophysics.biol.uoa.gr/gpDB/
UniProt Protein information http://www.uniprot.org/
NAVA Sequence Variants http://nava.liacs.nl/
ChEMBL Ligand data http://www.ebi.ac.uk/chembl/
Ensembl Genomic information 
and annotations
http://www.ensembl.org
Figure 4. Snake plot of the human β2 
adrenoceptor.
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very extensive retrieval possibilities, together allowing for the retrieval of all data types 
present in the GPCRDB. Subsets have been created for frequently requested data sets such as 
all human sequences and the human non-olfactory sequences. Protein family alignments can 
be downloaded in a number of different formats. Sequences, structures, ligand binding data 
and mutations can be downloaded from the protein detail pages. After querying the GPCRDB 
via the web pages, query result sets can be downloaded in FASTA format. A complete copy 
of the GPCRDB is freely available for in-house usage by academic and industrial researchers 
alike. 
QUERY
Users can query the GPCRDB via a number of different search pages. Identifiers, genes, 
species, descriptions, and protein family names can be used to search for GPCRs. There 
are a number of filters available to limit the search results. Users can indicate whether only 
GPCRs should be shown for which mutations, structures, oligomers, or ligand binding data 
are available. Mutations can be found via the mutant search page, where one can search 
by residue number (multiple numbering schemes are available) and/or residue types. The 
GPCRDB offers a BLAST service that allows users to BLAST their sequence against the 
sequences in the GPCRDB. All search options and the BLAST services are available via the 
web interface and as web services. A full SQL search facility will be made available in the 
near future to allow for complex queries and analyses.
Figure 5. Screenshot of the detail page of residue W175 in OPSD_HUMAN. Residue numbers in 
different formats are shown, the approximate location of the residue is visually indicated and available 
mutations and oligomer data for this residue are listed. 
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INFERENCES
The amount of available GPCR related data is too large for a human to grasp and disseminate. 
The GPCRDB contains a series of inference engines that determine interesting correlations 
between the data, while a series of software tools help the user with data reduction and 
abstraction.
Building alignments
The GPCRDB offers the possibility to create custom-made alignments. The alignments are 
created by using the procedure that is used for the parent GPCR families as discussed earlier. 
Users can select the proteins and residue positions that should be aligned, allowing for the 
creation of e.g. an alignment of all binding pocket residues for a selection of proteins (Figure 
6). The custom-built alignments are available for download and users can directly interact 
with the alignments using JalView. 
Predicting the effects of mutations
We have started to create a service where users can predict the effects of a point mutation. 
As for now, predictions are mainly based on human knowledge that is stored in a computer 
readable format. This information is combined with a number of simple analyses on a 
homology model of the receptor being mutated, such as looking for steric clashes and helix 
disruptions. Results are presented as text-fragments that explain the effects of the mutation 
on the structure. Care has been taken to ensure that the results are presented in a life scientist 
friendly manner. The text contains references to literature and is enriched with figures 
Figure 6. A list of proteins and an optional 
list of residue positions can be used to 
generate custom alignments. In this figure we 
have selected a number of proteins for which 
crystal structures are available. The GPCR 
binding pocket residue positions as proposed 
by Gloriam et al. (42) are used. The result 
will be an alignment of all pocket residues of 
the selected proteins.
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and animations of the mutation and its surrounding environment. In the near future more 
intelligence will be added to the software, such as incorporating the quantitative data from 
the mutations extracted from literature and ligand binding information.
Analysis of entropy derived patterns
We offer a page where users can interactively analyze the protein family alignments 
(Figure 2). Plots displaying entropy and variability scores are displayed with a 3-dimensional 
model and a multiple sequence alignments. Residues are linked in the three page elements, 
so that clicking on a residue position in the multiple sequence alignment will highlight the 
residue position in the structure as well as in the entropy and variability plots. This offers 
researchers a very intuitive way of looking at conservation scores, even at the subfamily 
or receptor level, and relating those scores to the 3D structure. In combination with above 
mentioned accessible data site directed mutagenesis candidate selection, homology modeling 
and ligand binding hypotheses generation can be performed. 
Annotating scientific literature
We have developed a new interface for the GPCR data in the form of a GPCR-specific 
PDF reader (manuscript submitted). This reader can annotate scientific literature on GPCRs 
on the fly, providing users with context sensitive data from the GPCRDB (Figure 7). This 
software is available upon request and will be made freely available at the day of publication 
of this article.
IMPLEMENTATION 
The data in the GPCRDB is stored in a PostgreSQL (http://www.postgresql.org) relational 
database. The web service interface is developed with the Apache CXF (http://cxf.apache.
Figure 7. An impression of the 
PDF reader (Utopia Documents 
(43), Utopia Documents-GPCRDB 
(submitted)) interface to the GPCRDB 
data. On the left side (A) a scientific 
paper (44) is shown that is annotated 
by the GPCRDB. Annotations are 
available for all the highlighted words. 
On the right side (B) an example of 
such an annotation (the mutation 
F339L) is displayed. A short, manually 
extracted description of the effects of 
this mutation is included (C). 
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org) web services framework. We offer both SOAP and REST endpoints. The web interface 
is built using the Apache Wicket (http://wicket.apache.org) web application framework. The 
database is accessed via a Hibernate (http://www.hibernate.org) object-relational mapping 
layer. The server is running within Sun’s Glassfish (http://glassfish.org) application server. 
FUTURE DIRECTIONS
In the near future we would like to extend the interactive facilities of the GPCRDB by 
offering users more tools to analyze the available data. The entropy-variability analysis pages 
are a good example of the types of services we will be offering. In addition to our main 
focus of data collection and integration we would like to extend our focus towards the more 
challenging field of knowledge integration. The mutation effect predictor is a pilot project 
to explore the things we can do by combining human expertise with computational power. 
We are in the process of transforming the GPCRDB from mainly a one-stop resource for 
GPCRDB data to a place where scientists can use tools to interact with the data and make 
predictions. 
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ABSTRACT
G protein-coupled receptors (GPCRs) constitute a large family of cell surface receptors 
that are involved in a wide range of physiological and pathological processes, and are targets 
for many therapeutic interventions. However, genetic models in the rat, one of the most 
widely used model organisms in physiological and pharmacological research, are largely 
lacking. Here, we applied N-ethyl-N-nitrosourea (ENU)-driven target-selected mutagenesis 
to generate an in vivo GPCR mutant collection in the rat. A pre-selected panel of 250 human 
GPCR homologs was screened for mutations in 813 rats, resulting in the identification of 
131 nonsynonymous mutations. From these, 7 novel potential rat gene knockouts were 
established as well as 45 lines carrying missense mutations in various genes, associated 
with or involved in human diseases. We provide extensive in silico modeling results of the 
missense mutations and show experimental data, suggesting loss-of-function phenotypes for 
several models, including Mc4r and Lpar1. Taken together, the approach used resulted not 
only in a set of novel gene knockouts, but also in allelic series of more subtle amino acid 
variants, similar as commonly observed in human disease. The mutants presented here may 
greatly benefit studies to understand specific GPCR function and support the development of 
novel therapeutic strategies.
INTRODUCTION
Treatment of animals with a mutagenic compound that introduces random mutations in 
the germ line is a very fast and efficient method for introducing a wide range of mutations in 
large sets of genes in vivo. In rodents, ENU has been shown to be the most potent chemical 
germ line mutagen (1). ENU-treatment of male animals causes adducts in the DNA of 
spermatogonial stem cells, which after several rounds of cell division, result in random point 
mutations and mutagenized sperm (2). F1 animals derived from outcrosses with wild-type 
females carry random heterozygous ENU-induced mutations in their genome. Subsequently, 
the DNA of these animals can be screened by a variety of techniques for the presence of 
mutations in pre-selected genes of interest (3, 4), with the goal to identify animals that carry 
induced variants that affect normal protein function, e.g. by the introduction of a premature 
stop or by affecting functionally important residues. 
The laboratory rat Rattus norvegicus is one of the most used model organisms in 
biomedical research and has been the preferred model for studying human physiology and 
pathology (5). As a highly diverged mammalian model (~60 million years with human 
and 20-40 million years with mouse (6)), the rat is highly complementary to the mouse, 
enabling phenotypic comparison of gene knockouts in both mammals to better understand 
the specific gene function in human biology. In addition, in specific cases the rat can have 
advantages in studying mammalian physiology and biology because of its relative large body 
size and the availability of well-established behavioral and neurological assays (7). While 
most rat knockout models have thus far been generated through ENU-driven approaches, 
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only recently alternative technologies emerged. Transposon-tagged mutagenesis (8), zinc-
finger nuclease-mediated knockout generation (9) and the isolation of pluripotent ES cells 
that potentially can be used for gene targeting (10, 11), now provide a range of possibilities 
for manipulating the rat genome and promises to boost the use of the rat as a versatile genetic 
model system. ENU-driven target-selected mutagenesis has specific characteristics that 
make it an attractive technology that is complementary to the other approaches (12). First, 
it is a relatively simple technology without any cell or oocyte manipulation steps. Second, 
it can easily be scaled up for high throughput and is a relatively cheap method, especially in 
terms of the number of animals used per knockout (in this paper ~100 rats). Thirdly, it offers 
the possibility to identify (allelic series of) more subtle variation because of amino acid 
changes that result in hyper- and hypomorphic alleles (3, 4). One of the major disadvantages 
of the ENU-based approach was its relative inefficiency. However, recently we increased 
the efficiency by about 2.5-fold by taking advantage of DNA mismatch repair (MMR)-
deficiency in the MSH6 knockout rat (13, 14), a system known to be involved in repairing 
ENU-induced lesions in the genome (15). Further efficiency improvements can be expected 
by implementing next-generation sequencing technology for mutation discovery. Another 
drawback of the method is that mutation generation is random and that only the discovery is 
done in a targeted fashion. In other words, generation of knockouts is relatively efficient, but 
obtaining a knockout for a specific gene is still challenging. However, ENU-driven target-
selected mutagenesis is a versatile technology for the systematic generation of large catalogs 
of knockouts and allelic variants of gene families or eventually all protein-coding genes. The 
latter approach in combination with efficient cryopreservation and rederivation protocols 
would generate a unique genome-wide resource for knockouts as well as mutant alleles 
reflecting human genetic variation.
Here, we applied the improved ENU-driven target-selected mutagenesis method for 
generating a unique resource of in vivo GPCR mutant rat models, consisting of both 
knockouts as well as (allelic series of) missense mutations. GPCRs are 7 transmembrane 
(TM) receptors, which regulate many cellular processes, including the senses of taste, smell, 
and vision, and control a myriad of intracellular signaling systems in response to external 
stimuli. Importantly, many diseases are linked to GPCRs and they represent by far the largest 
class of targets for current drugs as well as for the development of novel small-molecule 
medicines (16). Moreover, because of their role in the regulation of cellular function they are 
arguably one of the best-studied classes of proteins, although for many GPCRs their ligand 
as well as biological function remains to be elucidated. Furthermore, genetically altered 
GPCR animal models are scarce, especially in non-murine species, The use of a random 
mutagenesis approach for the generation of GPCR mutants is in principle very well suited 
for understanding in vivo receptor function as new insights can be obtained by completely 
knocking out specific receptors, but also by changing functionally important residues, e.g. 
involved in ligand binding or second messenger signal transduction. Importantly, the high 
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structural conservation between the different GPCRs allows for confident prediction of 
possible effects of amino acid changes. We systematically applied the ENU-driven target-
selected mutagenesis approach to a set of about 250 rat GPCRs that have clear orthologs to 
human GPCRs. In total, we identified 131 nonsynonymous mutations in 99 different GPCRs, 
including 7 novel potential knockout alleles and 45 missense mutants that were predicted 
to affect specific GPCR function or stability of folding of the protein. Characterization 
of selected models demonstrates that ENU target-selected mutagenesis is a powerful and 
efficient approach for in vivo functional studies on G protein-coupled receptors.
 
MATERIALS AND METHODS
ANIMALS AND ENU TARGET-SELECTED MUTAGENESIS PROTOCOL
All experiments were approved by the Animal Care Committee of the Royal Dutch 
Academy of Sciences according to the Dutch legal ethical guidelines. Experiments were 
designed to minimize the number of required animals and their suffering. ENU treatment of 
male MSH6 knockout rats (Msh61Hubr) was done as described (14). Animals were housed 
under standard conditions in groups of two to three per cage per gender under controlled 
experimental conditions (12-h light/dark cycle, 21±1°C, 60% relative humidity, food and 
water ad libitum). Genes of interest were screened using PCR amplification followed by 
capillary sequencing as described (14).
PROJECT MANAGEMENT AND PRIMER DESIGN USING LIMSTILL
The resequencing experiments were designed and managed using LIMSTILL, LIMS for 
Induced Mutations by Sequencing and TILLing (V. G., E.C., unpublished). This web-based 
publicly accessible information system (http://limstill.niob.knaw.nl) was used to generate 
projects and visualize gene structures based on Ensembl genome data, the design of PCR 
primers, and entry, archiving and primary interpretation of mutations. The primer design 
application within LIMSTILL is Primer3-based (44) and parameters are set to design primers 
with an optimal melting temperature of 58°C. The sequences of the primers used in this 
project are available upon request.
MUTANT EFFECT PREDICTION
Mutation data was retrieved from the GPCRDB (45), which contains a large number 
of mutants that were obtained from the tinyGRAP database (46) and mutations that were 
automatically extracted from literature by the software package MuTeXt (47). The mutants 
from the GPCRDB that were used in the analyses include mutants at the same position and in 
the same receptor as the novel mutants as well as mutants at corresponding residue positions 
in related proteins. Each mutant in the GPCRDB contains references to literature. The 
literature describing these mutations was manually checked for relevance and descriptions of 
the mutant. If the mutation in the mutated receptor or highly homologous receptor has already 
been described in literature and the results of the experiments are interpreted correctly, we 
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can be reasonably certain of the effects of the mutation on protein function.
When no good mutation data was available residue conservation in the multiple sequence 
alignments was analyzed. By analyzing residue conservation in multiple sequence alignments 
we can estimate if the mutant residue is likely to be tolerated. If residue conservation at 
the position of the mutant is high it is very likely that the mutant has a detrimental effect. 
If there is little variability the properties of the residues, i.e. charge or aromaticity, are 
likely to be important. When there is a lot of variability the effect of the mutant is probably 
largely determined by size constraints if the residue is located on the inside of the protein, 
or effects because of changes in hydrophobicity if the residue is located at the outside of the 
protein. Alignments of the primary protein family as well as the superfamily were used. The 
alignments were obtained from the GPCRDB. 
Mutants are best studied in the context of a receptor structure, where the local environment 
of the mutated residue can shed light on its function and tolerated substitutions. For this, 
we used the homology models of the receptors that were mutated. Homology models of the 
receptors were built automatically using in-house software. The recently resolved crystal 
structures (19-21) were used as templates from which the software automatically detected 
the best for each model. The alignments of the GPCRDB were used to align the model with 
the template.
The effects of the mutations were estimated by manually combining and interpreting the 
results of the mutant literature searches and the analyses of alignments and homology models 
and was performed by experts in this field of research. 
IN VITRO FUSION PROTEIN EXPRESSION STUDIES
Wild-type and mutant receptors were N-terminally HA tagged and cloned into the 
expression vector pcDNA3.1 (Invitrogen). The receptor fusion proteins were expressed in 
COS-7 cells, which were seeded on a coverslip, and 24 hours after transfection the cells were 
placed on ice and incubated with DMEM-buffered HEPES containing 0.2% fatty acid-free 
bovine serum albumin (DHB) for 15 minutes. Subsequently, the cells were incubated for 1 
hour with a polyclonal rabbit anti-HA (Abcam Inc, Cambrigde) on ice in DHB at a 1:250 
dilution. The cells were methanol-fixed and washed thoroughly with PBS and incubated 
for one hour in blocking buffer (1% BSA in 0.1% PBS-Tween) at room temperature. The 
cells were washed three times with PBS and incubated for 1 hour with a secondary anti-
rabbit antibody conjugated with FITC (Abcam Inc, Cambrigde) at room temperature in the 
dark. After three times washing with PBS the coverslips were mounted using Vectashield 
with DAPI (Brunschwig Chemie, Amsterdam) and analyzed using confocal microscopy. 
For western blotting COS-7 cells were lysed 24 hours after transfection and the proteins 
were separated on a SDS gel (10% acrylamide gradient, Bio-Rad) and transferred to a 
nitrocellulose membrane. The membrane was incubated for 1 hour at room temperature with 
either a 1:4,000, 1:500 or 1:2,000 dilution of respectively a polyclonal rabbit anti-HA antibody 
(Abcam Inc, Cambrigde), a polyclonal rabbit anti-human EDG2 (LPAR1) antibody (Abcam 
82 | CHAPTER 3
Inc, Cambrigde) or a polyclonal rabbit anti-actin antibody (Sigma Aldrich) in blocking buffer 
followed by an incubation for 1 hours with peroxidase-conjugated, anti-rabbit IgG diluted 
1:2,000 in blocking buffer at room temperature. Protein bands were detected by using the 
enhanced chemiluminescence detection method (ECL, Amersham Biosciences).
RESULTS
ENU TARGET-SELECTED MUTAGENESIS SETUP
The target rat GPCR genes for mutation screening were selected based on one-to-one 
orthology with human GPCRs (as defined in Ensembl database), where odorant receptors 
were excluded. GPCRs are ideal genes for mutation screening by PCR-based resequencing 
in an ENU target-selected mutagenesis setup because these genes are often encoded by only 
a single long exon, which maximizes the information content per target amplicon. Although 
the chance of identifying mutations in splice site residues, which often results in a knockout 
allele, is decreased, this is compensated by a higher number of nonsynonymous mutations. The 
genes of interest were screened using a nested PCR amplification setup followed by dideoxy 
resequencing (3). Although different methods for mutation retrieval can be used, like a yeast-
based assay (4), CEL1-based nuclease cleavage (17) or Mu transposase-based detection (18), 
resequencing is considered to be the golden standard since it is equally sensitive towards all 
types of point mutations and is well suited for scaling and automation. After a first round 
of amplicon testing a panel of 486 different amplicons covering 250 different GPCRs for 
screening was established (Table S1).
MSH6-deficient males (msh6-/-) were mutagenized with a predetermined optimal dose 
of 3 weekly treatments of 30 mg per kg bodyweight of ENU (14), which yielded 18 fertile 
founders (Table 1). Subsequently, mating the ENU-treated msh6-/- males with untreated 
females generated a mutant F1 population, harboring random heterozygous ENU-induced 
mutations. Only F1 animals were screened that were generated after a full cycle of 
spermatogenesis (>60 days after mutagenesis) to prevent retrieval of chimaeras. Genomic 
DNA of the F1 animals was isolated from a tail clip that was collected at 1 to 2 weeks of age 
and screened for the ENU-induced mutations in the preselected panel of genes-of-interest. 
F1 animals carrying interesting candidate mutations were weaned and the mutations were 
reconfirmed in independent assays. In total, we screened 813 F1 animals, covering 139 Mb 
of DNA (Table 1) and identified 193 unique mutations, resulting in a mutation rate of 1 per 
720 kb, which is in agreement with the previously described increased mutation frequency 
in msh6-/- rats (14). 
ENU-INDUCED MUTATIONS
Out of the 193 ENU-induced mutations, 163 are located in coding sequences and 131 result 
in nonsynonymous changes in 99 different GPCRs (Supplementary Table 2). We identified 
9 mutations that cause the introduction of a premature stop codon in the open reading frame 
SYSTEMATIC GENERATION Of IN VIVO G PROTEIN-COUPLED RECEPTOR MUTANTS IN THE RAT | 83
(ORF). These represent 5.5% of all coding mutations (Table 1) and corresponds nicely with 
the expected percentage of knockout alleles when considering codon usage in the rat and 
the mutation spectrum in a mismatch repair-deficient background (14). 122 mutations were 
identified that cause an amino acid change (missense). As expected, none of the non-coding 
mutations mutated a splicing donor/acceptor site.
IN SILICO ANALYSIS OF THE MUTATIONS
In order to categorize and prioritize the nonsynonymous mutations, the effects of the 
mutations on protein function was analyzed in silico by evaluating available experimental 
mutation data, analyzing residue conservation patterns in multiple sequence alignments 
and studying homology models of the mutated receptors. Since the structure of a protein 
is directly related to its function, the best way of estimating the effects of a mutant is by 
studying the protein structure itself. Unfortunately, there is very limited structural data 
available for GPCRs. However, based on alignment data and the few experimentally resolved 
protein structures (19-21) it is possible to build structure models of most class A GPCRs. 
The 9 nonsense mutations that introduce a premature stop codon in the ORF will result 
in truncated versions of the proteins and are most likely to result in complete functional 
knockouts of the genes (Fig. 1). The 122 missense mutations can be grouped in amino acid 
changes that likely affect protein function or stability, and changes that will have little or 
no effect (Supplementary Table 2). For 40 mutations we predicted that they are likely to 
affect receptor function and for 23 that they are likely to have no effect (Fig. 1). For 59 
mutations no good predictions could be made, which was largely because of the position 
Table 1: ENU mutation efficiency
Number of GPCR genes screened 250
Fertile foundersa 18
Screened F1 animals
b 813
Screened base pairs (bp) 139 x 106
Nonsynonymous mutations 131
             Nonsense 9
             Missense 122
Synonymous 32
Non-coding 30
Total mutations 193
Mutation rate 1 per 720 kb
 
aMSH6-deficient male animals were treated 3 times weekly with 30 mg/kg bodyweight ENU. Founders 
were considered to be fertile if at least one nest was produced more than 10 weeks after the last ENU 
treatment. bOnly F1 animals were screened that were born at least 10 weeks after the last ENU treatment. 
GPCR, G protein-coupled receptor.
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of these mutations in loop regions, where sequence conservation is low and where very 
little structural information is available. The damaging mutations can be further categorized 
in mutations that affect specific GPCR functions, like ligand binding, signal transduction, 
G-protein activation, or protein stability. Eight mutations were predicted to affect the process 
of ligand binding, because they involved a residue located in the putative ligand-binding 
pocket (Fig. 2A and B). Another 6 mutations are likely to affect signal transduction, for 
example, the mutant Prok2S364I, which involves a residue that is part of the ionic lock (Fig. 
2A and C) (22). 13 mutations were identified that are likely to affect G-protein activation 
by changing residues involved in the binding of the G-protein, like the W153R mutation in 
the highly conserved (D/E)R(Y/W) motif of Hcrtr2 (Fig. 2A and D). Finally, a total of 13 
mutations were identified that are likely to affect protein stability, for example, by changing 
a hydrophobic residue that sticks into the lipid bilayer into a hydrophilic one. 
For mutations with unclear predictions we made use of PolyPhen (23) and SIFT (24) 
software to predict the effects of the amino acid changes (Fig. 1). Fifteen mutations were 
predicted to be damaging by both programs, 20 were predicted to be damaging by one of the 
programs and 24 were predicted not to be damaging by either program.
131 non-synonymous mutations
40 mutation likely 
aect protein function
8 mutations likely
aect ligand binding
6 mutations likely
aect signal transduction
6 mutations likely aect
G protein activation
GPCR FUNCTION
PROTEIN STABILITY/FOLDING
13 mutations likely
aect stability
9 nonsense mutations
PROTEIN TRUNCATION
15 mutations damaging by
both Polyphen and SIFT
20 mutations damaging 
by only one program
24 mutations not damaging
 by both programs
UNCLEAR EFFECT
23 mutations with no eect
122 missense mutations
Figure 1. Systematic in silico analysis of the identified ENU-induced mutations. All mutations were 
grouped according to their predicted affect on GPCR function. Mutations that are likely to affect 
protein function can be further categorized depending on their effect on GPCR function. The group 
for which no predictions can be made by lack of structural data were analyzed with PolyPhen (23) and 
SIFT (24) software. 
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ARCHIVING THE MUTANTS
F1 animals carrying interesting mutations were outcrossed with untreated animals to 
establish the mutant lines and generate more heterozygous carriers. Mutants that were 
predicted to have no effect on GPCR function were archived by cryopreserving sperm 
of male carriers from either the F1 or F2 generation. The resulting resource can be used 
to revive these lines by intracytoplasmic sperm injection (ICSI) (18) at a later stage. In a 
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Figure 2. Illustrations of the mutant structural environments in homology models of the mutated 
receptors. (A) Schematic overview of a consensus GPCR with in red the mutation shown in (B), in 
orange the ionic pocket (22) and mutated residue in (C) and in yellow the (D/E)R(Y/W) motif and 
mutated residue depicted in (D). (B) An example of a mutation that is predicted to affect ligand binding. 
The mutant H410L in the neuropeptide receptor NPY5R is located in the putative ligand-binding 
pocket. The structure of the co-crystallized ligand of the β2-adrenergic receptor is shown in grey. 
Although the NPY5R receptor binds a different class of ligands the binding site location is expected 
to be similar. Substituting the histidine for leucine is likely to change ligand-binding affinity. (C) The 
mutant S364I in the prokineticin 2 (PROK2) is located just above the ionic pocket, which is involved in 
signal transduction from the ligand binding site to the G-protein binding site. A number of structural 
waters are located in this pocket. The substitution of the serine for isoleucine is likely to disrupt the 
ionic pocket because of steric constraints, a major change in hydrophobicity and loss of interactions 
with structural waters. (D) The mutant W153R in the hypocretin (orexin) receptor 2 (HCRTR2) is 
located in the (D/E)R(Y/W) motif, which is the most conserved part of the GPCR family and involved 
in receptor activation and subsequent G-protein coupling. The substitution of trypthophan for arginine 
will disrupt receptor activation.
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limited number of cases we were unable to cross F1 animals to the next generation, partly 
because of fertility problems, which is more commonly observed in F1 animals derived from 
ENU-mutagenized founders, or as a result of a dominant effect of the induced mutation. For 
example, the mutation of an aspartic acid (D74V) in the second TM domain of Agtr1a, which 
is part of the ionic pocket (22) and a highly conserved residue in GPCR super family, resulted 
in an extremely high blood pressure-like phenotype (increased liver, heart and dilated veins), 
lower bodyweight and severe testis atrophy, causing sterility and eventually death (data 
not shown). Completely in line with these observed in vivo effects, a similar amino acid 
change D74N was shown previously to affect AGTR1A function in vitro in COS cells (25). 
The mutants that were successfully crossed to the next generation were genotyped for 
carrying the mutation of interest as well as contra-selected for the mutation in Msh6. All F1 
animals are heterozygous for the latter mutation as the ENU-mutagenesis was done in msh6-
/- males that were subsequently outcrossed to wild-type females. Although no adverse effects 
are expected in a heterozygous Msh6 background, in later generations the mutation could 
become homozygous and result in the accumulation of more mutations and cancer (13). 
Therefore, we systematically selected F2 animals to eliminate this mutation from the lines.
Table 2 lists the rat mutants that were crossed to next generations and for which living 
carriers are available. These include 7 mutant lines with protein truncations and contain well-
studied receptors, like Mc4r, of which mutations in human have been associated with severe 
forms of obesity (26), as well as orphan receptors, like Gpr19 (Table 2). Furthermore, 45 
animals that carry mutations that likely affect GPCR function were crossed to following 
generations to establish a mutant line. These include 6 mutations that are predicted to 
affect ligand binding, 6 that may affect signal transduction and 9 that may affect G-protein 
activation. Additionally, 11 mutations that are predicted to affect protein stability and 13 with 
unclear effects on GPCR function or stability, but that were predicted to be damaging by both 
PolyPhen (23) and SIFT (24), were crossed to next generations.
fUNCTIONAL CONSEQUENCES Of ENU-INDUCED MUTATIONS
Mutations that result in the introduction of a premature stop codon most likely represent 
novel functional gene knockout models for these genes in the rat, similar as has been shown 
previously for the rat genes Brca2 (4, 27), Apc (28), Sert (29), Msh6 (13) and Pmch (30). 
Six of the nonsense mutants that were isolated in this screen cause protein truncations within 
or before the 7th TM domain and therefore lack the entire C-terminus, including the 8th 
helix, which is important for GPCR stability and function. The remaining ENU-induced 
premature translational stop was identified in the 8th helix of MC4R (Mc4rK314X), four 
amino acids before the palmitoylated cysteine residue (Fig. 3A). Most likely, this mutation 
results in a complete loss of receptor function, since the two isoleucines residues, which 
are located after the mutated residue (Fig. 3A) were shown previously to be essential for 
localizing MC4R to the plasma membrane (31). In addition, C-terminally truncated versions 
of another GPCR, namely the lysophophatidic acid receptor LPAR1 also fail to localize to the 
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plasma membrane (32), indicating the importance of the C-terminus for correct membrane 
expression. To test this hypothesis, we expressed N-terminally haemagglutinin (HA)-tagged 
MC4R with and without the ENU-induced mutation in COS cells. After transfection, intact 
non-permeabilized cells were incubated with an antibody against the HA-tag, which can only 
bind if the HA-MC4R fusion protein is correctly incorporated into the plasma membrane. 
Indeed, HA-tagged wild-type MC4R was clearly detectable at the plasma membrane, whereas 
no mutant receptor could be detected in the same assay (Fig. 3B). To test whether the mutant 
form was expressed at all in these cells, we detected the protein in fixed and permeabilized 
transfected cells and showed the presence of approximately equal amounts of expression of 
Figure 3. MC4RK314X fails to localize to the plasma membrane in vitro. (A) Schematic overview of 
MC4R in the rat. Red indicates the location of the ENU-induced premature translational stop. Grey 
indicates two isoleucine residues that were shown previously to be essential for membrane localization 
(31). (B) In vitro protein localization assays in transfected COS cells reveals plasma membrane 
localization for wild-type MC4R, but not for the mutated version of MC4R. Membrane localization was 
detected using N-terminally HA-tagged fusion constructs and extracellular availability of the HA tag 
in intact cells. (C) Both wild-type and mutant fusion proteins can be detected in fixed and permeablized 
COS cells, indicating that the mutant fusion protein is expressed, but fails to properly insert into the 
plasma membrane. 
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Figure 4. Lpar1M318R/M318R rats show a loss-of-function phenotype. (A) Schematic overview of LPAR1 
in the rat. Red indicates the mutated residue, which is located in the 8th helix and grey indicates the 
NPxxY motif. (B) In silico analyses of the effect of the mutation in Lpar1. The substitution of methionine 
by arginine is likely to cause a severe disruption of the hydrophobic interface between helix 1, 2 and 
7. This is mainly because of the fact that arginine is significantly bigger than methionine, therefore 
forcing a disruption of the local structure. The fact that a hydrophobic residue is substituted for a highly 
hydrophilic residue types only adds to the destabilization of the interface. (C) Homozygous mutant 
Lpar1 rats show a craniofacial disorder, using a measure independent of overall head size (eye-to-nose 
tip length / interocular distance), which was also observed in Lpar1 knockout mice (37). Error bars show 
± s.e.m. and * indicates statistical difference, p<0.01 (n=7 each genotype). (d) Homozygous mutant 
rats are smaller. Error bars show ± s.e.m. and * indicates statistical difference, p<0.01 (n=7 each 
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both wild-type and mutant HA-MC4R fusion proteins (Fig. 3C). This shows that Mc4rK314X is 
still expressed in vitro, but fails to localize to the plasma membrane, which is likely to affect 
normal receptor function. In line with these predictions, Mc4rK314X/K314X rats display a major 
increase in body weight as well as in the amount of peritoneal and subcutaneous fat (Fig. 
S1), which is a comparable phenotype reported for traditional knockout mouse models (33) 
suggesting loss of receptor function. 
Obviously, for missense mutations it is more difficult to robustly predict an affect. However, 
to confirm the value of the stringent bioinformatic predictions that we implemented, a mutation 
in Lpar1 that results in the change of a methionine into an arginine in the 8th helix (Fig. 4A) 
and that was predicted to be deleterious for protein function, was analyzed. Interestingly, 
aberrant lysophosphatidic (LPA) signaling in humans has been associated with carcinogenesis 
in humans (34) and specifically LPAR1 knockout mice show phenotypic changes observed 
in psychiatric disease (35). In the GPCR class A family the hydrophobicity of the affected 
residue is highly conserved and it is analogous to the phenylalanine of the NPxxYx
6
F motif 
in Rhodopsin. This residue sticks into a hydrophobic pocket and contacts the tyrosine of the 
same domain, which is important for the folding of the 8th helix. The amino acid change in 
our mutant will disrupt the hydrophobic interactions and additionally, an arginine is too big to 
fit in this pocket and will most probably result in incorrect packing of the 8th helix (Fig. 4B). 
As a consequence, the environment of G-protein binding will be disturbed by the mutation 
in Lpar1M318R, since it is thought that this helix interacts with the G-protein (36). Indeed, 
homozygous mutant rats showed LPAR1 loss-of-function phenotypes, like craniofacial 
disorder (Fig. 4C) and smaller size (Fig. 4D), which is comparable to the phenotype found 
in Lpar1 knockout mice (37). However, we also observed significant differences in the 
phenotypes between the two animal models. In contrast to mice, no neonatal lethality was 
observed in rats since homozygous mutants were born at the expected frequencies (29.5% 
± s.e.m. 8.7; n=4) and no hematomas were observed (37). The milder phenotype in the rat 
could be explained by the nature of the mutation, which is only changing a single amino acid 
residue instead of truncating or deleting the protein. However, species-specific differences 
can also not be ruled out. To study the molecular consequences of the nonsynonymous 
substitution, we analyzed the membrane expression in vitro using N-terminally HA-tagged 
versions of mutant and wild-type LPAR1 isoforms. We observed strongly reduced, yet 
detectable, membrane incorporation as compared with wild-type LPAR1 (Fig. 4E), while 
expression levels of both fusion proteins were equal (Fig. 4F). These in vitro data suggest 
genotype).  (E) LPAR1M318R is still expressed in the plasma membrane in vitro, although at much lower 
levels than wild-type LPAR1. N-terminally HA-tagged wild-type or mutant receptor were transiently 
expressed in COS cells. Intact cells were incubated with an antibody against HA before fixing and 
staining the cells. (F) Cell lysates of COS cells expressing wild-type or mutant HA-tagged LPAR1 show 
the comparable protein levels by western blot analysis. Both an antibody against the HA tag as well as 
one against human LPAR1 was used to show the expression of the fusion proteins.
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that the ENU-induced mutation results in a hypomorphic allele, which could explain the mild 
phenotype observed in vivo. More detailed experiments indicated that the decreased level of 
in vitro membrane expression of LparM318R is most likely the result of increased spontaneous 
membrane internalization, which fits with the role of the C-terminus in receptor activation 
and internalization (R.B., E.C., unpublished results).
Finally, this unique resource of GPCR mutants in the rat is not only suited for studying 
the in vivo effect of the mutated receptor in behavior (e.g. Gpr19, Gpr85), immunology 
(e.g. Ilr8b, Gpr65), or metabolism (e.g. Mc4r, Npy5r), but it can also be employed for the 
derivation of primary cell cultures and studying the molecular and functional consequences 
of the mutation ex vivo. Indeed, we isolated embryonic fibroblasts from LparM318R/M318R rats 
Table 3: Known human disease genesa
Gene Mutation Categoryb MIM Morbid Description (Accession)
Cx3cr1 I118K Protein stability/folding Human immunodeficiency virus type 1, susceptibility to 
(609423)
Coronary heart disease, susceptibility to (607339)
Macular degeneration, age-related (603075)
Drd3 S355P Unclear effectc Tremor, hereditary essential (190300)
Schizofrenia (181500)
Fshr V488A Protein stability/folding Ovarian hyperstimulation syndrome (608115)
Twinning, dizygotic (276400)
Ovarian dysgenesis 1 (233300)
Gnrhr I93T Protein stability/folding Fertile eunuch syndrome (228300)
Hypogonadotropic hypogonadism (146110)
Gpr56 R96H Unclear effectc Polymicrogyria, bilateral frontoparietal (606854)
Htr2a N54D Unclear effectc Major depressive disorder (608516)
Anorexia nervosa, susceptibility to (606788)
Schizofrenia (181500)
Obsessive-compulsive disorder 1 (164230)
Alcohol dependence (103780)
Lhcgr I446N G-protein activation Leydig cell hypoplasia, type 1 (238320)
Precocious puberty, male-limited (176410)
Mc4r K314X Protein truncation Obesity (601665)
Prokr2 S364I Signal transduction Kallmann syndrome 3 (244200)
Sstr5 V226A G-protein activation Pituitary adenoma, growth hormone-secreting (102200)
aAccording to OMIM database (http://www.ncbi.nlm.nih.gov/omim). bThe categories are based on 
expert interpretation of structural information and bioinformatic predictions unless stated differently. 
cStructural information was not available for these protein domains but bioinformatic analysis by both 
Polyphen (23) and SIFT (24) software predicted that these mutations are likely to have damaging 
consequences.
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to study the effect of this mutation in an in vitro system, without the necessity of creating 
transgenic cell lines (R.B., E.C., unpublished results).
DISCUSSION
Single nucleotide polymorphisms (SNPs) are the most common form of human genetic 
variation (38) and this class of variants is mimicked by the action of ENU that results in the 
introduction of random point mutations in the genome. Therefore, in vivo mutants generated 
by ENU-driven target-selected mutagenesis can be of great relevance for studying the 
function of genes and gene variants with effects on human physiology and pathology. Here 
we made use of this approach to generate mutant models for GPCRs in the rat. The strength 
of this approach is that in a single experiment a wide range of mutants can be isolated for a 
large set of genes of interest.
Although the genetic toolbox of the rat has very recently expanded significantly with 
techniques like transposon insertion mutagenesis (8), targeted zinc-finger nucleases-mediated 
knockout generation (9) and the availability of pluripotent rat ES cells (10, 11), ENU-driven 
target-selected mutagenesis has developed in the past years into a robust and highly efficient 
technique. In addition, this approach has the unique characteristic that it simultaneously can 
provide allelic series of knockout and other alleles, like hypo- and hypermorphic mutants. 
Also the screen described here resulted in multiple nonsynonymous mutant alleles for the 
same gene (Table S2). Such alleles can be highly informative for understanding gene function 
and the effects of disease-associated variants identified in human. Finally, the technique does 
not depend on special (ES) cell lines and/or advanced oocyte or embryo manipulation and the 
created mutants are not ‘transgenic’ of nature, since no artificial DNA construct is integrated 
into the genome. One disadvantage, however, of ENU mutagenesis could be the presence of 
background mutations. However, this is a complication that should be taken into account in 
most approaches for the generation of mutant animals, including homologous recombination-
based techniques as it has been shown that long-term culturing of ES cells does result in the 
accumulation of genetic changes (39). Nevertheless, the presence of background mutations 
can relatively easily be controlled or overcome by outcrossing heterozygous carriers to the 
parental strain (40) and the use of wild-type and heterozygote littermates as controls in 
phenotypic characterization studies.
Although the use of MMR-deficient background for mutagenesis has greatly increased 
the efficiency of ENU target-selected mutagenesis in the rat (14), further improvements to 
the approach can and are still being implemented. The availability of an archive of frozen 
F1 rats, which we and others (18) are currently generating can in principle be screened 
almost infinitely, and will be of great benefit to the rat research community. Additionally, 
the availability of next-generation sequencing platforms (41), combined with microarray-
based genomic enrichment (42), provides promising avenues for further increases in the 
efficiency of the ENU target-selected mutagenesis approach by rigorously scaling of the 
targeted mutation discovery effort.
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Taken together, we demonstrate that ENU-driven target selected mutagenesis is a highly 
effective and feasible approach for generating a unique and expandable resource of GPCR 
mutants in the rat. We established 7 novel potential genetic knockout rat models and over 40 
missense mutant lines, including amino acid changes in very conserved GPCR motifs like 
the (E/D)R(Y/W) motif and the ionic pocket, demonstrating the specific power of random 
ENU mutagenesis in vivo. Selection of the most promising models was aided by extensive 
bioinformatic analysis, which will also be instrumental for the efficient design of molecular 
characterization strategies. Notably, at least 10 mutant lines concerned genes, of which 
polymorphisms in the human orthologs are known to be involved in disease processes (Table 
3). Furthermore, many of the affected genes have been associated with one or more diseases in 
recent gene and genome-wide association studies, e.g. Gpr85 in a GWAS study for attention-
deficit/hyperactivity disorder (ADHD) (43), illustrating the relevance of these rat models 
for studying human disease (see http://geneticassociationdb.nih.gov, http://www.ncbi.nlm.
nih.gov/gap and http://www.genome.gov/gwastudies). Finally, all rat models described here 
will be made available to the community through the international rat knockout consortium 
(www.knockoutrat.org).
SUPPLEMENTARY DATA
For Tables S1 and S2 readers are referred to the The Pharmacogenomics Journal website 
(http://www.nature.com/tpj).
Figure S1. Mc4rK314X/K314X show increased 
body weight. (A) Representative picture of 
a Mc4rWT/WT, Mc4rWT/K314X and Mc4rK314X/K314X 
rat. (B) Growth curve of Mc4rWT/WT, Mc4rWT/
K314X and Mc4rK314X/K314X male rats. Error bars 
display s.e.m. (n=2 for each genotype).
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ABSTRACT
Information overload is compromising the ability of researchers to keep up with advances 
in their fields. Simultaneously, increasing time pressures are compelling us to get to 
information in relevant papers much more efficiently. Ideally, we want be to be able to jump 
seamlessly from a particular paper both to its underlying data and to other related information 
and literature at the click of a button. While full literature and data integration has remained 
elusive, we show here that the problem can be solved even in a large sub-discipline of the 
life sciences: GPCR research. In brief, we present an integrative tool that allows intelligent 
visualisation and exploration of, and direct interaction with, PDF articles. The software 
automatically retrieves data from the GPCR database (GPCRDB), displaying it both within 
and as an adjunct to an article, thereby allowing readers to extract more knowledge more 
swiftly from literature.
INTRODUCTION
It is widely accepted that information overload, in terms both of the growing volumes 
of biomedical data and of the associated peer-reviewed literature, is making it increasingly 
difficult for researchers to remain expert in their fields (1). Tools to help conquer the growing 
mountains of data and literature, and to link them more efficiently, are sorely needed (2, 3). 
Addressing this problem across all life sciences is a daunting prospect, and is especially 
challenging for static PDF files. However, to illustrate what can be done, we have integrated 
the Utopia Documents PDF reader (4) and the G protein-coupled receptor information 
system, GPCRDB (5), in such a way as to present to scientists, in a non-intrusive way, all 
GPCR-relevant data and information discussed in an article at hand. GPCRDB is a rich and 
comprehensive source of GPCR knowledge. Nevertheless, if resources like this are to be 
more than mere data silos, their contents must be understood in relation to ongoing research, 
and placed in the context of present and past literature; Utopia Documents is a new PDF 
reader that offers unique opportunities to do just this. A succinct illustration is given below.
 
RESULTS
For three concepts (proteins, residues, mutations), we selected data, links and knowledge 
that would allow users to navigate effortlessly from PDF versions of articles to all relevant 
information in GPCRDB. The power of this approach is illustrated in Figure 1: for a particular 
page of an article, this shows information that has been retrieved by the system, on-the-fly, 
for an arginine-to-alanine mutation in the murine thyrotropin-releasing hormone receptor.
Importantly, amongst the information returned by the system, are residue numbers mapped 
to a variety of commonly used numbering schemes. This simple feature both substantially 
saves time when trying to discover that same residue in other databases, and facilitates 
automatic detection of articles describing the same/similar mutations. The structural 
information returned comprises both manual and automatic analyses, providing a structural 
perspective on key concepts in the text, and making it much easier to critically assess authors’ 
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interpretations of their experimental results – this is especially important when reading old 
literature, particularly as it may allow today’s scientists to bring new interpretations to 
previous work in the light of current data. 
 
Figure 1. Information retrieved for mutation R283A in the mouse thyrotropin-releasing hormone 
receptor. On the left, part of a paper by Gao et al. (6) is shown with annotated concepts highlighted in 
red; on the right,  the retrieved information. Papers discussing the same mutation are listed, with links 
to PubMed. A short summary of the effects of the mutation is provided, together with links to GPCRDB 
pages giving details of other mutations at the same position, and to a YASARA (7) scene that displays 
the mutated residue in 3D. Information about the wild-type residue includes numbering in various 
schemes, a short description of its location and interactions, and a cartoon indicating its 3D location.
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DISCUSSION
This work was developed in response to the need to achieve tighter coupling between 
published articles and their underlying data as a crucial step towards knowledge discovery. 
The strengths of our approach are: in presenting users (researchers, referees, editors, etc.) 
with current, integrated, validated, internally consistent data and information in the context 
of literature; in alleviating many of the problems associated with navigating the numerous 
links between data and information in a particular field; and in displaying information in 
such a way that users neither struggle to access related topics in the article, nor drown in 
unnecessary information that still needs disambiguation – only data and information relevant 
to an article’s topic are made available. We based the approach on PDF files, as this is the 
most commonly read article format, and we focused here on GPCR research largely for 
illustrative purposes. Extracting new knowledge from scientific literature, putting data 
in articles in the wider context of the total body of accumulated knowledge, and helping 
establish modern interpretations of results published in the past, are needs felt across all life 
sciences; solving all of the problems that these entail will likely require both future cultural 
change and technological innovation. Our work with Utopia Documents and GPCRDB is not 
a panacea, but a significant first step towards exciting things to come.
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ABSTRACT
BACKGROUND: With the continued growth in the volume both of experimental G 
protein-coupled receptor (GPCR) data and of the related peer-reviewed literature, the ability 
of GPCR researchers to keep up-to-date is becoming increasingly curtailed. 
RESULTS: We present work that integrates the biological data and annotations in the 
GPCR information system (GPCRDB) with next-generation methods for intelligently 
exploring, visualising and interacting with the scientific articles used to disseminate them. 
This solution automatically retrieves relevant information from GPCRDB and displays it 
both within and as an adjunct to an article
CONCLUSIONS: This approach allows researchers to extract more knowledge more 
swiftly from literature. Importantly, it allows reinterpretation of data in articles published 
before GPCR structure data became widely available, thereby rescuing these valuable data 
from long-dormant sources. 
BACKGROUND
Recent decades have seen a massive increase in the amount of data available to 
researchers. Revolutionary high-throughput technologies have enabled data production on 
an unprecedented scale in many areas of the life sciences. To accommodate this increase in 
experimental data, we have also witnessed a database explosion, with both the number and 
size of specialised biological repositories growing enormously over the years (1). Most of 
these resources offer their own data formats, websites and programmatic interfaces.  This has 
made the task of retrieving information increasingly difficult and complex (2). 
GPCRDB (3) is one of the earliest examples of a Molecular-class Specific Information 
System (MCSIS). It collects, combines, validates and disseminates large amounts of GPCR-
related content, bringing together information (such as sequences, structures, mutations and 
oligomers) from other databases, and augmenting this with manually annotated data (such as 
mutations extracted from literature), as well as computationally-derived multiple sequence 
alignments and homology models. Its contents are validated, integrated, internally consistent 
(4) and updated regularly (3). GPCRDB thus functions as a one-stop shop for GPCR-related 
knowledge, relieving scientists of the burden of going through the process of finding multiple 
data sources, of learning how to use them, and of then retrieving, synthesising and integrating 
the retrieved information.
Much of the routine practice of communicating scientific knowledge is conducted through 
the process of reading and writing scientific papers, an invaluable method that has been 
used successfully for hundreds of years. However, it is now widely acknowledged that 
this approach imposes considerable constraints upon the type and quantity of biological 
information published: specifically, the data used to generate hypotheses and to perform 
experiments are not readily accessible to fellow researchers who use the results of their peers’ 
publications. 
Relating information between databases and literature has become increasingly difficult 
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with the growing quantities of data and documents available, and it is evident that new solutions 
are required to address this problem (5, 6). When reading about a mutation, a scientist might, 
for example, want to know the location of the mutated residue in the structure, or find other 
articles describing the same mutation. Although systems like GPCRDB provide scientists 
with access to focused information derived from the literature, subsequent exploration of 
concepts in related articles still poses practical hurdles (e.g., opening a browser window, 
navigating to the database, searching for the data). 
With the goal of bridging the gap between data and scientific articles, several initiatives 
have explored how to enrich scientific literature with repository data, either by manual 
annotation (7-9) or by automatic approaches (10, 11). The results of these projects are 
encouraging, but also point to what remains to be done. For example, Shotton et al. (9) 
have explored the use of semantic annotations, beautifully illustrating the possibilities of 
these types of technologies. However, providing enhancements of this quality on a routine 
basis is still far beyond our reach; this impressive example is limited to one paper, and a 
very large amount of manual input was involved. One of the most promising automated 
initiatives, the Reflect (11) system, provides annotations for a very large number of biological 
entities, covering genes, proteins and a large number of small-molecule compounds. These 
annotations contain an enormous wealth of data and hyperlinks to a multitude of information 
systems. However, automation of the process carries the price of a large number of errors; 
hence, vigilance and caution are required, coupled with a significant amount of manual effort 
to validate and disambiguate the results. In addition, the aforementioned approaches all focus 
on HTML/XML formats, and require users to read their articles in a Web browser, ignoring 
the de facto standard format of scientific literature: Adobe’s Portable Document Format 
(PDF). This is by far the most popular format for peer-reviewed science communication, for 
reasons that include the benefits of their permanence, device independence, and ubiquitous 
support and good readability. It therefore makes sense to exploit the PDF; the software tool 
Utopia Documents (12, 13) was developed for just this purpose. Behaving like a familiar 
PDF reader, Utopia Documents is a desktop application for reading and exploring papers. Its 
strength lies in being able to semantically annotate concepts in documents with additional 
relevant information and links to online resources. 
We report here a technology that allows on-the-fly annotation of GPCR-related PDF 
articles. By fully integrating the Utopia Documents PDF reader and the GPCRDB 
information system, we can present to the scientist, in a non-intrusive way, all possible data 
and information related to the topics discussed in the article at hand. This makes possible a 
paradigmatic change in the relationship between the PDF-reading scientist and Internet-based 
data resources, alleviating the troubles associated with navigating the many links between 
existing data and information in this field. The scientist neither struggles to get access to 
information related to topics within an article, nor is swamped by unnecessary information 
that still needs disambiguation; only data and information relevant to the topic of the article 
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is made available.
IMPLEMENTATION
The system comprises three parts: the Utopia Documents reader; the GPCRDB; and a 
module that performs the communication between the two. Users can annotate a document 
with GPCR-specific information with a single click, but, behind the scenes, the PDF 
annotation is a multi-step process:
1. Extracting the text from the PDF document
2. Identifying concepts (species, proteins, residues and mutations)
3. Creating relevant annotations based on GPCRDB data 
4. Adding the annotations to the document
1 and 4 are carried out by Utopia Documents, while 2 and 3 are performed by GPCRDB 
(Figure 1). The communication between the device running Utopia Documents and GPCRDB 
is done from within Utopia Documents by a GPCRDB-specific plugin. This plugin, written in 
the Python programming language, makes use of the publicly available Web service (SOAP) 
and Utopia’s plugin-API to facilitate the communication and data exchanges between the 
Utopia Documents reader at the scientist’s computer and the remote GPCRDB computing 
facilities. Within the plugin, the text is extracted from the PDF document and sent via the Web 
service to GPCRDB. There, the text is analysed automatically and annotations are created 
Figure 1. Schematic flow-chart of the annotation process. On the left, processes coloured red are per-
formed by Utopia Documents, processes in blue by GPCRDB. On the right, is a screenshot of an annotated 
paper(29) in the Utopia Documents PDF reader, in which all annotated concepts have been highlighted by 
pressing the space-bar (annotations appear as red highlights, both in the body of the text and in the docu-
ment margins). 
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that are passed back to the main Utopia client to be displayed on the article as highlighted 
regions. More information on plugins can be obtained from the paper by Attwood et al .13. 
IDENTIFYING CONCEPTS
Concepts for which we can provide information (proteins, residues and mutations) must 
be unambiguously identified to be able to present users with relevant information. Clearly, 
it is important to ensure that terms in the PDF are correctly mapped to terms in GPCRDB. 
Concepts must be found in the text and coupled to a unique database identifier, a process 
referred to as normalization (14, 15). In the case of a protein, this requires knowledge about 
the species from which it originates. The term ‘rhodopsin’, for example, cannot be normalised, 
whereas the words ‘human rhodopsin’ would map to the UniProtKB:Swiss-Prot identifier 
‘OPSD_HUMAN’. For residues and mutations, each occurrence needs to be identified and 
associated with one of the proteins mentioned in the text, a process called grounding (16-
18):  e.g., ‘Trp161‘ is meaningless, whereas ‘Trp161 in human rhodopsin’ maps to a unique 
residue in one specific protein, and is thus grounded on a normalised protein.
It is beyond the scope of this article to provide an exhaustive explanation of all algorithms 
and heuristics involved in normalisation and grounding. However, at the heart of both tasks 
lies the use of a metric based on word distances, in which combinations of terms that are 
close together in the text are favoured over more distant combinations. The distance metrics 
are combined with a number of heuristics, filters and validations. Some of the heuristics have 
been described elsewhere (16, 18, 19), while a series of related heuristics have been newly 
designed and implemented. In the following sections, we describe the most important steps 
involved in extracting and identifying proteins, residues and mutations.
Protein identification and normalisation
Protein identification is the non-trivial task of pinpointing words that represent a gene or 
protein. We use a dictionary-based approach. Dictionaries are populated with gene identifiers, 
protein identifiers and protein descriptions from all GPCRs in GPCRDB that are present 
in UniProtKB:Swiss-Prot (20). UniProtKB’s Swiss-Prot component is used because of its 
consistent mapping between protein sequences and their descriptions. Commonly observed 
synonyms not present in the database-extracted list were manually added to the dictionaries. 
The text is scanned for gene or protein occurrences using approximate dictionary matching, 
allowing for some variability. Separate dictionaries are created for gene identifiers, protein 
identifiers and protein descriptions, each with their own scoring metric. This makes it possible 
to set high penalties for mismatches between reference dictionary entries and detected gene 
or protein identifiers, while allowing more variability (i.e., the use of both Latin and Greek 
characters in protein descriptions) when scoring protein descriptions, taking into account 
their free-text and relatively changeable nature. The Linnaeus (21) system is used to find 
species occurrences in the text, and to normalise these occurrences to NCBI taxonomy (22) 
identifiers. The normalised species occurrences are then used to complete the normalisation 
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of the identified protein occurrences. 
Mutation and residue identification and grounding
Identifying point mutations and residues involves two subtasks. First, it is necessary to 
identify the mutation or residue terms discussed in an article. Second, the identified residues 
and mutations must be grounded. 
Three entities in the text need to be related to identify point mutations: the wild type 
residue, the mutant residue, and the position in the sequence where the substitution occurred. 
Point mutations are represented in the literature in a variety of ways. The most common 
representation is in the form ‘XnY’, where X is the single-letter code for the wild-type 
residue, n its location and Y the single-letter code for the substituted residue (e.g., ‘D98F’ 
denotes a change from aspartic acid to phenylalanine at position 98). However, there are 
many variations on this theme, ranging from the use of three-letter amino acid codes, as 
in ‘Asp98Phe’ and ‘Asp98 → Phe’, to more exotic notations, like ‘Asp98-Phe98’, ‘D98 to 
phenylalanine’ and ‘Asp 98 was mutated to phenylalanine’. Regular expressions are used to 
identify residues and mutations.
Articles about GPCRs refer to mutations and residues using one of four numbering 
schemes.  The most frequently used are the standard sequential numbering scheme and 
the scheme of Ballesteros-Weinstein (23). Other articles use the Oliveira scheme (24) 
(also known as the GPCRDB numbering scheme), or their own, article-specific scheme. 
The Ballesteros-Weinstein and Oliveira schemes are so-called general residue numbering 
schemes. These allow consistent residue numbering across multiple proteins, independent 
of their sequential numbers. The underlying principle is that residues with the same general 
residue number have equivalent locations in their tertiary structures and consequently in 
the multiple sequence alignments. In the widely used Ballesteros-Weinstein scheme, residue 
numbers are in the format ‘TM.n’, where the number before the period indicates the number 
of the transmembrane helix, and the number after the period indicates the residue position 
with respect to the most conserved residue position in the helix (e.g., ‘3.50’ denotes residue 
50 in TM domain 3). 
Some articles discuss residues and mutations using an article-specific numbering scheme. 
Often, standard sequential residue numbers are used that do not exactly map to the protein 
sequence in the database. This mismatch can arise owing to inclusion of signal peptides in 
the sequence, different isoforms, etc. In these cases, there is an offset by which the residue 
numbers must be corrected to obtain a valid mapping to the reference sequences in the 
database. A regular expression-based approach is taken to calculate the right offsets. When 
multiple offsets are possible (i.e., there are multiple ways of mapping the identified residues 
on the sequence), the offset is chosen that is closest to the residue numbers mentioned in the 
text. 
Residues and mutations are grounded mainly based on proximity to proteins mentioned 
in the text, favouring combinations that occur within the same sentence. Validation of 
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these combinations is performed by comparing the identified residues and mutations to the 
sequences of the candidate protein mentions, using similar approaches to those discussed by 
Horn et al. (19). Where general residue numbers have been used, the sequential numbers are 
retrieved from GPCRDB for all candidate protein mentions.
RESULTS
GPCRDB contains a substantial amount of information, but for this to be useful, users 
require more than just large collections of ‘data’. For the three concepts for which we provide 
annotations (proteins, residues and mutations), we have selected data, links and knowledge 
that we believe will benefit users when reading an article, allowing them to link effortlessly 
from the text to all relevant information in GPCRDB. Once a paper is annotated, red marks 
on the side of the pages indicate where annotated concepts are located, as shown in Figure 1. 
The intensity of the red marks increases with the number of annotations at those positions. 
All annotated concepts can also be highlighted simultaneously by pressing the space-bar. 
Proteins
Protein annotations contain links to a number of sources (Figure 2). A link pointing to the 
protein detail page in GPCRDB is always present. Here, users can find information relating 
to the protein sequence, mutations, homology models, ligand-binding data, and so on. In 
addition, a link to the protein family page is provided. From here, all other protein family 
members can be retrieved, multiple sequence alignments can be accessed, etc.
Protein annotations also contain links to UniProtKB for a detailed report on the protein, 
and, if available, a link to Ensembl for the genomic view. We provide a list of synonyms for 
the protein names. Structural information on GPCRs is still limited, but we provide links to 
structures when they are available. If oligomerisation information is available, we provide 
links to pages that contain the relevant details.
Residues
Residue annotations contain various links and a selection of data pertinent to that specific 
residue (Figure 3). The protein name is linked to its protein detail page in GPCRDB. The residue 
type is displayed, together with its residue number in several numbering schemes. General 
residue numbers are provided in two different schemes: the commonly used Ballesteros-
Weinstein scheme, and that of Oliveira et al. The sequential residue number is also shown. 
Sequential residue numbers in GPCRDB annotations may not be identical to residue numbers 
described in an article. If the software has detected a mismatch and made the appropriate 
corrections, this will be noted in the annotation. A one-line description of the location and 
interactions of the residue is given, based on manual analysis of currently available protein 
structures. A three-dimensional cartoon image of a GPCR structure is provided, in which the 
position of the residue is highlighted. This allows readers to directly place the information in 
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the article in a structural context. If the residue is located in a structurally conserved region of 
the Class A GPCRs, and thus has a general residue number in GPCRDB, a link is given that 
will create a YASARA scene containing the homology model of the protein with the residue 
highlighted in the structure. If the residue is part of a reported oligomerisation interface, 
links to more detailed descriptions of that interface are included. For each residue, a link is 
provided to a GPCRDB page summarising all known data and information for that residue, 
including information about available mutations at that position, and mutations at equivalent 
positions in other proteins.
Mutations
The mutation annotations also link to the protein detail page. If GPCRDB contains 
information about the same mutation from other literature, links to the relevant PubMed 
Figure 2. Protein annotation of the human A2a adenosine receptor. On the left, part of a paper by Gao 
et al.(29) is shown; annotated concepts are highlighted in red by pressing the space-bar. On the right, an-
notation for the A2a receptor (obtained by clicking on the words indicated by the grey arrow) is shown. The 
protein identifier and family are linked to the protein detail and protein family pages in GPCRDB, respec-
tively. In addition, links to a number of external resources are provided. An image of the protein structure 
(PDB code 3EML) is shown. Although not annotated in the text, the species mentioned (human, murine, 
bovine, rat) are used internally for protein normalisation.  
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pages are provided. This way, users can immediately look up literature that discusses the 
same mutation. If GPCRDB contains mutations at the same position in the same protein, but 
with a different mutated residue type, links to relevant GPCRDB pages are provided.
A link to a page that displays mutations at the same (equivalent) position in other proteins is 
always present. In addition to links to other literature or other mutations, GPCRDB contains a 
large amount of descriptive information about the effects of mutations – such information has 
been culled, over the years, from painstaking analysis of the literature, and manually added 
to the knowledgebase in the form of short summaries. Where such information is present 
in the GPCRDB for the mutation at hand, this information is provided automatically in the 
annotations displayed in the side-bar. If the mutation is located at a position in a structurally 
Figure 3. Annotation of residue Trp243 in the human adenosine A3 receptor. On the left, part of a paper 
by Gao et al.(29) is shown; annotated concepts are highlighted in red by pressing the space-bar. On the right 
are the residue annotations. The protein name is linked to the protein detail page in GPCRDB. Links are 
also provided to a page in GPCRDB listing all available information for this residue, and to a YASARA(30) 
scene, in which the residue is highlighted. Residue numbers are provided both in the sequential numbering 
scheme and in the Ballesteros-Weinstein and Oliveira (GPCRDB) schemes. A short description of the loca-
tion and interactions of this residue is provided, as well as a cartoon indicating its location in the receptor 
structure. 
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conserved region of the Class A GPCRs, and thus has a general residue number in GPCRDB, 
a link is given that will create a YASARA scene containing the homology model of the 
protein, with the wild-type and mutated residues highlighted in the structure. In addition to 
mutation-specific information, mutation annotations also contain general information about 
Figure 4. Annotation of mutation R283A in the mouse thyrotropin-releasing hormone receptor. On the 
left, part of a paper by Gao et al. (29) is shown; annotated concepts are highlighted in red by pressing the 
space-bar. On the right are the mutation annotations. Papers discussing the same mutation are listed, with 
links to PubMed. A short literature-based summary of the effects of this mutation is provided, together with 
links to GPCRDB pages giving details of other mutations at the same position, and to a YASARA scene, in 
which the mutated residue is highlighted and displayed with the mutant residue type. Information about 
the wild-type residue is also provided, which is identical to the information displayed for residue annota-
tions.
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the mutated residue. This residue-specific annotation is identical to the information displayed 
within residue annotations (Figure 4).
COMMUNITY ANNOTATIONS
With this work, we take the integration of literature data in GPCRDB one step further. 
Using the PDF reader, when a mutation is identified in a scientific article that is not yet 
known to the GPCRDB, this mutation is automatically integrated into the GPCRDB, making 
this information available from both the GPCRDB website as well as from the annotations 
within Utopia Documents. Thus, when a user reads another article discussing a mutation at 
the same position, links to the newly integrated article will appear as an integral part of the 
annotation display, allowing immediate navigation to the appropriate literature.
In addition, behind the scenes, for all articles annotated using the reader, sentences are 
extracted in which mutations are mentioned. This information, which effectively provides an 
at-a-glance summary of the article with respect to that mutation, is stored in the GPCRDB 
and made available from the GPCRDB website. Because we strive to include only the most 
highly relevant data and information in the annotations offered by Utopia Documents, this 
automatically extracted text is not displayed with the PDF reader, and is only accessible 
through the GPCRDB website. 
ANNOTATIONS AND THE RESCUE OF DATA
The integrated view of literature and data offered here is invaluable when reading articles 
published before the first X-ray structure of a GPCR, that of bovine rhodopsin (25), became 
available. Prior to that moment, researchers often interpreted their experimental results in 
the light of homology models. The quality of those models was usually very poor (26), and 
hence the interpretation of the experimental data was often far from optimal, and sometimes 
simply wrong. The experimental data are still valuable though; today, with more information 
available, scientists can re-interpret the data in light of current knowledge. As an example, 
Figure 5 illustrates an image from an old mutation study (27) in which the authors describe 
various mutations in the guinea pig histamine H1 receptor, building and validating a 
homology model using these data, and arguing, for example, that residue Trp161 plays an 
important role in receptor-ligand binding. This assumption was based on the effect of the 
mutation on receptor function, leading to a model in which Trp161 was (wrongly) modelled 
as being positioned in the ligand-binding site. 
By contrast, the annotation indicates that this residue, located in TM IV, points towards the 
membrane and possibly interacts with cholesterol (Figure 5). This is a completely different 
view from that proposed by the authors. Looking at the model provided by GPCRDB, based 
on sub-family specific profiles and the latest crystal structures, it can be seen that the position 
of Trp161 with respect to the ligand-binding pocket is completely obscured by TM III and 
hence that a direct role in receptor-ligand binding is highly unlikely (Figure 6).
The point here is not that the Wieland model is incorrect; as stated before, most models 
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were wrong before the structure of bovine rhodopsin was published. What is important is that 
this software can be used to detect these types of historical artifacts, relieving scientists of the 
task of validating the results of ‘old’ literature against current knowledge. It is important to 
emphasise that the published experimental data are still valuable, but need new interpretation: 
in a sense, the software rescues old data from articles that contain interpretations that we now 
know to be incorrect. With this tool, therefore, scientists can now focus on providing new 
views on experimental data in the light of current knowledge. For example, knowing that 
Trp161 is conserved and interacts with cholesterol in some receptor structures allows for 
the hypotheses that this residue is functionally important for dimer formation, potentially 
through cholesterol. Other hypotheses can be imagined too, but the only thing that seems 
certain is that Trp161 is not directly involved in ligand binding. 
APPLICATIONS
The system presented here is likely to be useful in a number of different scenarios. For 
example, for biocurators, it offers a rapid means of accessing reliable, contextualised GPCR-
relevant data: this would not only benefit future curators of GPCR-specific resources like 
Figure 5. Excerpt from the article by Wieland et al. (27). Trp161 is discussed as having interactions with 
the cis-aromatic ring of the ligand. The annotation of residue Trp161 is shown on the right as it appears in 
Utopia.
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GPCRDB, but would also facilitate the work of those who annotate more general repositories, 
such as UniProtKB:Swiss-Prot or InterPro (28). For journal editors, it offers a swift route to 
‘gold standard’ GPCR data that they may officially endorse as part of their manuscript mark-
up process. For life scientists and bioinformaticians in general, and for pharmacologists and 
target-discovery researchers in particular, it offers a convenient way to keep up with GPCR 
literature, and to find new articles and new links that they might otherwise have overlooked. 
For users of GPCRDB, it offers a swifter, more targeted and hence more convenient navigation 
system compared to simple Web-based browsing of the resource. Many other use cases are 
likely as the system is generalised to other superfamilies. 
CONCLUSIONS
The work presented here was developed in response to the need to achieve tighter coupling 
between published articles and their underlying data as a crucial step towards knowledge 
discovery. The strength of our approach lies in its ability to present users (life science 
researchers, bioinformaticians, researchers in the pharmaceutical industry, journal editors, 
and so on) with current, integrated, validated, internally consistent data and information in 
the context of literature being read. The annotations provided are extensive and detailed, 
and, importantly, include concepts such as ‘residue A interacts with the ligand’, ‘residue B 
is implicated as playing a role in oligomeric interactions’, ‘residue C is located in TM4 and 
points to the lipid environment’, ‘residue D is conserved in its sub-family’, etc. A substantial 
amount of knowledge is sequestered in such annotations. Taking mutation annotations as an 
Figure 6. The location of Trp161. On the left, the model from the paper by Wieland et al.(27) to which 
orange and red ellipses have been added to highlight helices III and IV respectively. On the right, the model 
retrieved from GPCRDB, with helices III and IV drawn in orange and red. The grey sphere shows the 
approximate position of the ligand-binding pocket.
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example, although trivial at first glance, the mapping of sequential residue numbers to those 
of general residue numbering schemes saves researchers large amounts of time in looking 
up the residue mentioned in the database and finding its associated general residue number. 
In order to reliably transfer information between different proteins, this is a necessary but 
very time-consuming process. The structural information consists of data from a variety 
of different manually- or automatically-generated sources, and provides scientists with a 
structural perspective on the concepts in the text, making it much easier to critically assess 
the authors’ interpretations of experimental results, which is crucially important when 
reading old literature. Linking mutation data to other articles in which similar mutations 
have been discussed saves users considerable effort. This is an onerous task to perform by 
hand, owing to the necessary conversions between various numbering schemes and residue 
numbering offsets. To summarise, this work helps GPCR researchers to optimally extract 
new knowledge from scientific literature by automatically putting data from a PDF article in 
the wider context of the total body of knowledge related to GPCRs.
AVAILABILITY AND REQUIREMENTS 
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GPCR-OKB: THE G PROTEIN COUPLED  
RECEPTOR OLIGOMER KNOWLEDGE BASE
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ABSTRACT 
Rapid expansion of available data about G Protein Coupled Receptor (GPCR) dimers/
oligomers over the past few years requires an effective system to organize this information 
electronically. Based on an ontology derived from a community dialog involving 
colleagues using experimental and computational methodologies, we developed the GPCR-
Oligomerization Knowledge Base (GPCR-OKB). GPCR-OKB is a system that supports 
browsing and searching for GPCR oligomer data. Such data were manually derived from 
the literature. While focused on GPCR oligomers, GPCR-OKB is seamlessly connected to 
GPCRDB, facilitating the correlation of information about GPCR protomers and oligomers. 
The GPCR-OKB web application is freely available at http://www.gpcr-okb.org 
INTRODUCTION 
G protein-coupled receptors (GPCRs) are transmembrane (TM) helical proteins that are 
implicated in many biological responses, and thus serve as targets for a variety of therapeutic 
compounds (Hopkins and Groom, 2002). Although still a matter of controversy for some 
GPCR subtypes, the very close proximity of two or more receptors has been demonstrated 
unambiguously in heterologous cell systems for several GPCRs using biochemical and 
biophysical techniques (1). The challenge now is to determine whether all GPCR complexes 
have functional significance in native tissues, as already demonstrated for a few pairs (2). 
Information supporting the existence of functionally relevant GPCR dimers/oligomers 
is described in multiple articles published in the literature. This creates a challenge to 
researchers trying to gather experimental evidence and/or computational predictions about 
any given oligomer. Our previous work focused on the design of an ontology (3) to organize 
information about GPCR oligomerization, and its functional consequences in vitro and in 
vivo. The ontology was well received (4), demonstrating significant interest in an electronic 
system to access GPCR oligomer information. In this article, we describe the GPCR-OKB 
system, which implements the GPCR-OKB ontology and an electronic front-end to organize 
information about GPCR oligomerization obtained from 167 published articles (as of January 
2010). 
METHODS 
DATA ACQUISITION 
The content provided in GPCR-OKB was extracted from articles published primarily 
during the past decade, and was recorded in the system in a format as close to the raw 
experimental data as possible to preserve objectivity. In cases where published evidence 
varied, the option ‘Evidence Varies’ highlighted the controversy. Thus, only original research 
papers were annotated; review articles were excluded. The latter, however, were checked to 
ensure that data from referenced original research articles were included in the GPCR-OKB. 
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SYSTEM DESIGN
The GPCR-OKB web application was developed with the Grails web application 
framework, and supports both browsing and structured searches. Information is stored in 
XML files that follow the GPCROKB XML schema designed in agreement with the GPCR-
OKB ontology (3; see http://www.gpcr-okb.org, The Ontology and Figure 1 in Supplementary 
Data for a summary of the types of information captured, and the relationships between them). 
XML files are versioned with the Subversion version-control system, and can be downloaded 
directly (see FAQ for download instructions). The GPCR-OKB web application loads these 
XML files at startup, indexes text fields, and starts serving web pages. The system has been 
tested with a variety of modern web browsers and has no specific requirements (see FAQ for 
a list of recommended browsers). 
For easy access to detailed information about individual subunits forming a GPCR 
oligomer, GPCR-OKB is linked to the latest release of the GPCRDB (5). Data are exchanged 
between GPCRDB and GPCR-OKB in XML format with an agreed-upon XML schema. 
BROWSING 
Information contained in GPCR-OKB can be browsed starting from any of the following 
titles: ‘Oligomers’, ‘Protomers’, ‘Methods’, ‘Phenotypic Changes’, ‘In Vivo Evidence’, 
‘Evidence for Physiological Relevance’ and/or ‘All Publications’. For simplicity, the GPCR-
OKB only refers to GPCR oligomers, although the majority of published experimental 
studies cannot discriminate between dimers, tetramers or higher order oligomers. Oligomer 
names are derived from the names of their constituent protomers, separated by a hyphen, 
in alphabetic and numerical order, following the recommendations of Ferre et al. (6), and 
with the organism in which they were characterized and the GPCR family name specified. 
When the same combination of protomers has been studied in different species, the GPCR-
OKB lists these combinations as different entries. Tables of data offer an option to download 
information in a tab-delimited format (see ‘Export to TSV’ button at the bottom of each 
table). 
STRUCTURED SEARCHES
The ‘Search’ tool at the top right side of each page (see Supplementary Figure 2) provides 
keyword searches across different types of information. To search for a certain oligomer, 
the user specifies the name of the oligomer constituent protomers in the input box. Initially 
configured to search only ‘Oligomers’, the search tool also allows to search for protomers (only 
those that are part of stored oligomers), methods, or to restrict oligomer searches to specific 
types of oligomers. The latter are oligomers (i) with demonstrated phenotypic changes with 
respect to the constituent protomers (e.g. specific signaling or ligand binding cooperativity 
events), (ii) with published information about predicted interfaces of dimerization/
oligomerization and (iii) with at least one or two of the following conditions satisfied: (a) 
evidence for physical association in native tissue or primary cells; (b) knowledge of specific 
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functional properties in native tissue; and/or (c) information from knockout animals or RNAi 
technology. These conditions are NC-IUPHAR recommendations for recognition of a bona 
fide functional GPCR oligomer, according to a recent report (7). 
RELATED SYSTEMS 
We are aware of at least two databases under development that provide information about 
GPCR oligomerization, i.e. the GRIP-DB system (8) and the gpDB relationship database (9). 
These systems, however, are primarily focused on predicting or storing knowledge pertaining 
to protein–protein interactions between GPCR subtypes, GPCRs with partner G-proteins 
and/or GPCRs with effector molecules. 
CONCLUSIONS 
In addition to information about protein–protein interfaces, the GPCR-OKB stores detailed 
biochemical, pharmacological and functional information about GPCR oligomers, including 
phenotypic changes, evidence for physiological/clinical relevance, effects of oligomer-
specific ligands and proposed mechanisms of activation. The system was designed to integrate 
seamlessly with the widely used GPCRDB for receptor protomers. The information included 
in GPCR-OKB was collected and presented in an objective manner to encourage productive 
and substantiated communication among the domain experts. The GPCR-OKB is expected 
to be very useful to the GPCR scientific community. 
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INTRODUCTION
The previous chapters of this thesis describe GPCRs and the design and usage of the 
GPCRDB (1). As is usual with bioinformatics projects, most time is spent on the design and 
implementation of the software. As we live in the era of eScience, we have kept a series of 
eScience paradigms in mind in the process. One of those paradigms is the re-usability of 
software. Most software that we wrote or incorporated in the GPCRDB is generic, i.e., can 
be used for other classes of molecules than GPCRs. The following chapter describes the 
NucleaRDB, a system that resembles the GPCRDB in all aspects, but one: the NucleaRDB is 
an MCSIS for nuclear hormone receptors. 
This chapter describes a series of aspects of the MCSIS design and implementation that 
either were non-trivial, or exemplary for a type of problem that needed to be solved along 
the way.
OVERVIEW
Conceptually, the MCSIS framework can be seen as a combination of three units:
1. Data import
2. Data storage
3. Data access
These units have partly been explained in the previous chapters that all have been published. 
In this chapter we describe a series of details that were either to specialist to be published, 
or removed from those articles at the request of the referees. Additionally, we present here 
the overall materials and methods section for the GPCRDB, discussing the data-model, the 
choice of programming languages, the webservice interfaces, etcetera.
DATA IMPORT
MCSIS systems contain almost by definition a wide spectrum of data types. A number 
of these data types are part of all MCSISes, like protein information that is extracted 
from UniProt (www.uniprot.org) or structural information from the PDB (www.rcsb.org). 
Sometimes data is family-specific so that software needs to be written that can deal with these 
specific data sources and integrate it in the MCSIS. The oligomerization information from the 
GPCR-OKB (2, 3) is an example of family-specific data. 
Retrieval
The problems encoutered along the path of an MCSIS designer are probably best illustrated 
by two anecdotes.
Philip Seeman collected many GPCR ligand binding constants in the 80’s and early 90’s 
of the previous century. He even published all these thousands of data items in a book. A 
GPCRDB user sent us a copy of that book with the remark “I think he would love it if you 
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would put these data in the GPCRDB”. Philip Seeman did not have an Email address yet in 
those days but another GPCRDB user called him up, got a pile of floppy-disks and permission 
to freely use the data. Unfortunately, by the time those floppies reached us, the particular type 
of Apple computer on which the floppies were written was already out of commission for four 
years. Yet another GPCRDB user, Friedrich Rippmann from Merck in Darmstadt, came to 
the rescue. Merck never disposed of old computers as that was too expensive. They just piled 
them up in an old warehouse. His system manager went to the warehouse got out five old 
Apples, managed to get one operational, read the old floppies (of which only one copy was 
left on earth, so he admitted being nervous when he put the first floppy in the nine year old 
drive), converted the data to HTML 1.0, and wrote them out on floppies that were formatted 
to also be useful by more modern Apples. These floppies were then loaded on Friedrich’s 
Apple, converted, and written on a modern floppy format. Friedrich brought the floppies 
by car to the EMBL where they were read on an Apple. The data was transferred to the 
GPCRDB linux system, and software was written to convert the HTML files into something 
more database friendly. A few hundred records had to be manually corrected because they 
got corrupted somewhere along the long conversion path. It was a cumbersome project, but 
worth it as the data has been, and still is, accessed hundreds till thousands of times per week.
The first anecdote comes from the previous GPCRDB manager, Florence Horn, who so 
tragically died in 2006. The second example is from my own work. The GRAP / TinyGRAP 
(4, 5) database was produced by Øyvind Edvardsen and Kurt Kristiansen at the university of 
Trømsø. About 7 years ago, Øyvind decided to take up a job in industry and put the mutation 
data on a stand-alone computer in a corner of the university›s computer room. A few years 
later, management of the Trømsø computer centre considered a very old SUN computer a 
safety risk, so they switched it off; exit GPCR mutant data. Fortunately, a Trømsø system 
manager was willing to switch on the computer one more time and produce a database dump 
on a DAT tape, and sent it to us. Unfortunately, there was no SUN computer available in 
Nijmegen old enough to deal with that data dump. However, 10 years after the near loss of 
the ligand binding data, eScience had progressed and virtual computers had been invented. 
Wilmar Teunissen set-up a virtual SUN computer and could read the data dump. We could 
then export all data to a more modern format and convert it for inclusion in the GPCRDB.
By the way, when the EBI wanted to get all GPCRDB data for inclusion in their EBeye 
search machine, it took less than two days  to get all the work done, and the EBI now gets 
monthly GPCRDB updates 100% automatically. I guess these examples also illustrate 
beautifully the importance of eScience for the life sciences.
We use various ways of retrieving required data for building an MCSIS, and not all data 
retrieval projects are as treacherous as those described above. Some data is stored in local 
files, others are obtained from remote sources via the web, and yet other sources are retrieved 
more dynamically via web services.
The data sources that are available via the web tend to be easy to parse and integrate. 
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This is due to the fact that these sources often provide their own, relatively well-specified, 
naming schemes or vocabularies. For the older data sources, the internal structure and naming 
conventions are often not explicitly stated, and careful inspection of the data is necessary to 
elucidate its meaning and structure. 
For the GPCRDB, older data sets, such as the ligand binding data sets from P. Seeman 
and J. de Graaf (N.V. Organon), as well as mutation data from the tinyGRAP database and 
Florence Horn’s MuteXT (6) pages are stored locally and loaded from disk for each build of 
the system. The data that contains oligomerization information is obtained via the web from 
the GPCR-OKB research. This is done for each new build, ensuring that the most up-to-date 
information is used.
Maarten Hekkelman maintains the CMBIs MRS database information system (7). MRS 
keeps up-to-date versions of a large series of databases including very important ones for the 
GPCRDB such as SwissProt (8), UniProt (9), and the PDB (10).
The MRS web service endpoint (http://mrs.cmbi.ru.nl/mrsws/search/wsdl) is used for 
retrieving information for the individual GPCR proteins. For each protein the appropriate 
record is retrieved from MRS. Based on the information present in this data, additional data is 
retrieved from MRS, e.g. information about the species is obtained from the MRS taxonomy 
database after extracting the UniProt species record. 
For each separate data source, the data must be parsed and converted to the MCSIS data 
model. Code is available that maps the ‘raw’ data to the MCSIS data model, after which it 
can be stored in the database. 
Integration
Often there are multiple sources for one data type. For instance, ligand binding information 
FI   melat00095
AC   P49217
DE   MELATONIN RECEPTOR TYPE 1A (MEL-1A-R).
OS   PHODOPUS SUNGORUS (STRIPED HAIRY-FOOTED HAMSTER) (DJUNGARIAN HAMSTER).
LI   3-Methylindole
LR   2-[*I]IODOMELATONIN
KD   1992
RA   4. DUNCAN, M.J., TAKAHASHI, J.S., and DUBOCOVICH, M.L.
RT   2-[125I]Iodomelatonin binding sites in hamster brain membranes: 
     Pharmacological characteristics and regional distribution.
RL   Endocrinology 122:  1825-1833 (1988).
CC   Hamster brain
//
Figure 1. An example of a ligand binding record from the dataset provided by P. Seeman, after all 
conversions and manual corrections. Clearly, a lot of domain-specific understanding is needed to 
properly harvest this wealth of information. Ontologies were not used often in the 80’s of the previous 
century, so we had to retrofit the data to a data model,
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is provided by datasets from P. Seeman and from J. de Graaf, and from external resources 
such as GLIDA (11) or ChEMBL (12). All these data come in their own format and need to 
be converted to the MCSIS internal data model. As an example, an already converted record 
from the Seeman ligand binding data set is shown in figure 1.  
A representation of the Java class that is used to handle ligand binding data is shown in 
figure 2.  This Java class represents the general data model for ligand binding data, onto 
which all data from different sources must be mapped.
As can be seen when looking at the two figures, a number of steps are involved in converting 
the Seeman data to the Java model. Most importantly, a mapping must be constructed from 
the two-character keys from the record to the fields in the class. For most fields this is trivial, 
for example the ‘LI’ field contains the ligand information, whereas the ‘LR’ field contains 
information about the radioligand used. The ‘AC’ field contains the accession code of the 
protein, which must be mapped to a protein in the database. When we are looking at the 
experimental data, things are becoming more difficult. In this record the experimental value 
is stored in the ‘KD’ field. When only a radioligand is present, the KD field contains a Kd 
value. When there are a radioligand and a ligand present in the record (as is the case in figure 
3), the value is not a Kd value but a Ki value. If, however, the value starts with ‘C=’, eg 
‘C=700’, the value 700 is an IC
50
 value. Fortunately, not all data sources are as problematic as 
this example, but it shows that for each new data source the data must be extensively analysed 
and a deep understanding of the domain-specific details is needed before the software can 
even be written that deals with this data. Margot Beukers, as domain expert in pharmacology, 
has been instrumental in deciphering these ligand binding data.
Validation
Some data types can easily be validated before they are incorporated in the system. When 
ambiguous residue types such as ‘X’, ‘B’ , ‘Z’ or ‘J’ are present in a sequence these sequences 
are discarded. Mutation data can also be easily validated. Mutations are combinations of a 
protein identifier, a residue number, a wild-type residue type and a mutated residue type. 
ProteinLigandBindingData
ligand
ligandBindingType
measurementType
measurementValue
radioLigand
protein
reference
commments
dataOrigin
Figure 2. The ProteinLigandBindingData class.
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Before incorporating the information in the database, a check is performed that ensures that 
the combination of the protein, residue number and wild-type residue type is valid. In other 
words, the software checks if this mutation can exist in a specific protein. Additionally, a 
check is performed that eliminates cases in which the wild-type residue type is the same 
as the mutated residue type. This type of validation is used to ensure reliable and high-
quality data. Similar validation steps are used in validating the text-mining results for the 
GPCR-specific PDF reader. There, additional ‘soft’ validation steps are applied. For instance, 
if the residue ‘P450’ is detected in a sentence where the word ‘cytochrome’ is also used, 
this residue is removed from the result. This is because this sentence most likely discusses 
cytochrome P450, and not residue P450 in a GPCR. Another example is P40, this possible 
residue is ignored when the term ‘nonidet’ is found in the same sentence; P40 refers to a 
frequently used detergent. In total a couple dozen such ad hoc rules have been implemented.
Calculation
Sequence data, ligand binding constants, mutant information, structural data, and oligomer 
interactions make up the experimentally determined primary data.  In addition to providing 
experimentally determined information, the MCSISes also provide computationally derived 
data. Homology models, correlated mutation scores and multiple sequences alignments are 
examples of such computationally generated data.
Multiple sequence alignments
We make use of two distinct approaches to generate multiple sequence alignments (MSAs). 
We use hand-optimized sub-family specific profiles to create the alignments for the sub-
families (the leafs of the family tree). The domain expert Laerte Oliveira has created these 
1091 profiles once by hand. WHAT IF (13) aligns the sequences against these profile using 
an iterative approach in which the fine details of the profiles automatically are adjusted from 
GPCRDB update to GPCRDB update.
A local version WHAT IF is used to generate alignments and calculate alignment-derived 
data. A web-service version of WHAT IF is available, but we chose to use a local instance 
SeqNo  ArbNo A   OPEN  ELON WEIGHT                                     SS
   43  130   N   8.00  2.00  100    [0.05 0.05  . . .   1.45 0.0.5 .]  TM1
Figure 3. Header and data record from a sub-family specific profile. The ‘SeqNo’ contains the sequential 
residue number (not used), the ‘ArbNo’ column contains the general residue numbers, the ‘A’ column 
contains the consensus residue type. The ‘OPEN’ and ‘ELON’ records are used in the alignment and 
contain gap open and gap elongation penalties. After that, for all of the 20 residue types a score is listed 
(partly omitted here for clarity), followed by a ‘SS’ column indicating the secondary structure element 
for this residue
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because of the amount of CPU time required to generate the alignments and the huge amount 
of data that needed to be transferred via the web otherwise.
Secondary structure information and general residue numbers (called arbitrary sequence 
numbers in WHAT IF terminology) are available from the profiles (figure 3), and after 
the alignment is completed WHAT IF exports this information for each aligned residue, 
which is subsequently stored in the database. The result is that the residues in the TM 
domains, helix VIII and sections of the loops are labelled with a general residue number. 
For the families and super-families (the nodes in the family tree), we make use of the general 
residue numbers that were generated from the sub-family alignments. For all the sequences 
that are being aligned we select from the database all the general residue positions that the 
sub-families have in common. The alignment is then created by listing, for each sequence, the 
residues at the selected positions. Parent family alignments are thus not built using standard 
alignment algorithms but are created by selecting from the sub-family alignments residues 
that are likely to share the same position in the three-dimensional structure.
Homology models
Homology models are constructed using a separate script written by Coos Baakman. Using 
the generic residue numbers of both sequences an alignment between the query sequence and 
the template sequence is created. Thus, residues that have the same general residue numbers 
are placed at the same position in the alignment. The subsequent modelling is performed with 
YASARA. Due to the massive CPU time required the modelling script runs separate from the 
GPCRDB build script.
Correlated mutations
Correlated mutation scores are available for all families. These scores are calculated from 
the multiple sequence alignments (described above), using the CORMUT option in WHAT 
IF, which determines the correlated mutations, i.e. pairs of residues that mutate in tandem 
during evolution. The results of this analyses are stored as a matrix in the database. 
DATA STORAGE
The data model and the database schema are identical for all MCSIS instances. The 
database schema is tightly coupled to the Java classes; based on the data model (the structure 
of the classes and their relations), a database schema is generated by the Hibernate (www.
hibernate.org) library. More details about what the Hibernate library does and why it is used 
in the MCSIS framework can be found in the architecture section. The data model has been 
the result of a process of fifteen years that included many people mainly from the CMBI, 
Organon, the EMBL, and UCSF. Currently the data for the GPCRDB and the NucleaRDB 
are stored in a PostgreSQL (www.postgresql.org) relational database, but due to the use of the 
Hibernate library (www.hibernate.org) the MCSIS framework is in no way tied to a specific 
SQL vendor. The MCSIS database schema is illustrated in figure 4. A more readable version 
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is available from the GPCRDB.
DATA ACCESS
The MCSISes provide fast and easy access to all data and information. Access to the data is 
provided through various interfaces. The first and best-known interface is the web site. This 
interface is meant for human consumption, and can be used from a web browser. The second 
interface, the web services interface, is meant for automated consumption. This web service 
interface comes in two flavours, a SOAP and a REST interface. Third, the Utopia Documents 
(14) PDF reader interface provides its own unique interface to the data. 
Web interface
The web interface provides the four fundamental facilities to be provided by information 
systems; browse, query, retrieve, and inference.
Browse
The GPCRDB’s web interface allows the user to easily navigate from one data type to 
another and often suggests multiple routes to explore the data, thereby hopefully generating 
ideas and questions while the user navigates the system.
The web interface is built using Apache Wicket (wicket.apache.org). Wicket is Java-based 
and all web pages internally consist of a combination of a Java class and an HTML template. 
The Java classes contain all ‘business-logic’ of the pages, determining the contents, whereas 
the HTML template determines how the pages are rendered.
Figure 4. The MCSIS database 
schema. The main elements are 
the proteinFamily, protein and 
residue tables. This is a compact 
representation of the database 
schema, a version that contains 
explicit mentions of all the columns 
can be found at the GPCRDB.
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Query
Users can query the database via a number of search forms. Internally, for each of the 
search forms, query objects are constructed that contain all the information and restraints 
supplied by the user. For each query, such a query object is automatically translated to an 
SQL query, which is then passed on to the database. Results of the queries are automatically 
converted into Java objects, which can be easily passed on to the Java classes that build 
the web pages. Using this approach, all the classes that query the database only deal with 
Java objects, and no conversions between SQL and Java or Java and HTML are necessary. 
Another advantage of this approach is that the query objects can be reused; they are also 
available from the web service endpoints, providing the same functionalities as the form-
based versions on the website. This allows a programming end-user from anywhere in the 
world to include GPCRDB queries in his or her in-house software.
Retrieve
Retrieving data can be done in various ways, depending on the data being retrieved. The 
GPCRDB website offers a set of pre-packaged files for very large sets that are not suitable for 
on-the-fly preparation (e.g. files containing all alignments and all the mappings of individual 
proteins to the GPCR families). Individual protein family alignments can be downloaded in 
a number of different formats from the protein family pages. Sequences, structures, ligand 
binding data and mutations can be downloaded from the protein detail pages. The website also 
offers ways to retrieve data based on search results; for earch search type the web interface 
can convert the search results on-the-fly to a downloadable text file.  In addition to using the 
website for retrieval, the web services can also be used to retrieve data. The web services 
offer very extensive retrieval possibilities, together allowing for the retrieval of all data types. 
To retrieve specific subsets, the same search objects as discussed in the section above can be 
used in the web service interfaces, providing fine-grained control on what to retrieve.
Inference
Due to the amount of data present in an MCSIS, tools are needed that find correlations 
between the data and help users with data reduction and abstraction. A number of tools, 
such as the service that allows users to build their own custom alignments, together with 
the entropy-variability analysis pages, are an integral part of the MCSIS framework. Other 
services are partly implemented in the MCSIS, whereas other parts are located remotely. 
The BLAST interface is an example of this; the BLAST process itself is invoked from the 
MRS web service endpoint, but the user input and display of results is implemented in the 
MCSIS framework. The mutation effect prediction service from the GPCRDB is another 
example. The selection of the protein and mutated residues is implemented in the GPCRDB, 
but the analysis and display of results is performed externally by a program written by Coos 
Baakman. Predictions are mainly based on human knowledge that is stored in a computer 
136 | CHAPTER 7
readable format. This information is combined with a number of analyses on a homology 
model of the receptor being mutated, such as looking for steric clashes and helix disruptions. 
Results are presented as text-fragments that explain the effects of the mutation on the 
structure. This external software is not bound by the rules for the GPCRDB software, and is 
written in Python.
Web services
In addition to providing a web interface that is meant for human consumption, in the 
modern eScience era automated access is becoming more and more important. The MCSIS 
framework allows for extensive access to its data; direct queries can be performed to retrieve 
data, search facilities are provided, as well as services that allow for data conversion and 
services that perform extensive calculations. The web services are available both as a REST 
and as a SOAP endpoint. Table 1 lists a number of examples of the functionalities that are 
offered by the MCSIS web services.
Table 1. Examples of functions available from the MCSIS web services.
Function Description
getProtein Retrieve a Protein object from the database
getAlignmentFasta Retrieve an alignment in FASTA format
getResidues Retrieve all individual residue objects of a protein
searchProteins Search for proteins 
searchMutations Search for mutations
blastSequence Perform a BLAST search
createAlignment Create a custom alignment
getMentions Get all concepts (proteins, residues, mutations) from a 
text
PDF reader
The Utopia Documents PDF reader is used to provide a whole new interface to the MCSIS 
data. Based on extensive text analysis and validation, relevant concepts are detected in 
full-text articles, and associated information is automatically retrieved from the database, 
formatted in a user-friendly way and provided to the user as annotations that can be shown 
when and where the user wants it within the context of the PDF article. The text mining is 
performed in a special module that is part of the web application (discussed in greater detail 
below). For the communication between the Utopia Documents PDF reader and the MCSIS 
web application the web services are used. 
ARCHITECTURE & DESIGN
The MCSIS framework is comprised of three parts. The first part deals with the collection, 
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integration, validation and calculation of data. The second part provides access to all data and 
information in various ways. The third part, a relational database, forms the bridge between 
the first and the second part and is shared by both the first and the second part. The architecture 
of the system reflects this; two distinct software products perform the roles of collecting data 
and providing access to it. A java program that runs from the command line (mcsis-build) 
is used to collect and integrate all data and store this data in a relational database, curate the 
data, and add computational value. The second product, a web application (mcsis-web), is 
responsible for providing users with access to the data that was stored in a database, together 
Figure 5. High-level overview of the structure of the MCSIS software. The major packages (the build 
application and the web application) of the MCSIS system share the same modules that contain all data 
models, the infrastructure needed for storing and retrieving data from a database, and tools needed to 
interact with other data sources
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with providing access to additional services. Although the roles these products perform are 
very different, they do have a large part of their internal makeup in common. A number 
of modules, all with their own roles and responsibilities, make up the MCSIS framework. 
Figure 5 shows how the modules are related. 
The entire MCSIS system is written in Java (www.java.com). Java was chosen for its 
cross-platform compatibility and the availability of many high-quality libraries and tools 
that aid in improving the design and code quality. Libraries like Spring (www.springsource.
org), Hibernate (www.hibernate.org) and CXF (cxf.apache.org), which will be discussed 
later in greater detail, make Java a great programming language to develop modular, loosely 
coupled, and web-oriented software.
Groups of classes that have similar roles and responsibilities are grouped together in modules 
(figure 5). This allows for easy maintenance and re-use of existing small modules in larger 
modules or applications. Maven (maven.apache.org) handles the building and integration of 
these modules in functional packages, together with providing the right dependencies such as 
database drivers, web service libraries etc. for the build. The Hudson Continuous Integration 
server (hudson.java.net) is responsible for retrieving project code from an SVN repository, 
running unit tests, and invoking Maven to build the modules.
The source code is extensively documented and available upon request. 
In the following sections the individual modules that make up the MCSIS framework will 
be discussed. 
MODULES
The mcsis-core, mcsis-client, mcsis-tools and mcsis-miner modules are not functional 
applications on their own, but provide the mcsis-build and mcsis-web with data types, 
behavior and infrastructure needed to perform their tasks, such as providing access to a 
database and talking to remote data sources. 
The mcsis-build and mcsis-web modules are the two packages that are responsible for 
collecting, creating and storing the data (data import), and presenting it to the users in various 
ways (data access). These two packages perform very different functions, but internally they 
have a lot in common. The mcsis-web and mcsis-build modules are very generic; they contain 
no family-specific information. Everything that is specific for a particular family is stored in 
family-specific modules. Examples are parsers for family-specific data sources, and contents 
of family-specific web pages and help-information. By packaging the mcsis-web module 
together with the mcsis-gpcrdb-web module, the GPCRDB web application is created. The 
NucleaRDB web application is created when the mcsis-web module is combined with the 
mcsis-nucleardb-web module.
mcsis-core
The mcsis-core module provides all the elements needed to work with MCSIS concepts. 
Examples of such concepts are proteins, structures, literature references, etc. The module 
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contains information on how these concepts relate, and how they can be stored and retrieved 
from a relational database. The mapping of the MCSIS concepts (or objects) to a relational 
database is performed by the Hibernate package. Hibernate is a so-called object-relational 
mapping (ORM) tool that solves a large part of the inherent problems when dealing with 
the persistence of (Java) objects into a relational database. Necessary mapping details are 
provided to Hibernate as annotations in the model objects. Hibernate supports a number of 
query languages or styles that can be used to retrieve data from the underlying database. 
Native SQL can be used, but queries can also be constructed from the Java objects themselves. 
The biggest advantage of this is that changes in the ‘Java object world’ are automatically 
reflected in the SQL queries. Another important advantage is that by using this approach the 
underlying database type can easily be changed depending on a users need; moving from a 
PostgreSQL to an Oracle database does not affect the code in any way, and no rewriting of 
query statements is necessary. Currently the data is stored in a PostgreSQL database.
The mcsis-core package contains a number of Data Access Objects (DAOs) that are 
responsible for retrieving and storing data from and to the relational database. Other modules 
can use these DAOs by using dependency injection, a feature provided by Spring’s Inversion 
of Control (IoC) container. The main advantage of the IoC design pattern (also known as 
Dependency Injection, DI) is that classes remain loosely coupled, as the IoC container handles 
their instantiation and initialization. This model allows new versions of components to be 
swapped for old ones and dummy modules to be put in place for testing without requiring 
changes to the code. This leads to software that has less code but more flexibility. When using 
the DAOs, the initialization of the database connections, together with details such as query 
caches and connection pools are handled by Hibernate and Spring. 
mcsis-client
Many data that is stored in an MCSIS system is obtained from local data sets, but the MCSIS 
system also retrieves a large part of its data from remote sources, or provides links to specific 
Table 2. Remote data sources that can be accessed via the mcsis-client module. 
Database Type of data
MRS Biomedical databases:
- SwissProt
- UniProt
- RefSeq
- Taxonomy
- PDB
PICR Protein mapping data for various databases
Chebi Small molecule data
ChEMBL Bioactive small compounds data
PubMed Biomedical literature
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pages at remote sources. For example, protein information is retrieved from the UniProt 
database, and information on literature reference is retrieved from PubMed. The mcsis-client 
module functions as the access point to all kinds of remote data sources and programmatic 
interfaces such as the MRS BLAST service, or the Linneaus species identification service. 
For each remote data source (table 2) or remote service (table 3) an access point is available 
that allows querying and retrieving data. 
Most of the listed data sources and services provide web service access points. Apache’s 
CXF, a java framework to develop web services, automatically generates Java code from the 
WSDL files. The mcsis-client module contains a class that provides a client object for each 
service. This makes the services available to any Java class without needing any ‘boilerplate 
code’ that deals with the specifics of the used database. 
mcsis-tools
The mcsis-tools module contains a number of classes that are used throughout the system. 
Functions that are often needed are provided by this module: reading and writing files, 
calculating checksums, converting alignments between several formats, loading property 
files, converting ProSite (15) patterns to regular expressions, etc.
mcsis-miner
Annotating scientific literature with the Utopia PDF reader is an integrated aspect of 
the system.  All code that performs the text mining and subsequent gathering of relevant 
information for the found concepts, together with storing the results of the text analyses 
in a database, is provided by the mcsis-miner package. Details of how the text mining is 
performed are discussed in chapter 5. 
Splitting the text up into sentences and subsequent tokenization is performed using classes 
form the LingPipe package (www.alias-i.com/lingpipe). LingPipe also provides a large part 
of the needed infrastructure for the identification of proteins in the text. To minimize wait 
time for users of the PDF reader, the text mining code is heavily multi-threaded.
mcsis-build
The mcsis-build module contains all the code necessary for collecting, validating and 
integrating the data for an information system. This module depends on the mcsis-core, 
mcsis-client, mcsis-tools and mcsis-family-build modules. Packaged together, an executable 
Table 3. Remote services that can be accessed via the mcsis-client module
Service Type of service
MRS BLAST BLAST
YASARA Modelling, Structure visualisation
Linnaeus Species identification
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jar file is created, which can be run from the command line. The mcsis-build module provides 
the mcsis-core module with the information needed to gather and store information in a 
relational database. The mcsis-client module contains the access points to remote sources 
needed for collecting the data. Classes from the mcsis-build module contain all the code that 
parse general (i.e. non-family specific) local and remote data sources, create the appropriate 
data objects and run of external programs, e.g. to create alignments (WHAT IF), and build 
phylogenetic trees (ClustalW;  16). The family-specific modules contain parsers and 
references to data sources that are specific for a protein family.  The mcsis-build module can 
also interact with the LifeScience Grid (www.sara.nl/project/life-science-grid) for running 
calculations, and with the ToPoS server (topos.grid.sara.nl/4.) for conveniently managing 
jobs that are running on the grid. The LifeScience Grid offers access to a very large number 
of CPU nodes, together with an interface to submit jobs to the system. When computational 
tasks are parallel in nature, using a distributed computation system such as the LifeScience 
Grid can offer enormous speed benefits. Using the Grid, the collection of GPCR sequences 
and assigning them to a GPCR family, computation time has been reduced from more than a 
week to just a few hours. 
mcsis-web
The mcsis-web module provides a single point of access for all interactions with the outside 
world. It offers a web interface together with SOAP and REST web service endpoints. The 
web interface is built using the Apache Wicket framework (wicket.apache.org). Wicket is 
Java-based, and can use any of the existing aforementioned modules. The web application can 
therefore use the existing mcsis-core module to talk to the database and use all the available 
class models. Also all the clients that are used in the mcsis-client package are available to the 
web server, requiring no extra code. The web interface is responsible for providing the four 
fundamental facilities of information systems; browsing, retrieval, query, and inferencing. 
The web service interfaces are created automatically from the source code using Apache’s 
CXF framework. The web service interfaces provide a great part of the functionality that is 
also provided by the web interface such as searching, BLASTing and retrieving proteins, 
but also a number of services are available via web services only. The best example is the 
Utopia PDF reader annotation functionality. The communication between the PDF reader 
at the client’s computer and the server uses the SOAP endpoint for querying the system and 
retrieving results that are annotated with information. Family-specific information (e.g. the 
main page with information about the MCSIS) is available from the family-specific web 
package. 
The module depends on the mcsis-core, mcsis-tools, mcsis-client, and mcsis-miner 
modules. The mcsis-web module is packaged as a Web application Archive (war) flle that can 
be run in any Java EE application server. Currently the Glassfish application server (glassfish.
java.net) is used.
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CONCLUSIONS
The MCSIS framework is a modular framework that follows the e-Science paradigms. 
The software is reusable, scalable, and can be used both by scientists and computers. Where 
possible, the implementations have been decoupled from the design, and interoperability 
has been incorporated in the design from the beginning. By using the Grid for performing 
large-scale computations, the framework is future proof; it will easily be able to deal with the 
ever-increasing number of available sequences. By providing a number of different interfaces 
to access and interact with the data, the potential of the data is increased; it can be used as 
input for large-scale computations by scientists from all over the world, but it can also be 
placed in the context of one scientific article where a scientist is studying the details of one 
particular residue.
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NUCLEAR RECEPTORS
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ABSTRACT
The NucleaRDB is a Molecular Class-Specific Information System (MCSIS) that collects, 
combines, validates, and disseminates large amounts of heterogeneous data on nuclear 
hormone receptors. It contains both experimental and computationally derived data. The 
data and knowledge present in the NucleaRDB can be accessed using a number of different 
interactive and programmatic methods and query systems. A nuclear hormone receptor-
specific PDF reader interface is available that can integrate the contents of the NucleaRDB 
with full-text scientific articles. The NucleaRDB is freely available at http://www.receptors.
org/nucleardb
 
INTRODUCTION
Nuclear receptors (NRs) are ligand-inducible transcription factors that regulate processes, 
such as homeostasis, differentiation, embryonic development, and organ physiology. A total 
of 49 human NRs have been identified (1). Their ligands are lipophilic compounds such 
as steroids, thyroid hormone, vitamin D3, and retinoids (2). The endogenous ligands are 
not yet known for 30% of the NRs (3).  Because nuclear receptors are involved in almost 
all aspects of human physiology and are implicated in many important diseases including 
cancer, diabetes, and osteoporosis, understanding of these receptors has major implications 
for human biology and for the development of new drug treatments. Nuclear receptors are 
targets for pharmaceutical industries with similar importance (4) as the G protein-coupled 
receptors (GPCRs), ion channels, and kinases.  
Due to the increasing amounts of experimental and computational data buried in numerous 
databases and scientific articles, the task of extracting, combining and validating this data is 
becoming an increasingly large hurdle for the individual scientist. Databases that revolve 
Figure 1. Screenshot of the 
NucleaRDB family page. The 
family tree is shown on the 
left with the thyroid hormone 
family expanded. On the 
right-hand side the data for 
the selected family is shown.
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around a single protein family can help researchers in using all data needed for their research, 
while relieving them of the onerous tasks related to the retrieval of many data from different 
sources (5).
The NucleaRDB is a data source that holds many different data types in a well-organized 
and easily accessible form (6). The data are validated, internally consistent, and updated 
regularly. The NucleaRDB provides access to the data via various interfaces, which depending 
on the users’ needs, are suited either for automated access or interactive usage. 
DATA CONTENTS
PRIMARY DATA
The NucleaRDB contains three different primary data types: sequences, structures, and 
mutations. Sequences and structures were updated as described previously (7). Mutation data 
was obtained from the Nuclear Receptor Mutation Database (8) and fully integrated in the 
NucleaRDB. In addition, a large body of mutations was extracted from the literature by the 
software package MuteXt (9). 
COMPUTATIONAL DATA
A large and diverse collection of computationally generated data are present in the 
NucleaRDB. Multiple sequence alignments (MSAs) form the heart of the system and allow 
users to easily transfer information between different proteins. MSAs are available for all 
families and subfamilies, and can be viewed using JalView (10) or can be directly downloaded 
in a number of formats. MSAs were created as described previously (7).
Correlated mutation analyses (CMA) can be used to identify groups of residues that mutate 
in tandem. Residues that show correlated mutation behavior are likely to be functionally 
related, and networks of those correlating residues indicate functional units (11). Correlation 
scores are available for all (sub-)families.
The entropy and variability for a position in a MSA can be an indicator of the evolutionary 
pressures exerted at that position (12). Entropy and variability scores are available in tabular 
form and via an interactive page displaying an integrated view via plots, tables, and structure 
Table 1. Contents of the NucleaRDB.
Proteins 3764
Families 123
Mutations 1543
Protein structures 613
Structure models 3764
Species 339
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models.
In addition to the already large amount of structural information that is present in the 
NucleaRDB, homology models based on multiple template structures have been built for all 
NRs. All structure models were built using YASARA (13) and are available for download or 
can be viewed directly using Jmol (14). 
INFORMATION RETRIEVAL
All data in the NucleaRDB web interface are extensively connected, allowing for easy 
navigation between different data types. The main way of accessing the NucleaRDB’s 
contents is via the hierarchical family tree. For each family users can access the individual 
receptors, multiple sequence alignments (and all derived data and analyses such as correlation 
scores and protein distance networks), mutations, structures, and models. All pages contain 
links to all related data and information. Extensive search facilities are available, allowing 
the search for proteins, sequences, structures, families, and mutations using various search 
criteria and filters. A BLAST service is available that allows users to run their own sequences 
against the NucleaRDB. 
All data types and search facilities are accessible from the web pages as well as from the 
web service endpoints, allowing users to write workflows or in-house software that uses the 
NucleaRDB.
 
ANNOTATING SCIENTIFIC LITERATURE
Utopia Documents (15, 16) is a new PDF reader that offers unique opportunities to place 
information and knowledge in the context of scientific literature. We have integrated the 
NucleaRDB with the Utopia Documents PDF reader in such a way as to present to scientists, 
in a non-intrusive way, all NR-relevant data and information discussed in an article at hand. 
Annotations are provided for proteins, residues, and mutations mentioned in the PDF. For each 
of these concepts the annotations contain carefully selected information, as well as pointers to 
relevant web pages and related scientific literature. An example is shown in figure 2. The PDF 
reader presents the scientist, in a non-intrusive way, all relevant data and information related 
to the topics discussed in the article. This alleviates the troubles associated with navigating 
the many links between existing data and information available from the many articles in this 
field. The scientist neither struggles to get access to information related to topics within an 
article, nor is swamped by unnecessary information that still needs disambiguation; only data 
and information relevant to the topic of the article is made available.
IMPLEMENTATION 
The data in the NucleaRDB is stored in a PostgreSQL (www.postgresql.org) relational 
database. The web service interface is developed with the Apache CXF (cxf.apache.org) web 
services framework. We offer both SOAP and REST endpoints. The web interface is built 
using the Apache Wicket (wicket.apache.org) web application framework. The database is 
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accessed via a Hibernate (www.hibernate.org) object-relational mapping layer. The server is 
running within Sun’s Glassfish (glassfish.org) application server. 
CONCLUSION
The NucleaRDB provides researchers with a single point of access for nuclear receptor-
related data. Not only does the NucleaRDB hold a large amount of information, it also 
provides a broad scope of tools and dissemination facilities, relieving scientist of many of the 
tasks that come with collecting, validating, and integrating many diverse data.
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Figure 2. An impression of the 
Utopia Documents PDF reader 
interface to the NucleaRDB 
data. On the left side a part 
of a scientific paper (17) is 
shown that is annotated by the 
NucleaRDB. Annotations are 
available for all the highlighted 
words. On the right side an 
example of such an annotation 
(the mutation R274A) is 
displayed.
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Wetenschappers die in het begin van de 20e eeuw de eerste pharmacologische experimenten 
uitvoerden gebruikten weefsels en hele klieren als studiemateriaal en eenvoudige apparatuur 
om hun metingen mee te verrichten. De resultaten van deze experimenten waren meestal 
eenvoudig, zowel in grootte als complexiteit; in die tijd konden wetenschappers toe met 
het gebruik van pen en papier om de details van hun experimenten en resultaten vast te 
leggen. Dit is haast niet te vergelijken met de manier waarop de wetenschap tegenwoordig 
de elementen van het leven bestudeert. In plaats van het bestuderen van hele weefsels en 
klieren kunnen nu individuele elementen in een levende cel op atomair niveau onderzocht 
worden. Wat eerst de heilige graal van de levenswetenschappen was, het ontrafelen van de 
genetische code van de mens, is geworden tot een routineklus. Als gevolg van deze enorme 
toename in resolutie, gepaard met razendsnelle ontwikkelingen in de ‘high-troughput’ 
technieken is zowel de hoeveelheid als de complexiteit van de gegenereerde experimentele 
data onvoorstelbaar toegenomen. De computer is hierdoor niet meer weg te denken uit de 
wetenschap; gespecialiseerde software is nodig voor het opzetten van experimenten en het 
adminstreren en integreren van de resultaten.
Om het mogelijk te maken om deze enorme hoeveelheden gegenereerde data op te slaan 
en te delen met andere wetenschappers is er een groot aantal online databases gemaakt die 
ontworpen zijn om een bepaald type biologische data te bevatten. Voorbeelden hiervan zijn 
de Protein Data Bank (PDB), waarin informatie zit opgeslagen over de structuur van eiwitten, 
UniProt, waarin informatie is opgeslagen over eiwitsequenties en Chembl, welke informatie 
over de binding van kleine moleculen aan eiwitten bevat. Al deze databases zijn van enorme 
waarde voor wetenschappers, want ze bevatten data van hoge kwaliteit die bovendien up-
to-date is.  Echter, het merendeel van de levenswetenschappers richt zijn onderzoek op 
een bepaald eiwit of eiwitfamilie, in plaats van op een bepaald datatype. Het verzamelen 
van  alle benodigde informatie voor hun experimenten is een enorme klus, omdat voor 
elk benodigd datatype een aparte bron geraadpleegd moet worden. In plaats van meerdere 
databases die slechts één bepaald type data bevatten, hebben wetenschappers meer aan één 
database die meerdere types gevalideerde en geintegreerde data bevat, gecombineerd met 
gebruikersvriendelijke manieren om deze data op te halen, en die speciaal gericht is op het 
domein waarbinnnen zij onderzoek doen. 
Systemen die zich richten op een specifieke klasse moleculen worden ‘Molecular Class-
Specific Information Systems’ (MCSIS) genoemd. Al in 1991, voordat het World Wide Web 
bestond, werd een eerste aanzet gegeven tot het ontwikkelen van een dergelijk systeem, 
waarbij G protein-coupled receptors (GPCRs) werden gekozen als eiwitfamilie waar het 
systeem op gericht zou zijn. In 1992 werd het GPCRDB-emailsysteem gemaakt, en in 
1994 werd dit omgezet in een systeem gebaseerd op HTML pagina’s. Sinds die tijd staat 
de GPCRDB bekend als hét systeem voor het ophalen en verzamelen van allerlei GPCR-
gerelateerde informatie. GPCRs werden gekozen omdat deze moleculen vaak een rol spelen 
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bij ziekten en hierdoor ook voor de pharmaceutische industrie van enorm belang zijn. Daar 
komt bovenop dat GPCRs, vanuit de bioinformatica gezien, enorm interessante moleculen 
zijn. GPCRs zijn ingewikkelde moleculen, waarvan niet precies bekend is hoe ze hun vele 
functies vervullen. Omdat er weinig structuurdata beschikbaar is moet dit probleem opgelost 
worden met de data die wel beschikbaar is. MCSIS systemen zoals de GPCRDB stellen 
wetenschappers in staat om zoveel mogelijk van deze moleculen te begrijpen door hen te 
voorzien van verschillende, maar geintegreerde data.
In dit proefschrift staan de resultaten beschreven van de zoektocht naar nieuwe manieren 
om MCSIS systemen te maken en te gebruiken. Het proefschrift begint met een algemene 
introductie. Deze introductie bestaat uit twee delen, die ieder afzonderlijk zijn gepubliceerd als 
overzichtsartikelen in twee boeken. Het eerste deel, hoofdstuk 1a, behandelt de geschiedenis 
van het onderzoek naar GPCR eiwitten, vanaf de eerste experimenten in het begin van de 20e  
eeuw tot aan de publicatie van de eerste kristalstructuren van ligand-gemedieerde GPCRs in 
2007. Deze geschiedenis is aangevuld met een overzicht van de belangrijkste uitdagingen in 
het GPCR onderzoeksveld. Het tweede deel van de introductie, hoofdstuk 1b, geeft een kort 
overzicht van een aantal technieken die gebruikt kunnen worden om MCSIS systemen te 
maken en informatie te extraheren uit ‘multiple sequence alignments’.
De GPCRDB wordt uitvoerig behandeld in hoofdstuk 2. De GPCRDB bevat een breed 
spectrum aan zowel experimentele als computationeel gegenereerde data gerelateerd aan 
GPCRs. Dit hoofdstuk beschrijft hoe al die data verzameld en geintegreerd kan worden, 
alsmede hoe deze data op een doordachte manier aan de gebruikers aangeboden kan worden. 
Hoofdstuk 3 laat zien dat het beschikken over een verzameling van geintegreerde data als de 
GPCRDB essentieel kan zijn voor het aansturen van experimenteel onderzoek in laboratoria. 
In dit hoofdstuk wordt beschreven hoe, gebruik makende van de data in de GPCRDB, 
voorspeld kon worden welke ratten uit een grote verzameling van gemuteerde ratten 
geselecteerd moesten worden voor uitgebreide karaterisatie. Ook laat dit hoofdstuk zien dat 
voorspeld kon worden hoe groot de impact van de mutaties op het normale functioneren van 
de receptors was.
Om het onderzoek uit hoofdstuk 3 uit te voeren moest een groot aantal wetenschappelijk 
artikelen gelezen worden, een tijdrovende en vervelende taak. De hoeveelheid (GPCR) 
literatuur neemt alleen maar toe, en daarmee worden het soort studies als beschreven in 
hoofdstuk 3 steeds moeilijker om uit te voeren. Deze toename is een algemene tendens, de 
hoeveelheid gepubliceerde artikelen is zo groot aan het worden dat het voor wetenschappers 
eigenlijk niet meer mogelijk is om al het onderzoek in hun veld op een efficiente manier bij te 
houden. Om GPCR-wetenschappers in staat te stellen effectiever om te gaan met informatie 
in de literatuur en data in databases is gezocht naar manieren om deze te integreren. In 
hoofdstuk 4 en 5 wordt het resultaat van deze zoektocht, een GPCR-specifieke PDF lezer, 
uitgebreid beschreven. Deze PDF lezer haalt automatisch informatie op vanuit de GPCRDB 
die nauw aansluit op wat er in de literatuur beschreven wordt. Het aanvullen van literatuur 
met informatie uit de GPCRDB leidt niet alleen tot het sneller extraheren van informatie uit 
een artikel, maar kan er ook voor zorgen dat literatuur langer ‘houdbaar’ blijft, doordat een 
artikel telkens aangevuld kan worden met nieuwe data en de laatste inzichten.
Hoofdstuk 6 laat zien dat MCSIS-technologie gebruikt kan worden om andere systemen 
mee in te richten. De GPCRDB werd gebruikt als basis voor een database waarin informatie 
opgeslagen ligt over oligomeren, de GPCR-OKB. 
De technische kanten van de MCSIS systemen komen aan bod in hoofstuk 7. Hier wordt 
uitgebreid ingegaan op de architectuur en de implementatie details die het mogelijk maken 
om op een eenvoudige manier systemen als de GPCRDB te ontwikkelen voor andere 
eiwitfamilies.
Hoofdstuk 8 laat zien dat de technologieën die beschreven staan in hoofdstuk 2, 4, 5 en 
7 daadwerkelijk kunnen worden toegepast op andere eiwitfamilies. Het informatiesysteem 
NucleaRDB bevat heterogene informatie over nuclear receptors, en geeft op dezelfde wijze 
als de GPCRDB toegang tot uitgebreide data gerelateerd aan nuclear receptors. 
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